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Abstract 
 
Chronic pain imposes substantial challenges to medical practice as the treatment options for 
its clinically relevant manifestations are limited. Owing to lack of knowledge about the exact 
molecular mechanism underlying pathological pain conditions, pain therapeutics currently 
available target molecules with key physiological functions in our body. Thus, they are 
accompanied by severe side effects, which limits effective dosage prescription. Bearing 
these difficulties in mind, it is highly desirable to identify the proteins and their associated 
complexes that are differentially regulated and function at the forefront of noxious stimulus 
detection. The goal of this study was to identify and characterize multiprotein complexes in 
the context of nociception in mice. On the one hand, I followed a unbiased mass 
spectrometry (MS)-based approach to characterize the changes in expression of a large set 
of proteins in the dorsal root ganglia (DRG). DRG harbour the somata of nociceptors, the 
primary afferent sensory neurons that express distinct molecular sensor of painful stimuli. 
On the other hand, I aimed to reveal the scaffold of proteins interacting with the Transient 
Receptor Potential V1 (TRPV1) ion channel, a polymodal sensor of irritant chemicals and 
noxious heat.  
 
In order to elucidate the molecular underpinnings of chronic pain, several large-scale 
profiling studies have been performed. However, the generated lists of regulated candidate 
proteins are often inconsistent with scarce overlap. This could be explained by inherent 
technical limitations of used proteomics methods, such as low reproducibility. Emerging 
data-independent acquisition mass spectrometry (DIA-MS) has the potential to allow for 
standardized and reproducible quantification across many samples. Here, we applied DIA-
MS on DRG isolated from mice subjected to two mouse models of chronic pain to define 
global changes in the DRG proteome. More specifically, we compared the abundance of 
2,526 DRG proteins across the two pain models and their respective controls. Considerable 
and pain-model specific alterations in the abundance of several dozen proteins as well as 
within functional protein networks were detected. These were validated with several 
orthogonal methods.  Amongst others, the analysis of mouse pain behaviours verified that 
meaningful protein alterations both on the level of single proteins and signalling networks 
were revealed with our workflow.  
 
The involvement of TRPV1 in different chronic pain states has been well documented and 
together with its enriched expression in DRG renders TRPV1 a promising target for novel 
analgesics. However, several TRPV1 antagonists that reached clinical trials are challenged 
by severe side effects because of interference with physiological functions of TRPV1. An 
interesting alternative to TRPV1 blockage might be the targeting of such TRPV1 interaction 
partners that are specific for e.g. inflammatory pain. This strategy would provide a means to 
suppress pathological pain states whilst leaving nociceptive pain intact. However, very little 
is known about the protein scaffold of TRPV1 during different pain states. Here, I present 
the Vesicle transport through interaction with t-SNAREs homolog 1B (Vti1b) as a novel 
pain-specific interactor of TRPV1. Vti1b modulates TRPV1 sensitization within an 
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inflammatory milieu in vitro. Normal functioning of the TRPV1 is left intact. In vivo virus-
mediated knockdown of Vti1b diminished the development of thermal hypersensitivity upon 
CFA injection in mice. The knockdown does not affect CFA-evoked mechanical 
hypersensitivity or capsaicin-induced nocifensive behaviour. In a second step, a functional 
proteomics approach was employed to identify the TRPV1 interactome under CFA-induced 
inflammatory pain in mouse DRG neurons. Comparison of the interactomics data between 
the control and CFA group revealed a significant regulation of the TRPV1 interactome upon 
induction of inflammatory pain. For instance, Vti1b was found to be less abundant in TRPV1 
protein complexes upon inflammation. Overall, this study strongly supports the notion that 
protein-protein interactions specific for pathological pain exist. 
 
In summary, these two mass spectrometric studies represent a unique resource on (I) the 
differential expression of membrane proteins during pathological pain and (II) the dynamics 
of TRPV1 interactors during inflammatory pain. Acquired data may contribute to the 
characterization of the molecular mechanisms underlying pathological pain and may 
therefore facilitate the development of more effective therapeutic strategies. 
  





Pain is defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage” by the International 
Association for the Study of Pain (Merskey and Bogduk, 1994). It acts as a sensor for 
potentially harmful environmental stimuli. It informs about internal organ dysfunction, and 
is therefore crucial for the physical integrity of our body and, thus, our survival. Humans 
with rare congenital insensitivity to pain suffer from recurrent injuries and self-mutilation 
often followed by severe infections, since no protective behaviour is triggered (Cox et al., 
2006; Indo et al., 1996; Leipold et al., 2013).  
On the other hand, pain is the number one reason worldwide for seeking medical attention. 
If the pain persists long after the initial cause has been eliminated, and becomes chronic, it 
loses its evolutionary, protective aspect, and becomes a disease in its own right. Chronic pain 
is a highly debilitating condition and can profoundly affect quality of life. It is often 
associated with comorbidities such as depression and anxiety. The resulting loss of 
productivity together with the high cost of treatment turn chronic pain into a burden for 
society as a whole (Breivik et al., 2013; Dueñas et al., 2016). Chronic pain affects nearly 
20% of the adult European population and imposes substantial challenges to patients and 
physicians alike, as current options for pain treatment are limited (Breivik et al., 2006). A 
Europe-wide survey reported that pain management is inadequate in about 40% of affected 
people (Breivik et al., 2006).  
Currently available treatment options include nonsteroidal anti-inflammatory drugs, 
anticonvulsants, antidepressants and opioids (Turk et al., 2011). Yet, treatment remains a 
challenge, as the majority cause adverse side effects such as constipation, nausea and 
sedation, thus limiting their effectiveness (Kroenke et al., 2009). The main reason is that the 
exact molecular mechanism underlying different chronic pain syndromes are not known. 
Medication targets molecules ubiquitously expressed in the body and interferes with their 
key physiological functions. Thus, major efforts are being made to discover the molecular 
underpinnings of chronic pathological pain to allow for causative treatment. 
 
1.2 Nociception and pain – from the detection of noxious stimuli in the 
periphery to the sensation of pain  
Nociceptive pain is categorized as a submodality of somatosensation, which also comprises 
the important senses of proprioception, touch and thermosensation. 
The first step in the complex neural process that ultimately leaves us with the very subjective 
and emotional sensation we call pain, involves the activation of nociceptors. Nociceptors are 
a specialized subtype of primary afferent sensory neurons with the ability to encode external 
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noxious stimuli into electrical signals. They innervate the skin, blood vessels and internal 
organs, and are equipped with distinct receptor molecules which transduce potentially 
harmful stimuli into electrical signals. These are then transmitted via several relay stations 
to higher brain centres. The brain not only creates a conscious percept of pain but also 
initiates the appropriate protective behavioural and emotional responses. (Basbaum and 
Jessell, 2013) 
Three main classes of nociceptors can be distinguished dependent on the set of ion channels 
and receptors expressed: (I) thermal – excited by temperature extremes (for humans <~15°C 
and >~40-45°C), (ii) mechanical – activated by intense mechanical pressure and (iii) 
polymodal – excited by both mechanical, thermal and chemical noxious stimuli (Dubin and 
Patapoutian, 2010). There is also a fourth, rather enigmatic class, the “silent” nociceptors 
that start to respond to noxious thermal and mechanical stimulation only after sensitization 
by inflammatory processes accompanying tissue injury (Gold and Gebhart, 2010; Schmidt 
et al., 1995). Nociceptors can also be distinguished due to differences in the diameter of their 
fibres correlating with the conduction speed of action potentials. The so-called C-fibres, 
which comprise the major part of nociceptors, have thin, unmyelinated axons (diameter of 
0.2-1.5 μm) allowing conduction speeds of no more than 0.4-1.4 m/s. Aδ-fibres, on the other 
hand, are on average 2 to 5 μm in diameter, thinly myelinated with conduction velocities of 
5-30 m/s. Hitting our toes for example on a table-leg, we feel an initial, fast onset pain, 
usually sharp and well localized that has been linked to the Aδ-fibres. The “second” slow- 
onset pain, conveyed by C-fibres is described as dull, throbbing and diffusely located. In 
addition, the expression of certain neuro-peptides (see below), or transmembrane proteins as 
well as responsiveness to distinct growth factor are used as markers to classify this highly 
heterogeneous population of neurons.(Basbaum and Jessell, 2013) 
Nociceptors contain three main parts, a soma, a peripheral and a central process. The somata 
of nociceptive neurons are organized in peripheral sensory ganglia. Of these, the dorsal root 
ganglia (DRG) are lined up along the spinal cord (Fig. 1.1). Their neurons are mainly 
responsible for limb and trunk innervation; facial innervation is ensured by the trigeminal 
ganglia (TG). A subset of vagal afferent sensory neurons innervating the lung and 
oesophagus that are suggested to be nociceptors have their somata in the sympathetic nodose 
and jugular ganglia (Basbaum and Jessell, 2013; Kollarik et al., 2010). 
Nociceptors possess a pseudo-unipolar morphology, i.e. from their soma a single, short 
process emanates and bifurcates into a peripheral and central process. Near to the target 
organ the peripheral process branches out and terminates into free nerve endings. Terminals 
of the central axon synapse on second-order neurons in the dorsal horn (DH) of the spinal 
cord (SC; Fig. 1.1). 
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At the central synapse, the major excitatory neurotransmitter is glutamate; a subgroup of 
nociceptors also releases several neuro-peptides as co-transmitters (substance P (SP), 
calcitonin gene-related peptide (CGRP), somatostatin and galatin). The modulatory action 
of the co-transmitters on the firing properties of the DH neurons underlie synaptic plasticity, 
a basis for the sensitized processing of nociceptive input occurring under pathological pain 
conditions. (Basbaum et al., 2009) 
The afferent fibres project to distinct laminae of the unilateral dorsal horn; the C-fibres 
terminate on laminae I and II, whilst Aδ-fibres synapse on neurons in both the laminae I and 
V. Both projection neurons as well as excitatory and inhibitory local interneurons are 
Figure 1.1: Key stations along the ascending pain pathway 
Primary afferent sensory neurons detect noxious and innocuous chemical and physical stimuli in the periphery and encode 
them into electrical signals that are conveyed via several relay stations to the brain. The dorsal root ganglion (DRG) houses 
the somata of these pseudo-unipolar neurons that possess a peripherally and a centrally projecting process. Within the DRG 
several subtypes of primary afferent neurons can be distinguished: (I) small- to medium-diameter cells giving rise to C-
fibres and Aδ-fibres, respectively: mainly nociception and thermosensation; (II) large-diameter neurons with Aα/β-fibres: 
mainly touch and proprioception. The sensory information can be processed in local neuronal circuits in the first relay 
station, the dorsal horn of the spinal cord, before it is sent via the thalamus to higher brain areas where the percept of pain 
is finally created. Adapted from Bourinet et al., 2014. 
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targeted by the presynaptic terminals of the nociceptors. Fibres of the projection neurons 
give rise to five major ascending tracts in the antero-lateral system to convey the nociceptive 




IV. cervicothalamic and 
V. spinohypothalamic tract. 
The most important one is the spinothalamic tract carrying multi-modal sensory information 
to both lateral and medial nuclei of the thalamus. The sole electrical stimulation of this tract 
elicits the perception of pain. From the thalamus the nociceptive information gets distributed 
to different cortical areas. There is not one specific pain centre, but several structures 
processing multimodal information are targeted (Apkarian et al., 2005). For the sensory 
discriminative component of pain, the somatosensory cortex is responsible. Several other 
structures such as the insular cortex (limbic structures) and cingulate circuit are believed to 
mediate the emotional and aversive component of pain perception. Also, the fibres of the 
other minor tracts are thought to contribute to the affective component of pain. The 
spinomesencephalic tract terminates on the mesencephalic reticular formation as well as the 
periaqueductal gray (PAG) in the brainstem and parabrachial nuclei from where neurons 
project to the amygdala. Information carried along the spinohypothalamic tract is integrated 
in the hypothalamic nuclei eliciting neuroendocrine and cardiovascular responses. (Basbaum 
and Jessell, 2013) 
The percept of pain can be greatly influenced by the emotional state, past experiences, and 
attention. The most remarkable example is that of soldiers being severely wounded in 
combat but only report pain once they have left the battlefield (Beecher, 1946). Descending 
pathways arising from the brainstem (RVM and PAG) and higher brain areas (cingulofrontal 
regions, the amygdalae and the hypothalamus) can significantly modulate the processing of 
nociceptive input. Modulation can be either inhibitory or facilitative, and the transmitters 
involved are serotonin, monoamines and endogenous opioids. There is no anatomical 
distinction between paths that potentiate or inhibit the response of presynaptic and 
postsynaptic spinal pain transmission neurons. Even the same transmitter can have dual 
effects depending on the subtype of receptors it binds or the functionally distinct neurons it 
targets. (Millan, 2002)  
 
1.3 Sensitization of the nociceptor – paving the way for pathological 
pain 
The intricate interplay of the different structures along the pain pathway allows for a 
reasonable interpretation of the initial nociceptive insult in the context of previous 
experience and current bodily state which should result in the most appropriate action for 
survival. Yet, due to ongoing inflammation, injury and disease, pain can become 
maladaptive and remain long after the initial cause has disappeared. Pain and the 
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accompanying bodily reactions not only lose their usefulness in the sense of serving any 
protective function but also lead to great suffering for the patient. Despite intense research, 
the underlying pathophysiological changes underlying manifold chronic pain syndromes are 
not fully understood leaving poor treatment options. (Vardeh et al., 2016) 
Under physiological conditions, the nociceptor is tuned to respond only to high threshold 
stimuli that signal an impeding or actual threat to body integrity, and trigger the signal 
transmission cascade finally initiating withdrawal or any other appropriate reactions to avoid 
(further) damage. In case of tissue damage, the subsequent inflammation in the tissue causes 
the nociceptors to transiently adapt a heightened responsiveness. This is to limit further 
damage, aid wound healing and repair (inflammatory pain, e.g. heightened skin sensitivity 
to touch due to sunburn). Once the underlying cause or disease has healed, the 
hypersensitivity state and/or pain should subside. Yet, for mostly unknown reasons it 
becomes persistent in some cases. Thus, eventually, a disease manifests itself. (Costigan et 
al., 2009) 
This persistent pain manifests as 
I. hyperalgesia – exaggerated response to a noxious stimulus, 
II. allodynia – normally innocuous stimuli elicit pain and 
III. spontaneous pain – pain percept in the absent of any identifiable peripheral stimulus. 
These symptoms underlie a variety of clinical pain syndromes that can have different 
aetiologies. Apart from persistent inflammatory pain, we define neuropathic pain – any pain 
caused by injury or disease to the somatosensory system, and dysfunctional pain – 
amplification of nociceptive signalling in the absence of either inflammation or neural 
lesions. Whilst some neuropathic pain conditions are initiated and maintained at the CNS 
(such as pain resulting from thalamic stroke or spinal cord injury), many have started with 
an insult of peripheral nerve fibres. This can be mechanical injury, ongoing metabolic 
diseases (e.g. painful diabetic neuropathy), action of neurotoxic substances (e.g. 
chemotherapy-induced neuropathic pain), due to infections (e.g. post-herpetic neuralgia and 
HIV-associated neuropathy) and invasion of tumours. (Costigan et al., 2009) 
 
1.3.1 Peripheral sensitization – functional changes in nociceptors 
If there is tissue damage, the activated nociceptors, injured cells and resident and attracted 
immune cells release inflammatory mediators into the injured area. Several amines, kinins, 
growth factors, prostaglandins, chemokines, as well as ATP and protons constitute what is 
called the “inflammatory soup” and act in-/directly on nociceptors to sensitize them (Woolf 
and Ma, 2007). Some of these molecules, for instance, the cytokines tumour necrosis factor 
α (TNFα), interleukin-1β (IL-1β) and IL-6 (Ritner et al., 2009), seem to be mainly 
responsible for potentiating the inflammatory response itself. Others act via their respective 
receptor (mostly ligand-gated ion channels and G protein-coupled receptors (GPCR)) that 
are expressed by the nociceptors. They thereby activate intracellular signalling cascades with 
downstream mediators such as protein kinase C (PKC), PKA, phosphoinositide 3-kinase 
(PI3K) and MAP kinases ERK and p38. The targets of these kinases are amongst others the 
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ion channels that are essential for the transduction process at the nociceptive terminals as 
well as the ones generating action potentials and conveying central transmission. Their 
phosphorylation results mainly in the potentiation of their action either due to alteration in 
ion channel kinetics or in the increased trafficking of functional channels to the plasma 
membrane, thereby lowering the threshold of activation such that also innocuous stimuli 
excite nociceptors. Furthermore, previously silent nociceptors are activated by the 
inflammatory mediators and start to respond to stimuli. This increased processing of external 
stimuli manifest as hyperalgesia and allodynia. (Basbaum et al., 2009; Woolf and Ma, 2007)  
Chronic pain patients often report spontaneous pain. Spontaneous pain is thought to result 
from aberrant ectopic discharges in absence of a stimulus in the peripheral terminals (von 
Hehn et al., 2012). Injuries to the axonal part of the nociceptor trigger changes in expression, 
trafficking and clustering of certain types of voltage-gated sodium channels important for 
the generation and conduction of action potentials. This causes unstable oscillations of the 
membrane potential which gives rise to abnormal firing (Amir et al., 2002). Ectopic activity 
is not only generated in the injured fibres but also in the adjacent uninjured ones (Wu et al., 
2002). 
Heightened sensitivity and persistent activity of the peripheral nociceptor inevitably affects 
the second-order sensory neurons in the DH that undergo several phenotypic changes. 
Amongst others, alterations occur in the glutamatergic neurotransmission leading to increase 
in synaptic strength. This activity-dependent neuroplasticity further enhances processing of 
nociceptive signals (central sensitization; (Kuner, 2010)). 
 
1.4 TRP ion channels – polymodal signal integrators  
Every step of nociception – from the initial transduction of noxious stimuli to the generation 
and propagation of action potentials and the synaptic transmission in the SC – is mediated 
by a group of transmembrane proteins, namely ion channels (Waxman and Zamponi, 2014). 
Fig. 1.2 summarizes the key ion channels in the primary afferent nociceptive neuron. 
Collectively, they shape the activation characteristics of nociceptors. Any dysregulation in 
their expression due to injury or disease can cause an enhancement of neuronal excitability 
underlying chronic neuropathic and inflammatory pain (Delmas, 2008).   
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Figure 1.2: Key ion channels for nociception  
Located at the peripheral terminals (1) of primary afferent neurons, e.g. TRP ion channels transduce noxious 
stimuli of different modality into membrane depolarisations. Action potentials are initiated (1) and propagated 
(2) along the afferent fibres via activity of voltage-gated potassium and sodium channels. At the central 
terminals (3), voltage-gated calcium channels are activated by the incoming action potentials and cause 
neurotransmitter release at the synapse. Below the scheme, examples of the involved ion channel subgroups 
are mentioned. CaV, voltage-gated calcium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated 
channel; K2P, two-pore potassium channel; KCa, calcium-activated potassium channel; KNa, sodium-activated 
potassium channel; KV, voltage-gated potassium channel; NaV, voltage-activated sodium channel; TRP, 
transient receptor potential ion channel. Reprinted by permission from Springer Nature: Nature Neuroscience,  
Regulating excitability of peripheral afferents: emerging ion channel targets. Waxman and Zamponi, 2014. 
 
In the last decades, members of the Transient Receptor Potential (TRP) superfamily of ion 
channels have been discovered for the detection and transduction of a wide range of noxious 
or innocuous chemical and physical stimuli. Their name “transient receptor potential”, refers 
to the phenotype observed in the electroretinogram from mutant Drosophila melanogaster 
that, when exposed to intense prolonged light stimulus, exhibited a transient instead of the 
rather sustained wild type response (Minke, 2010). TRP channels are key players in a 
diversity of sensory systems, for instance, vision, thermosensation and osmoregulation. They 
allow animals to sense changes in the environment and therefore critically guide their 
behaviour. Not surprisingly, TRP-related channels are found to be conserved amongst 
invertebrates and vertebrates (Nilius and Flockerzi, 2014).   
So far 28 TRP genes have been found in mammals. Generally, they are non-selective cation 
permeable channels, with many of them showing a relatively high permeability for calcium. 
Their family togetherness is based mainly on sequence homology as both selectivity and 
activation modus varies a lot. They share a common structure of 6 transmembrane spanning 
domains with intracellular located N- and C- terminals; formation of tetramers is required 
for a functional channel. The cytosolic domains contain many sites for regulation by protein 
kinases, chaperones, and scaffolding proteins. Based on the degree of homology in their 
amino acid sequence the following subgroups have been defined: TRPC (Canonical, 
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TRPC1-7), TRPA (Ankyrin, only TRPA1), TRPM (Melastatin, TRPM1-8), TRPML 
(Mucolipin, TRPML1-3), TRPP (Polycystin, TRPP1-3), and TRPV (Vanilloid, TRPV1-6).  
(Nilius and Owsianik, 2011) 
It is remarkable with TRP channels that one single channel can be activated by a surprisingly 
broad range of both external and internal sensory stimuli which endows them to act as 
polymodal signal integrators of changes in the tissue and cellular environment (Clapham, 
2003). Given this important role as “cellular sensors” (Clapham, 2003) and their expression 
in several cell types in nearly every tissue, it is not surprising that mutations in TRP genes 
underlie a diversity of human diseases affecting the cardiovascular, renal, skeletal and 
nervous system (Kaneko and Szallasi, 2014).  
1.4.1 TRP channels – transducer of nociceptive stimuli 
Some members of the superfamily of TRP channels are tuned to detect noxious stimuli and 
are involved in pathological pain states. Among these are TRPV1-4, TRPM2, 3 & 8, TRPA1 
(Sousa-Valente et al., 2014) as well as TRPC1 & TRPC6 (Alessandri-Haber et al., 2009). 
Apart from TRPC1 & TRPC 6, they belong to the “thermoTRPs”, a subgroup of TRP 
channels that display an increase in open probability of the channel to a certain temperature 
range (Fig. 1.3).  
 
Figure 1.3: Thermosensitive TRP channel in sensory neurons 
ThermoTRPs comprise a subgroup of TRP channels that are activated by temperatures ranging from noxious cold to 
noxious heat. Non-thermal activators of each thermoTRPs are displayed at the top with many of them being known to 
induce thermal and pain sensations in humans. The distinct activation thresholds and maximal activation of these channels 
measured in heterologous expression systems are depicted below. Uncertainty of the slopes are indicated with dashed lines. 
Reprinted from Progress in Molecular Biology and Translational Science, 131, Mickle, Shepherd and Mohapatra, Sensory 
TRP channels: The key transducers of nociception and pain, 73-118, 2015, with permission from Elsevier. 
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Acting in the first line of stimulus detection and being sensitized under pathological pain 
conditions, render them – some more than others – prime targets for the development of 
novel analgesics. So far TRPV1 and TRPA1 – both showing an enriched expression in 
neurons of peripheral ganglia –  have attracted the most attention with respect to their role 
in pathological pain states (Sousa-Valente et al., 2014).  
TRPA1 is a key player in different types of pain (Nassini et al., 2014). The channel shows 
an enriched expression in nociceptive neurons and in DRG a high co-expression with TRPV1 
(Story et al., 2003). TRPA1 is activated by a wide range of heterogonous compounds that 
induce acute painful burning sensation like pungent natural compounds, e.g., mustard oil 
(MO), or environmental irritants. A variety of inflammatory mediators and by-products of 
oxidative and nitrative stress can either directly activate TRPA1 or sensitize the channel 
contributing to pain hypersensitivity in several animal models of pathological pain (Nassini 
et al., 2014). Trpa1-deficient mice display profound deficiencies in pain response to MO and 
formalin as well as exhibit attenuated mechanical allodynia upon inflammation (Bautista et 
al., 2006; da Costa et al., 2010; Kwan et al., 2006; McNamara et al., 2007). Also, in several 
rodent models of neuropathic pain, the genetic ablation and pharmacological inhibition of 
TRPA1 results in diminished cold and mechanical hyperalgesia, making it a prime target for 
the development of novel analgesics (Nassini et al., 2014). Moreover, a gain-of-function 
mutation in human TRPA1 is causative of Familial Episodic Pain Syndrome (FEPS). 
Individuals with FEPS suffer from episodic pain attacks mainly localized in the upper body 
and triggered by fatigue and fasting (Kremeyer et al., 2010). 
TRPV1, a sensor of noxious heat and a variety of irritable endo- and exogenous molecules 
as well as the focus of project II of this thesis, is going to be discussed in more detail below.  
1.5 TRPV1 – the capsaicin receptor  
The molecular identity of the “capsaicin receptor” was revealed in 1997 by expression 
cloning of the respective gene from a rodent sensory neuron cDNA library that was followed 
by measurement of calcium influx upon capsaicin and heat stimulation (Caterina et al., 
1997). Early on, TRPV1 caught the interest of pharmaceutical companies as a target for 
novel analgesics. Both the fact that inhibition of TRPV1 was shown to have therapeutic 
value in several animal pain models and its enriched expression in the DRG render TRPV1 
a promising target for the development of effective new analgesics with minimal adverse 
side effects. Yet, 20 years after its initial cloning, no TRPV1 antagonist has been approved 
by the FDA (U.S. Food & Drug Administration). The emergence of adverse side effects in 
(pre-)clinical trials of 1st generation TRPV1 antagonist (Gavva et al., 2008; Patapoutian et 
al., 2009; Rowbotham et al., 2011) impeded the initial enthusiasm for inhibiting TRPV1 for 
pain relief.  Some antagonists evoked hyperthermia, confirming the debated role of TRPV1 
in the maintenance of body temperature (Gavva et al., 2007). Others interfered with the 
function of TRPV1 as a sensor for noxious heat – reported elevated heat thresholds in study 
participants could lead to accidental burn injuries (Carnevale and Rohacs, 2016). A better 
strategy therefore would be to inhibit only the pathologically active TRPV1 (Fernández-
Carvajal et al., 2012). 
Introduction  | 10 
1.5.1 General features of TRPV1  
TRPV1, the founding member of the vanilloid subgroup of TRP channels, exhibits the same 
basic modular architecture as other TRP group members, i.e. 6 transmembrane domains (S1-
S6) with S5 and S6 being linked by a hydrophilic pore loop (Fig. 1.4). Both N- and C- termini 
are cytosolic. Four of the transmembrane modules assemble to form a functional channel 
with the S5-linker-S6 determining the ion pore as shown by high-resolution cryo-electron 
microscopy studies (Cao et al., 2013; Liao et al., 2013). Opening of the ion pore leads to an 
influx of mono- and bivalent cations (permeability PCa2+/PNa+ ~ 5) (Nilius and Flockerzi, 
2014). 
 
Figure 1.4: Structure and interaction sites of a TRPV1- subunit  
A functional TRPV1 ion channel consists of 4 of the displayed subunit. Each of the subunits comprises 6 transmembrane 
domains (TMD) with a pore loop between TMD 5 and 6, and intracellular N- and C-termini. The N-terminus contains 6 
ankyrin repeats (A). Examples of stimuli activating or modulating TRPV1 are displayed together with their interaction 
sites. Adapted from (Julius, 2013). 
 
In vivo, TRPV1 seems to predominantly form homo-tetramers.  Co-expressing TRPV1 in 
heterologous expression systems along with TRPV2 or TRPV3 leads to assembly of 
heteromers, yet, to a lesser degree than homo-tetramers (Hellwig et al., 2005; Smith et al., 
2002). One study suggested the formation of TRPV1-TRPV2 heteromers at a low level also 
in rat DRG (Rutter et al., 2005). Any physiological relevance of this heteromer formation 
however, might be minor in vivo given that TRPV1 and TRPV2 have been shown to be 
mostly expressed in non-overlapping populations of sensory neurons (Ahluwalia et al., 2002; 
Caterina et al., 1999). 
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1.5.2 Tissue expression of TRPV1  
TRPV1 is predominantly expressed in small- to medium-diameter neurons of the peripheral 
sensory and sympathetic ganglia giving rise to C-fibres, both the non-peptidergic and 
peptidergic (i.e. SP- and CGRP-expressing) population, and to lesser degree to Aδ-fibres 
(Cavanaugh et al., 2009; Helliwell et al., 1998; Tominaga et al., 1998; Yu et al., 2008).  
TRPV1 expression in the peripheral nervous system (PNS) was also reported in sensory 
nerve fibres innervating airways/lung (Kollarik and Undem, 2004) and in the urinary tract/ 
bladder (Avelino and Cruz, 2006). Non-neuronal tissues with TRPV1 expression are the 
epithelium of the gastrointestinal tract (Ward et al., 2003), the cardiovasculature (Peng and 
Li, 2010), and in the skin epidermis (Inoue et al., 2002). 
Apart from the PNS, TRPV1 is also expressed in the CNS albeit to a much lower extent. 
Amongst others, presynaptic TRPV1 in the DH of the SC has been reported to contribute to 
modulation of synaptic transmission in the laminae I, II under pathological pain conditions 
(Spicarova et al., 2014).  
A multitude of different methods with varying outcomes has been used to explore the 
expression of TRPV1 in the brain. In general, TRPV1 expression has been reported in 
diverse regions and nuclei, amongst others, the hypothalamus, thalamus, entorhinal cortex, 
and hippocampus, several parts of the rhombencephalon as well as mesencephalon 
(Cavanaugh et al., 2011; Cristino et al., 2006; Gibson et al., 2008; Musella et al., 2009; Tóth 
et al., 2005). Yet, the physiological function of TRPV1 in the different brain areas remains 
poorly understood (Kauer and Gibson, 2009). For instance, Marsch et al. proposed a role for 
TRPV1 in synaptic plasticity in the hippocampus (Marsch et al., 2007). Trpv1-deficient mice 
exhibited reduced sensitized and conditioned fear as well as anxiety and ex vivo, a decrease 
in long-term potentiation in a hippocampal circuit important for learning and memory was 
observed (Marsch et al., 2007).  
1.5.3 Agonists of TRPV1  
TRPV1 was the first TRP channel identified to be intrinsically heat-sensitive (under 
physiological conditions >42°C, (Tominaga et al., 1998)). In addition, TRPV1 is responsive 
to a wide range of exo- and endogenous ligands – mostly irritant chemicals and endogenous 
allogenic molecules. Besides capsaicin, also other irritant natural compounds, for instance, 
piperine (black pepper), allicin (garlic), camphor, gingerol (ginger) and eugenol (clove oil) 
can activate TRPV1. Also, toxins from plant (resiniferatoxin), spiders, snakes, and jelly fish 
are amongst the agonists of TRPV1 (Julius, 2013). 
Many of the endogenous activators are derivatives of arachidonic acid that are synthesized 
by the body under inflammatory conditions and injury. Examples are prostaglandins, 
leukotriens and endocannaboids such as anadamide or N-arachidonoyldopamine (Vriens et 
al., 2009). Local tissue acidosis, as seen under inflammation, ischemia and tumour growth 
can in extreme cases activate TRPV1 (pH<6.0) and under more moderate conditions (pH 
6.5) enhance sensitivity to heat and other agonists. This dual effect was found to be mediated 
by protons interacting with different extracellular residues of TRPV1 (Jordt et al., 2000; Ryu 
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et al., 2007). The proton-mediated sensitization leads to a shift in the heat threshold of 
TRPV1 to body temperature (Julius, 2013). 
While the application of capsaicin is known to evoke pain in humans, topical application of 
low concentration capsaicin creams is well-established as an analgesic. Recently, 
QUTENZA™ (Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., 
Chertsey, Surrey, UK), a cutaneous patch with 8% capsaicin has been approved by the FDA 
for the treatment of peripheral neuropathic pain other than diabetic origin, e.g. post-herpetic 
neuralgia and HIV neuropathy. Local application of a high dose of capsaicin is suggested to 
lead to a degeneration of TRPV1-expressing intra-epidermal nerve fibres due to excessive 
activation of TRPV1. Studies in healthy volunteers showed that the die-back of the fibres is 
reversible.  Unwanted side effects are minor and mainly related to the application of the 
capsaicin to the skin. (Uçeyler and Sommer, 2014)  
Thus, QUTENZA™ is a promising example for the effectiveness of targeting peripheral 
expressed TRPV1 for treatment of neuropathic pain. 
 
1.5.4 Modulation of TRPV1 function and surface expression 
1.5.4.1 Sensitization of TRPV1  
Within the plethora of pro-algesic mediators released upon tissue damage and subsequent 
inflammation, many are able to modulate TRPV1 function, which underlies enhanced 
nociceptor excitability and ultimately contributes to hyperalgesia. Many of the inflammatory 
mediators modulate TRPV1 indirectly via stimulation of their own receptors expressed by 
the nociceptor and act on the channel via activation of second messenger cascades. This 
often results in the phosphorylation of TRPV1 with alterations either in the open probability 
(i.e. the activation threshold) of the channel or translocation of the channel to the plasma 
membrane. (Julius, 2013) 
For instance, the inflammatory mediator bradykinin (Bk) is critical to TRPV1 sensitization 
under inflammatory conditions. If injected intradermally it elicits profound thermal 
hypersensitivity, which is impaired in Trpv1-KO mice (Chuang et al., 2001). Bk binds to its 
Gq-coupled Bk1 receptor causing ultimately an activation of PKCε, which in turn 
phosphorylates TRPV1 at serine 502/800 (Bhave et al., 2003). Also, prostaglandin E2 
(PGE2)-binding to its Gs-coupled EP4 receptor leads to a phosphorylation of TRPV1 in this 
case by PKA at serine 116 (Mohapatra and Nau, 2003). Phosphorylation mediated by the 
PKC are thought to mainly result in an increase of the open probability of the channel at 
standard membrane potentials (Bhave et al., 2003; Matta and Ahern, 2007; Numazaki et al., 
2002; Vellani et al., 2001). In a recent study by Mathivanan et al., however, bradykinin was 
also found to increase the surface trafficking of TRPV1 (Mathivanan et al., 2016). 
Sensitization mediated by PKA are rather thought to reverse the desensitization state of the 
channel ((Bhave et al., 2002), see below). 
Moreover, phosphorylation by kinases acting downstream of the NGF receptor TrkA results 
in increased translocation of the TRPV1 to the plasma membrane (Stein et al., 2006; Zhang 
et al., 2005).  How exactly phosphorylation of TRPV1 promotes trafficking to the plasma-
membrane remains elusive. The interaction of TRPV1 with other proteins, for instance, the 
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GABAA receptor associated protein (Laínez et al., 2010) as well as several SNARE-proteins 
(Camprubí-Robles et al., 2009; Morenilla-Palao et al., 2004) has been shown to regulate 
TRPV1 surface-expression.  
1.5.4.2 Desensitization of TRPV1  
An interesting feature of TRPV1 is its desensitization, a reduction in channel activity, which 
occurs during prolonged or repetitive stimulation of the channel with capsaicin or other 
agonists and might underlie the paradoxical analgesic properties of capsaicin application. 
The increase in intracellular free calcium upon channel activation has been reported to 
trigger this (mostly) reversible channel inactivation preventing a cytotoxic calcium overload 
of the nociceptor (Koplas P. A. et al., 1997). Yet, it should be noted that upon removal of 
extracellular calcium in patch clamp experiments, the channel desensitization is not 
completely abolished (Koplas P. A. et al., 1997; Mohapatra and Nau, 2003). 
Several mechanisms have been proposed for the calcium-mediated desensitization. One is 
that the incoming calcium binds to calmodulin (CaM), which then activates the Ca2+/CaM-
dependent phosphatase calcineurin (Docherty et al., 1996). Calcineurin in turn 
dephosphorylates TRPV1 (Mohapatra and Nau, 2005). This is underscored by studies 
showing that the calcium-dependent desensitization can be reduced/reversed by PKA- and 
PKC-mediated phosphorylation of several sites (Bhave et al., 2002; Mandadi et al., 2004, 
2006; Mohapatra and Nau, 2003; Numazaki et al., 2002) . On the other hand, Ca2+/CaM was 
shown to interact with the ankyrin-repeats of the N-term of TRPV1 to trigger desensitization 
(Lishko et al., 2007; Rosenbaum et al., 2004). Also, the calcium-mediated depletion of 
phosphoinositides has been reported to contribute to the inhibition of channel activity after 
capsaicin stimulation (Liu, 2005; Lukacs et al., 2013). 
The long-term desensitization of TRPV1-expressing nociceptors has been suggested to be 
accompanied by alteration in the level of plasma membrane-resident TRPV1: Sanz-Salvador 
et al. reported a rapidly induced endocytosis of TRPV1 in a time- and dose-dependent matter 
with subsequent degradation in lysosomes (Sanz-Salvador et al., 2012). 
1.5.5 Involvement of TRPV1 in pain conditions 
Early reports on the pain-inducing properties of capsaicin application in rodents and humans 
and the seemingly paradoxical analgesic effect of prolonged capsaicin exposure (e.g. 
(Carpenter and Lynn, 1981)) supported a potential role for the capsaicin receptor in pain 
signalling in vivo long before its molecular identification.  
Whilst capsaicin-induced nocifensive behaviour was abolished in Trpv1-KO mice, they did 
not show profound deficits in noxious heat-evoked nociceptive behaviour suggesting further 
molecules to be involved in the detection of heat in vivo (Caterina et al., 2000; Davis et al., 
2000). However, the development of thermal hyperalgesia after inducing inflammatory pain 
was greatly impaired in Trpv1-KO mice. This is the case for both acute thermal 
hypersensitivity after hind paw injection of bradykinin (Chuang et al., 2001) as well as 
complex inflammatory pain paradigms induced by Complete Freund’s Adjuvant (CFA) or 
carrageen injection (Caterina et al., 2000; Davis et al., 2000). In skin, sciatic nerve, DRG 
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and SC TRPV1 protein and/or mRNA was found to be upregulated upon inflammation 
(Amaya et al., 2003; Carlton and Coggeshall, 2001; Ji et al., 2002; Tohda et al., 2001).  
Whilst in the case of the global knockout of Trpv1 only thermal hyperalgesia was attenuated, 
the systemic administration of TRPV1 antagonists not only attenuated thermal but also 
mechanical hyperalgesia in the CFA model of inflammatory pain, which could be explained 
by developmental compensation in the global Trpv1-KO (Gavva et al., 2005; Kanai et al., 
2007; Pomonis et al., 2003; Walker et al., 2003).  
The role of TRPV1 in a wide range of neuropathic pain models – from painful diabetic 
neuropathy to nerve transection/ligation models – has been investigated intensively. 
However, its contribution to neuropathic pain is less well understood than in painful 
conditions linked to inflammation (Mickle et al., 2016). Several studies reported alterations 
in the expression profile of TRPV1 in DRG neurons. Interestingly, most report an overall 
downregulation of TRPV1 in the DRG after nerve injury (Hudson et al., 2001; Schäfers et 
al., 2003). However, when distinguishing between damaged and non-damaged neurons, 
TRPV1 was found to be upregulated in the uninjured nerve fibres/neurons and 
downregulated in the injured ones (Fukuoka et al., 2002; Hudson et al., 2001; Kim et al., 
2008). Consequently, RNAi-mediated knockdown as well as antagonists of TRPV1 
diminished stimulus-evoked pain hypersensitivity in models for the partial ligation and 
injury of the sciatic nerve (Christoph et al., 2006, 2008; Kanai et al., 2005; Pomonis et al., 
2003). 
 
1.6 Targeting protein-protein interactions for pain relief 
As exemplified with the occurrence of adverse side effects when blocking TRPV1 activity 
for pain relief, the direct targeting of nociceptive ion channels, and TRPV1 in particular, 
may not be the ideal starting point for developing novel analgesics. Therefore, researchers 
look for alternative strategies to inhibit only the pathophysiological hyperactivity of the ion 
channel. One alternative is to look for state-dependent antagonists, yet, another promising 
one might be instead of targeting TRPV1 directly, to prevent crucial TRPV1 interactions 
that only take place under pathological pain conditions. (Fernández-Carvajal et al., 2012)  
Proteins fulfil their diverse function in a cell not as “lone warriors”. They assemble into 
multiprotein complexes – known as “protein machines” (Alberts, 1998) –  enabling them to 
fulfil critical tasks, for instance, transmembrane signal transduction. Only the dynamic 
interactions between the involved proteins ensure the correct activity and specificity of the 
complexes. However, protein-protein interactions (PPIs) could occur at a wrong time and 
duration, or location, or due to a loss of an interactor not take place at all (Zinzalla and 
Thurston, 2009). Aberrant PPIs have been discovered to be the molecular basis of many 
diseases, for instance, neurodegenerative diseases (Ryan and Matthews, 2005). 
Targeting disease-specific PPIs, without interfering with other functions of the involved 
proteins, has great potential to yield highly selective drugs. The high tissue selectivity and 
modifying cellular function only in a subtle way should allow for minimal side effects 
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(Blazer and Neubig, 2009). This would be highly desirable for chronic pain therapeutics as 
the currently available treatment options are only effective for a minority of cases, and are 
accompanied by severe side effects limiting the use of an effective dosage.  
Receptors and ion channels have a unique position at the very beginning of the transmission 
of pain messages. Since they show dysregulated expression and alterations in their intrinsic 
channel properties during pathological pain states, interfering with the responsible PPIs may 
offer an attractive strategy for developing novel analgesics. The interference could be both 
stabilizing in case of analgesic PPIs, or if a PPI promotes the excessive activation of a 
nociceptive ion channel, the PPI would be prevented. In recent years, the modulation of PPIs 
for several ion channels/receptors involved in pain signalling has been shown to alter pain 
perception in rodents. (Rouwette et al., 2015) 
For instance, a seminal study by Liu and colleagues showed that uncoupling the Scr kinase 
from the NMDA receptor complex led to analgesia in both models of inflammatory and 
neuropathic pain (Liu 2008). Activity of NMDA receptors underlies neuroplasticity and is 
key to pain hypersensitivity, yet, blocking these channel for pain relief is deleterious  as they 
fulfil important physiological functions in the CNS (Lynch and Watson, 2006). The Src 
kinase is known to enhance NMDA function via phosphorylation and is anchored within the 
NMDA receptor complex (Salter and Kalia, 2004). Liu et al. designed a peptide mimicking 
the binding interface of Scr and its adaptor protein within the NMDA complex to disrupt the 
interaction in vivo. Intrathecal and intravenous administration of the cell-permeable peptide 
attenuated pain behaviours in rodents, not only in models for inflammatory pain, but also in 
peripheral nerve injury. Remarkably, uncoupling the interaction did not affect cognitive 
functions, locomotion or basal pain thresholds (Liu et al., 2008). This study highlights the 
potential of targeting ion channel complexes to achieve analgesia with minimized side 
effects.  
Also, TRPV1 (mal)functioning is critically shaped by PPIs. In the following, a few examples 
for interactions whose relevance has been shown for TRPV1-mediated nociceptive 
signalling in vivo are given.   
1.6.1 AKAP79/150 
AKAP79/150, a member of the A-Kinase anchoring protein family (AKAP), is a scaffolding 
protein with binding sites for TRPV1 as well as the kinases PKC and PKA that are activated 
downstream of cellular signalling cascades initiated by the inflammatory mediators Bk and 
PGE2 and ultimately sensitize TRPV1 (Btesh et al., 2013; Jeske et al., 2008, 2009). 
Preventing the binding of either the kinases or TRPV1 to AKAP79/150 has been shown to 
abolish the sensitization of TRPV1 by Bk and/or PGE2 not only in vitro but also in vivo: 
Schnitzler et al. reported reduced PGE2-induced thermal hyperalgesia in genetically-
modified mice missing the PKA binding-site of AKAP79/150 compared to wild type mice 
(Schnizler et al., 2008). Subsequently, Fisher and colleagues used a peptide mimicking the 
binding site of TRPV1 and AKAP79/150 to uncouple their interaction in vivo and could 
thereby reduce thermal hypersensitivity in two inflammatory pain models. Notably, basal 
pain thresholds in the absence of inflammation were unchanged (Fischer et al., 2013). 
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1.6.2 GABAB1 receptor 
Recently, Hanack et al. reported the physical and functional interaction of TRPV1 and the 
GABAB1 receptor subunit that counteracts the hyperactivity of TRPV1 under pathological 
pain conditions, yet does not interfere with acute TRPV1-mediated pain (Hanack et al., 
2015): The authors could show that an autocrine feedback mechanism exists in which the 
neurotransmitter GABA is released from peripheral nociceptive terminals upon activation of 
TRPV1 and stimulates the GABAB1 subunit triggering a non-canonical signalling pathway 
that in the end reverts TRPV1 sensitization. A robust decrease in heat hyperalgesia was 
observed in several inflammatory pain paradigms in mice treated with the GABAB agonist 
baclofen.  The administration of baclofen did not affect acute capsaicin-evoked nocifensive 
behaviour or the basal thermal pain threshold. (Hanack et al., 2015)  
This shows that the activation of GABAB1 modulates selectively the excessive TRPV1 
activity occurring under pathological conditions and consequently, offers an interesting 
mechanism to interfere with TRPV1-mediated hypersensitivity. 
 
1.6.3 TMEM100/TRPA1 
A subgroup of TRPV1-expressing nociceptors co-expresses the TRPA1 channel (Bautista et 
al., 2005; Story et al., 2003) and several studies have suggested a physical and/or functional 
interaction of both channels (Akopian et al., 2007; Salas et al., 2009; Staruschenko et al., 
2010). TMEM100, a membrane adaptor protein has been shown to be able to bind both 
channels and thereby regulate the association of TRPA1 and TRPV1 (Weng et al., 2015): 
The genetic ablation of Tmem100 in mice led to a reduction in TRPA1-mediated but not 
TRPV1-mediated acute pain model as well as to attenuated mechanical hyperalgesia upon 
inflammation – for whose development TRPA1 is thought to be more relevant than TRPV1. 
Mechanistically, TMEM100 selectively potentiates the activity of TRPA1 by relieving it 
from the inhibitory effect TRPV1 has been proposed to exert on TRPA1. Strikingly, a mutant 
of TMEM, TMEM100-3Q, was shown to exert the opposite effect, i.e. stabilizing the 
TRPV1-TRPA1 complex and therefore, decreased TRPA1 activity in a TRPV1-dependent 
manner. Injection of a cell-permeable mimicking peptide of the mutant form led to a 
reduction in TRPA1-mediated nocifensive behaviour and hypersensitivity in wild type mice, 
but not in Trpv1-deficient mice. Additionally, in TRPV1-mediated pain paradigms no 
attenuation was observed in treatment with the mimicking peptide showing that the analgesic 
effect is selective for TRPA1 and depends on TRPV1. (Weng et al., 2015) 
The above stated interactions and their successful manipulation for pain relief, demonstrate 
that fine-tuning of pain-specific interaction might offer a better strategy for interfering with 
chronic pain than completely suppressing the activity of certain key players in pain 
signalling. But how to detect pain-specific interactions most efficiently with a low false 
positive rate? In the last few years, the method of choice for detecting PPIs has become 
“functional proteomics” (Schulte et al., 2011), which is the combination of affinity-based 
co-purification of the target protein (“bait”) and associated proteins (“preys”) from native 
tissue and tandem mass spectrometry for the identification of the co-purified interactors.  
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1.7 Mass spectrometry as a tool for the identification of pain-related 
proteins and protein complexes 
The quest for potentially “druggable” key player in chronic pain is dependent on the 
identification of proteins that show a clear regulation between the physiological and 
pathophysiological state (Antunes-Martins et al., 2013). Several large-scale gene expression 
profiling studies have been conducted of nociceptors and of animal models of pathological 
pain, and gave insight into significant pain-related changes of the transcriptome (Alvarado 
et al., 2013; Lacroix-Fralish et al., 2011; Manteniotis et al., 2013; Usoskin et al., 2015). 
However, the changes on mRNA level are not translated 1:1 to the protein level but are 
estimated to account for only 40% of the variability in protein levels (Schwanhäusser et al., 
2011). Therefore, direct exploration of the proteome might be better suited to capture 
disease-related changes of the proteome and discover key players in pathological pain. 
Liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) is an analytical 
technique that allows large-scale identification of proteins in complex native biological 
samples (Aebersold and Mann, 2003), and has proven its ability to elucidate protein 
complexes and signalling pathways crucial for different cellular functions as well as 
pathological processes (Choudhary and Mann, 2010; Riley et al., 2016). Most commonly, 
so called “shotgun” mass spectrometry is used for large-scale proteomics studies. In Fig. 
1.5, an outline of a classical “shotgun”/discovery-based tandem MS experiment is given: 
 
Figure 1.5: Outline of the different steps of a typical proteomics experiment 
Adapted by permission from Springer Nature: Nature, Mass spectrometry-based proteomics. Aebersold and 
Mann, 2003. 
 
The proteins to be identified are isolated from the tissue or cell types of interest – both crude 
cell lysate or less complex samples such as enriched subfractions of certain cellular 
components or proteins can be subjected to MS (1). Endoproteases, most commonly trypsin, 
digest the proteins in the sample into shorter peptides (2) that are then separated by LC to 
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regulate the flow of peptides into the on-line coupled mass spectrometer. Before entering the 
mass spectrometer, the peptides become ionized and evaporated by electrospray ionization 
(ESI; 3). In the first stage of mass analysis, a mass spectrum (MS1; the mass analyser 
acquires the mass to charge ratio (m/z) of the peptides) is acquired from the peptides ions 
entering the mass analyser at a given point in time. Subsequently, the computer generates a 
list of peptides that are then isolated and fragmented; commonly the fragmentation is induced 
by collision with inert gas molecules. From the fragment ions another mass spectrum (MS2) 
is captured. In a final step, the peptides and consequently the proteins contained in the sample 
are identified by matching the acquired spectra with protein sequence databases.    
(Aebersold and Mann, 2003) 
Shotgun proteomics has also been applied to several pain models of chronic pain, as well as 
tissue samples from human chronic pain patients to identify candidate proteins for chronic 
pain conditions (Huang et al., 2008b; Melemedjian et al., 2013; Niederberger and 
Geisslinger, 2008; Vacca et al., 2014; Zou et al., 2012). However, the lists of proteins 
regulated only show sparse overlap (Gomez-Varela and Schmidt, 2016). On the one hand, 
this could be attributed to differences in sample preparations. On the other hand, in most of 
the mentioned studies the mass spectra were acquired in the data-dependent acquisition 
(DDA) mode, which is common in shotgun proteomics. This acquisition technique however, 
comes along with some inherent technical constraints (Law and Lim, 2013): In DDA, after 
acquisition of a MS1 survey scan, only a limited number of the peptide ions (precursor ions) 
are selected for the fragmentation and the subsequent serial fragment ion scans (which are 
necessary for the identification and quantification). The selection is done in real-time by the 
mass spectrometer with a preference for the most abundant precursor ions of each MS1 scan. 
Furthermore, the number of selected precursor ions is restricted by the instrument’s cycling 
time, which determines the number of possible MS2 scans. Thus, as long as the number of 
detected precursor ions exceeds the number of available MS2 scan cycles, the set of peptides 
identified across different samples of an experiment is not reproducible (Domon and 
Aebersold, 2010). Tabb et al. reported that the overlap between technical replicates of an 
average LC-MS/MS experiment ranges from 35-60% (Tabb et al., 2010). Also 
“undersampling” can become problematic in an average DDA-MS experiment given that the 
fraction of all peptides being identified in a given sample can be as low as 10-20% (Michalski 
et al., 2011). Therefore, the semi-stochastic nature of DDA peptide sampling limits its use 
for the exact and reproducible quantification of 1000s of proteins across many highly 
complex samples such as tissue lysates (Law and Lim, 2013). 
In recent years, researchers have developed methods to overcome the limitations of DDA. 
They are based on an unbiased “data independent acquisition” (DIA).  In DIA-MS cyclic 
scans are performed throughout the LC run after each survey scan. The parallel 
fragmentation of all detectable precursor ions within sequential isolation windows ranging 
from a few m/z to the entire mass range is triggered. Dependent on the number of chosen 
isolations windows a respective number of MS2 spectra are collected after each survey scan. 
(Law and Lim, 2013) 
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For each of the scans both the acquired MS2 spectra (m/z vs. intensity) and also the retention 
time are collected and stored in digital data maps. The spectra are highly complex as a single 
spectrum comprises all the fragment ions of several precursors ions fragmented in parallel. 
This chimeric nature of the spectra makes it difficult to use the traditional database search 
approach for the identification of the peptides. In one implementation of DIA, SWATH-MS 
(Sequential Windowed Acquisition of All THeoretical fragment ion mass spectra; (Gillet et 
al., 2012)), this problem is circumvented by the use of sample-specific spectral libraries. 
These reference libraries are compiled from previously acquired and analysed MS2 spectra 
from several highly optimized DDA runs of the sample of interest. They contain the fragment 
ion signals, their relative intensities and their chromatographic behaviour, all information 
needed to uniquely identify and quantify a peptide (Schubert et al., 2015). Accordingly, the 
unknown peptides signatures stored in the data maps can then be identified by looking for 
the best match in the library. The targeted search of spectral libraries allows the standardized 
and accurate quantification of a large number of proteins across many samples and 
laboratories (Collins et al., 2017). Furthermore, the availability of spectral libraries from a 
multitude of different large-scale experiments is ever increasing and offers the possibility to 
re-query the digitally-stored peptide signatures with any spectral library of interest to test 
new hypotheses in silico (Law and Lim, 2013). 
DIA-MS has already been successfully applied to determine how protein abundances, 
modifications and interactions change across disease states (Bruderer et al., 2015; Lambert 
et al., 2013; Liu et al., 2014; Surinova et al., 2015) and therefore holds the promise to be of 
use in deciphering pain-related changes of the proteome. 
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1.8 Aims of the study 
Chronic pain imposes substantial challenges to medical practice as the treatment options for 
its clinically relevant manifestations are limited. Owing to lack of knowledge about the exact 
molecular mechanism underlying pathological pain conditions, currently available pain 
therapeutics target molecules with key physiological functions in our body. Thus, they are 
accompanied by severe side effects limiting effective dosage prescription. In the light of 
these difficulties, identification of proteins and their associated complexes that exert their 
function in the first line of noxious stimulus detection, and are differentially regulated among 
pain states, is highly desirable to develop better analgesics. The goal of this study was to 
identify and characterize multiprotein complexes in the context of nociception in mice. To 
this end, the study was divided into two major lines of research: 
(I) Characterization of the differential regulation of membrane proteins in sensory 
neurons in different models of chronic pain, using emerging DIA-MS to allow for 
standardized and reproducible quantitation of the DRG membrane proteome. Given 
the essential function of membrane proteins, especially ion channels and receptors, 
in nociceptive signalling, defining their differential regulation is key for 
understanding nociception in general and related pathophysiological processes like 
chronic pain. 
(II) Investigation of the scaffold of proteins interacting with the ion channel TRPV1 
under inflammatory pain. TRPV1 channels serve as one of the major noxious 
stimulus detectors in sensory neurons and are crucial for the development of several 
pain modalities, rendering TRPV1 a promising target for novel analgesics.  Despite 
intensive study of TRPV1, little is known about proteins interacting with TRPV1 
selectively under pathological pain conditions.  
 
1.9 Contribution of co-workers to this study 
- Dr. Roland Bruderer (Biognosys AG, Zuerich, Switzerland): DIA-MS acquisition 
and quantitative data analysis including statistics for project I (see section 2.1.7.1). 
- Dr. Olaf Jahn (Proteomics group, MPIem): MS acquisition and first steps of the 
quantitative analysis (see section 2.1.7.2) for project II. 
- Dr. Sebastian Kuegler (UMG, Göttingen) produced the virus particles for project II. 
- The Master students Reham Abdelaziz and Allison Barry (both IMPRS 
Neurosciences) performed some experiments for the project II under the author’s 
teaching and supervision. These have been reported in their Master theses. 
- Niklas Michel (Ph.D. student in my host lab) performed the electrophysiological 
recordings. 
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2 Material and Methods 
2.1 Methodology 
Methods sections marked with * have been used for part I and are based on Rouwette et 
al., 2016. Parts marked with # have been used for part II and most of the sections are based 
on Sondermann et al., 2019. 
2.1.1 Animals  
Male adult C57Bl/6J mice, 6-8 weeks old at the time of injection or surgery, were used for 
all experiments.* 
Adult C57Bl/6J mice, 8-10 weeks old at the time of treatment, were used (in the following 
referred to as wild type (WT) mice). In addition, Trpv1-knockout (KO) B6.129X1-
Trpv1tm1Jul/J (Stock# 003770, The Jackson Laboratory) and Vti1b knockout ((Atlashkin et 
al., 2003), kind gift from G. Fischer von Mollard, Bielefeld, Germany) mice, 8-10 weeks old 
at the time of treatment were used. Except for the behavioural testing of Vti1b knockout 
mice, only male mice were used for experiments. # 
All mice were in-house bred and kept in a humidity- and temperature-controlled 
environment under a 12 h light/dark cycle. They had access to food and water ad libitum. 
All animal experiments were approved by and carried out in compliance with institutional 
guidelines as well as the guidelines of the Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit of Lower Saxony, Germany.*#  
 
2.1.2 Biochemistry  
2.1.2.1 Preparation of membrane-enriched fractions of lumbar DRG * 
The protocol used for preparation of membrane-enriched fractions was modified from (Lu 
et al., 2009). All buffers were prepared at the day of the experiment. 
Snap-frozen ipsilateral lumbar DRG (lDRG) of 10-13 mice per condition were homogenized 
with help of a teflon glass douncer in a buffer with a high salt concentration (2 M NaCl, 10 
mM Tris/HCl, pH 7.5, 1× cOmplete protease inhibitor cocktail). For removal of cell debri, 
homogenates were centrifuged at 600×g for 10 min at 4°C. Supernatants were spun down at 
16,000×g for 15 min at 4°C, and the pellets re-suspended in 100 µL carbonate buffer 
(0.1 mM Na2CO3, pH 11.3). The samples were again centrifugated at 16,000×g for 15 min 
at 4°C. This step was repeated once. Subsequently, pellets were dissolved in 100 µL of 1% 
RapiGest in ammonium bicarbonate buffer (50 mM (NH4)HCO3, pH 8.5) and incubated 
overnight at 4°C, for solubilisation of membrane proteins. Samples were then pelleted at 
16,000×g for 15 min at 4°C with the supernatant equalling the membrane-enriched fraction. 
For precipitation of proteins, 5× the sample volume of ice-cold acetone was added to the 
supernatants and samples were precipitated for 2 h at -20°C, and precipitates pelleted at 
14,000×g for 30 min at room temperature (RT). Pellets were rinsed with pre-chilled 80% 
ethanol and again centrifuged at 14,000×g for 30 min, RT. Supernatants were discarded, and 
pellets air-dried. For the in-solution digest, 10 µL of 1% RapiGest in ammonium bicarbonate 
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buffer (ABC buffer) were added followed by 10 µL of 50 mM dithiothreitol (DTT) in 25 
mM ABC buffer, and samples were reduced at 850 rpm for 1 h at 56°C on a thermoshaker 
(Eppendorf). Next, 10 µL of 100 mM iodoacetamide in 25 mM ABC buffer were added and 
samples were alkylated at 850 rpm for 1 h at 37°C. To reach an enzyme to protein ratio of 
1:20, 70 µl of trypsin (Promega) solution in 25 mM ABC buffer were added and samples 
were digested overnight at 37°C. Subsequently, samples were acidified with 20 µL of 5 % 
trifluoroacetic acid, incubated for 2 h at 37°C, and spun down at 16000×g for 30 min. After 
lyophilisation of supernatants, samples were stored at -20°C until further use. The in-solution 
digest was performed by Monika Raabe, MPIbpc. 
In total 3 biological replicates were done for each experimental group, yielding in total 12 
samples that were submitted to MS (see section 2.1.7.1) 
2.1.2.2 Co-immunoprecipitation (CoIP) of TRPV1 # 
Ipsilateral lDRG of CFA- and Vehicle-injected WT mice (10 mice per biological replicate) 
and bilateral LDRG from Trpv1-KO mice (5 mice per biological replicate) were freshly 
dissected. In total 9 samples (3 biological replicates) were submitted to MS (see section 
2.1.7.2). 
All steps of this protocol were performed on ice or at 4°C with pre-chilled reagents and all 
incubation steps under constant agitation (on a tube rotator). All buffers were prepared 
freshly before use. Homogenization of tissue was done with help of a glass teflon dounce 
homogenizer in 500 µL/sample solubilisation buffer (SB; 0.1 M NaCl, 0.05 M Tris-HCl, 
0.32 M sucrose, 1 mM DTT, 1% n-Dodecyl β-D-maltoside, 1× complete protease inhibitor 
cocktail) and subsequent shearing was done 5× with a 20G needle and 10× with a 25G 
needle. The tissue homogenate was solubilized for 1 hour and cell debris was removed by 
centrifugation at 2,500×g for 10 min. Tissue lysates were “precleaned” by incubating with 
50 µL prewashed magnetic Dynabeads Protein G for 1 h in order to decrease the unspecific 
binding to the affinity matrix (Dynabeads Protein G+IgG). Twelve micrograms of the 
respective antibody (see Table 2-2 for antibodies) were incubated for 4 h. followed by 
addition of 50 µL prewashed Dynabeads Protein G. After overnight incubation the samples 
were rinsed once with SB and then eluted in 40 µL of 1× Tris-Glycine/SDS Sample Buffer 
+1 mM DTT at 70°C for 10 min with careful mixing every 2 min.  
In case of CoIPs from transfected HEK cells that were not submitted to MS analysis, but 
were analysed by immunoblot, all steps of the CoIP were done as described above, but with 
the following additional steps:  
Transfection and harvesting of HEK293 cells: Cells were seeded on 10 cm dishes (5-7 per 
condition), and 24 h later they were transfected with TRPV1-YFP and/or Vti1b-myc-
DDK/pCMV-Sport6 plasmid (see Table 2-3 for details on plasmids). Per dish 1 mL of 
transfection mix was added (1 mL OPTI-MEM, 12 µL FuGENE HD, x µg plasmid). Four 
micrograms of TRPV1-YFP and 4-6 μg Vti1b/pCMV-Sport6 plasmid were added per dish. 
The amount of Vti1b/ pCMV-Sport6 was changed from 4 to 6 µg across replications with 
no noticeable difference, but always kept consistent between conditions for a given 
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experiment. To keep DNA amounts similar between conditions the pCMV-Sport6 empty 
vector was added. 
Forty-eight hours after transfection (cell confluency of ±80%), cells were harvested in 5 mL 
PBS/dish and centrifuged at 1000 rpm for 5 min. The cell pellet was re-suspended in 1 mL 
PBS, transferred to an Eppendorf cup, and centrifuged further for 5 min at 1000 rpm. The 
resulting pellet was re-suspended in 500 µL SB, and processed as described above (from the 
solubilisation step onwards) with modifications: 
- before addition of antibody, 20 µL of the supernatant was saved for immunoblot 
analysis (equals the “input”) and 
- the elution buffer consisted of 1x LDS Sample Buffer +1x Reducing Agent in SB. 
 
2.1.2.3 Gel-electrophoresis and western blot *# 
Protein samples were dissolved in 1x LDS Sample Buffer +1x Reducing Agent and heated 
to 70°C for 10 min followed by separation via 1D NuPAGE® (Life Technologies). As a 
marker for protein size Novex Sharp Pre-stained Protein Ladder was used. Pre-casted 
NuPAGE® Bis-Tris 4-12% gradient gels were loaded with the proteins and electrophoresis 
was done in 1× NuPAGE® MOPS SDS running buffer. The voltage used was 200 V and 
running time varied, depending on sample separation, from 40-50 min. Subsequently, 
proteins were transferred to PVDF membranes with the iBlot® Gel Transfer Device (Life 
Technologies, program #3, transfer time 7 min). For blocking of unoccupied binding sites of 
the membranes, they were incubated with 5% milk/PBS for 30 min at RT. Next, the blots 
were incubated with primary antibodies (diluted in 1% milk/PBS; see Table 2-2) for 2 h at 
RT and additionally at 4°C, overnight, 3-5× diluted. Membranes were washed with PBS (3× 
short, 3× 5 min), followed by incubation of respective secondary antibodies for 1h at RT. 
After extensive washing with PBS (3× short, 3× 5 min), immuno-labelled proteins were 
detected by near-infrared light (Odyssey; LI-COR Biosciences). 
 
2.1.3 Molecular Biology  
2.1.3.1 Cloning of the AAV6-Vti1b miRNA construct and virus production # 
Design of microRNA (miRNA)  
The miRNA targeting mouse Vti1b was designed using the BLOCK-iT™ RNAi Designer 
from Thermo Fisher Scientific (https://rnaidesigner.thermofisher.com/rnaiexpress/) and 
correct folding of the oligonucleotides controlled by the RNAfold WebServer (offered by 
ViennaRNA Web Services, http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). 
The sequence of the miRNA follows the general structure: 
5' TGCT overhang – G+antisense target sequence – TTGGCCACTGACT (Loop sequence) 
– Sense ∆2 nt target sequence – CAGG 3' overhang. 
Sequence targeted by the “miRNA 231”/Vti1b miRNA: 
TAGTTTCTCAGCTTAGACATCG 
Sequence of the Vti1b miRNA, flanked by a BamHI and a HindIII restriction site                




The oligonucleotide was synthesized and inserted into a pUC57-Kan plasmid via the BamHI 
and HindIII sites by GenScript Inc. USA (Piscataway, NJ, USA) 
Cloning of the AAV6-Vti1b miRNA-EGFP construct  
The AAV6-control miRNA vector used as backbone plasmid was a kind gift from Sebastian 
Kügler (UMG, Göttingen) and contained one cassette with co-cistronic expression of EGFP 
and a negative control miRNA with random sequence under the neuron-specific promotor 
human synapsin 1 as well as a WPRE (woodchuck hepatitis virus posttranslational control 
element) element (Sousa-Ferreira et al., 2011). 
Both the AAV6 vector as well as the pUC57-miRNA 231 were digested with FastDigest 
BamHI (FD0054, Thermo Scientific) and FastDigest  HindIII (FD0504, Thermo Scientific) 
for 60 min at 37°C in 1×FastDigest Green Buffer to remove the control miRNA sequence or 
the pUC57-backbone, respectively. In addition, during last 20 min of incubation Fast 
Alkaline Phosphatase (EF0654, Thermo Scientific) was added. The digests were separated 
by agarose-gelelectrophoresis and the bands of interest excised. The DNA was purified using 
the NucleoSpin Gel and PCR Clean-up kit (Machery-Nagel) according to manufacturer’s 
instructions. For the ligation the vector and insert were mixed at a 1:4 ratio and incubated 
with 1U of T4-DNA Ligase (15224-017, Life technologies) in 1×T4 DNA Ligase buffer 
overnight at 14°C. 
Transformation of the ligation product into SURE® 2 Supercompetent Cells was done 
following manufacturer’s instructions and cells were plated on LB agar plates (with 
Ampicillin) and grown overnight at 37°C. Colonies were picked the following day and 
allowed to proliferate overnight in LB medium at 37°C.  Subsequently, isolation of plasmid 
DNA was carried out using PureLink® silica membrane columns that selectively bind 
plasmid DNA (PureLink® Quick Plasmid Miniprep Kits) following manufacturer’s 
instructions and stored at -20°C until further use. 
Sequencing of generated plasmid verified the correct insert sequence (sequencing was done 
in-house: AGTC lab, MPIem), and a SmaI (#FD0664, Thermo Scientific) digest confirmed 
the integrity of ITR (inverted terminal repeats) in the AAV6-backbone vector. 
Production of recombinant AAV6-virus particles  
The production of viral particles was performed by Sebastian Kügler (UMG, Göttingen) and 
as described before (Shevtsova et al., 2005). In short, recombinant AAV6-viruses were 
propagated in transiently transfected HEK293 cells using pDP6 as the helper plasmid. 
Purification of viral particles was performed by iodixanol step gradient ultracentrifugation 
and affinity chromatography over a heparin column on an Äkta FPLC. After extensive 
dialysis of eluted particles against PBS, the purity was determined by SDS-PAGE and 
genome titres by qPCR. 
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2.1.3.2 RNA isolation, cDNA synthesis and real-time quantitative PCR (qPCR) # 
To validate the siRNA-mediated knockdown of Vti1b in primary cultures of LDRG neurons, 
total RNA was extracted from neurons transfected with either Vti1b siRNA or negative 
control siRNA using the NucleoSpin RNA XS kit according to the manufacturer's 
instructions. The concentration and purity of isolated RNA was determined via 
photospectrometry. If necessary, RNA was stored at -80°C until further use as template for 
cDNA synthesis. 
Leftovers of genomic DNA (gDNA) were digested and cDNA was reverse transcribed from 
total RNA (approx. similar amounts across conditions, ± 250 ng) using the QuantiTect 
Reverse Transcription Kit, following recommendations of the manufacturer. If not used 
immediately as template for gene amplification by qPCR, cDNA was stored at -20°C, until 
further use. 
Primer for the two house-keeping genes (mouse β-actin and mouse GAPDH) and mouse 
Vti1b were designed with the Roche Universal Probe Library Assay Design Center (see 
Table 2-5 for primer sequences). The real time qPCR for comparative gene expression 
analysis was done on a Roche Lightcycler 480 platform with SYBR™ Green fluorescence 
detection. For the qPCR in 384-well plates, 200 nM of each primer (reverse and forward), 
up to100 ng of cDNA and 1×Power SYBR Green PCR Master Mix, containing all necessary 
PCR constituents, were diluted with ddH2O to reach a final volume of 20 μL. Samples were 
prepared in triplicates and a no-template control (no cDNA, but ddH2O) and a gDNA control 
(no reverse trancriptase had been added at the cDNA synthesis step) were run in parallel to 
control for unspecific and gDNA amplification, respectively.  







Time  10 min 15 s 60 s 
Temperature 95°C 95°C 60°C 
40 cycles 
 
For confirmation of the specificity of the amplified products a melting curve analysis was 
run.  
The so-called threshold cycle (Ct) values – the cycle, in which SYBR green fluorescence 
was higher than the background fluorescence – correlates with the initial transcript amount 
and were normalized to the two reference genes, β-actin and GAPDH. Vti1b knockdown 
efficiency was calculated by the comparative 2-ΔΔCt method by Livak and Schmittgen (Livak 
and Schmittgen, 2001). 
 
2.1.4 Immunohistochemistry  
2.1.4.1 Tissue processing for immunohistochemistry # 
Mice were sacrified by CO2-inhalation, decapitated and lDRGs 1-5 dissected.  If treatment 
was applied to only one hind paw, ipsilateral and contralateral lDRG were collected 
separately.  
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The tissue was fixed in 4% formalin/PBS for 3-4 h at 4°C and cryo-protected overnight in   
30 (w/v) % sucrose at 4°C. For cutting, tissue was frozen in Tissue-Tek O.C.T. (optimal 
cutting temperature). Sections of 10 µm thickness (step-serial mode) were cut with a cryostat 
(Leica), mounted on SuperFrost Plus slides and stored at -80 °C until further use. 
For the IHC of tissues from AAV6-injected mice: Transcardial perfusion of the mice prior to 
tissue dissection. Mice were anesthetized by intraperitoneal (i.p.) injection of a 
Ketamine/Xylazine solution (100 mg Ketamin + 10 mg Xylazine (medistar) per kg 
bodyweight diluted in sterile PBS) and after loss of reflexes, the thorax was opened, and a 
cannula inserted into the left ventricle. The right atrium was cut immediately before starting 
the perfusion with ice-cold PBS. After washing out of all blood, mice were perfused with  
10 mL of ice-cold 4% formalin/PBS. Dissected tissue was post-fixated in 4% formalin/PBS 
for half an hour at 4°C and processed as described above. 
 
2.1.4.2 Fluorescence immunohistochemistry (IHC) # 
After thawing of frozen sections for half an hour at RT, sections were permeabilised and 
blocked for 30-60 min with 0.4% Triton X-100/PBS containing 5% serum (either donkey or 
goat serum, dependent on host species of antibodies used). Next, primary antibodies in 0.1% 
Triton X-100/PBS + 1% serum were applied overnight at 4 °C. After 3 washes in PBS, 
sections were incubated for 2 h, RT, with the respective Alexa Fluor conjugated secondary 
antibodies in PBS + 1% serum and 0.1% Triton X-100. Unbound antibodies were rinsed 
with PBS and sections were mounted in SlowFade™ Gold Antifade Medium containing 4',6-
Diamidino-2-Phenylindole (DAPI). See Table 2-2 for used antibodies. 
 
2.1.4.3 Image acquisition and analysis # 
For all immuno-histological studies digital images of the stained tissue sections were 
acquired on a Zeiss Axio Observer Z1 inverted epifluorescence microscope with either 10× 
or 20× air objectives or 40× and 63× oil immersion objectives. For all experimental groups 
the acquisition parameters were kept identical. Also, “secondary antibody-controls” 
(primary antibody was omitted) were imaged in parallel to the sample sections (data not 
shown). Conditions to be compared were processed concurrently using the same cultural/ 
tissue preparation. NIH ImageJ/Fiji (Schindelin et al., 2012, 2015) was used to analyse raw 
images. Cells were counted as positive for the immuno-label, if their mean intensity (in 
arbitrary units (i.a.u.)) exceeded the mean background intensity + 3×standard deviation from 
at least 10 randomly chosen unstained cells. For the Vti1b stainings the background was 
determined on sections from Vti1b-KO mice and transferred to WT tissue sections. only 
sections that were at least 50 µm apart were considered in order to avoid double-counting of 
DRG neurons. Only for presentation purposes brightness & contrast were adjusted in ImageJ 
and Adobe Photoshop CC2017. 
The statistical analysis was carried out using GraphPad Prism 5.01 and 6.01 (San Diego, 
USA). If two groups were compared either the Mann Whitney test or the unpaired two-sided 
Student's t-test was used where appropriate; for comparison of multiple groups one-way 
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ANOVA, two-way ANOVA (depending on number of variables; followed by either Holm-
Sidak’s or Bonferroni posttests), or Kruskal-Wallis test with Dunns’ multiple comparison 
test where appropriate. P-values that were smaller than 0.05 were considered significant and 
denoted with * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
2.1.5 Cell culture, cell stainings & in vitro functional assays  
2.1.5.1 Dissociated cultures of lumbar DRG neurons # 
For each primary lDRG neuron culture, 4 CFA- or Veh-injected WT mice were euthanized 
by CO2-inhalation and ipsilateral lDRGs 1-5 were dissected. In case of non-treated WT mice, 
lDRG of both sides from 2 mice were isolated. 
Mice were decapitated and spines removed from the trunk. Next, a laminectomy was 
performed to remove the roof of the vertebral canal and expose the underlying spinal cord 
and DRG. LDRGs 1-5 were identified by using the last rib as a landmark for thoracic DRG 
13 (Malin 2007) and carefully dissected. The tissue was collected in 1 mL serum-free media 
(DMEM/Hams’ F12) and 1 mL Collagenase (12 mg/mL; 1:1 ratio) was added. Tissue was 
digested for 60 min at 37°C, 5% CO2 and afterwards triturated to ensure effective digestion. 
Papain solution (10 U/mL) in serum-free media was added, (final Papain dilution 1:10) and 
the cells were further incubated for 30 min at 37°C, 5% CO2.  
Subsequently, cells were pelleted at 1000 rpm for 1 min and re-suspended in 1 mL 
DMEM/Hams’ F12 with 10% horse serum. For separation of cell from debris, first, an 
additional 1 mL media with serum was added, followed by 2 mL of Bovine Serum Albumin 
(BSA) that were carefully added under the cell suspension creating a separate layer. The 
BSA/cell suspension column was centrifuged for 10 min at 1000 rpm resulting in a cell pellet 
and a layer of cell debris between BSA and medium.   
Medium/BSA was removed and in case of cultures without transfection, the cells were then 
re-suspended with DMEM/Hams’ F12 with serum and supplemented with growth factors 
(see below). Twenty microliters of the cell suspension were plated per coverslip (12 mm 
diameter, coated with Poly-D-lysine (1.0 mg/mL) and Laminin (20 µg/mL), then incubated 
for 20 min at 37°C, 5% CO2 before filling up the medium to 1 mL. 
 
2.1.5.2 Nucleofection of DRG neurons # 
Transient transfection of DRG neurons with siRNA or plasmid DNA was done via 
electroporation (“nucleofection”) using the 4D-Nucleofector™ System (X unit, 16-well 
20μL NucleocuvetteTM Strips, Lonza AG). 
The cell pellet after the BSA column was re-suspended in 36 μL of P3 Primary neuron 
nucleofector solution with supplement (Lonza AG). The cell suspension was divided for 
experimental and control condition. The required amount of siRNA/plasmid (500 ng 
mCherry + 300 ng Vti1b/ pCMV-Sport6, or 500 nM siRNA; see Table 2-3, 2-4) was added 
to the cell solution (final volume 20 µL), and transferred to a cuvette for electroporation via 
program DC104. Afterwards RPMI medium with low calcium was added to each cuvette 
well (45 µL, RT) for recovery and cells were plated on PDL/Laminin-coated coverslips. 
After a 15-min recovery period at 37°C, 1 mL of DMEM/Hams’ F12+GFs was added per 
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well.  To reduce toxicity, half of the media was refreshed after 2 h at 37°C, 5% CO2. Cells 
were used either 48 h after transfection for overexpression studies, and 72 h after siRNA 
transfection in various in vitro assays (see below). 
Growth factor combinations used: For DRG cultures targeting TRPV1 only nerve growth 
factor (NGF, 100 ng/mL) was added. In the case that TRPA1 was the object of the 
experiment a combination of growth factors was used: 50 ng/ml BDNF, 50 ng/mL GDNF, 
100 ng/mL NGF, 50 ng/mL NT-3, and 50 ng/mL NT-4.  
 
2.1.5.3 Human Embryonic Kidney (HEK)293 cells and transient transfection # 
Coating of coverslips 
For immunocytochemistry, HEK293 cells were plated on PDL (1 mg/mL) + Laminin          
(20 µg/mL)-coated coverslips; in case of calcium imaging and electrophysiology on 
fibronectin (50 µg/mL)-coated coverslips; or fibronectin-coated MatTek dishes for Live 
labelling and Proximity Ligation Assay. Coatings were done at the day of the experiment. 
 
Maintenance 
HEK293 cells were maintained in DMEM + GlutaMAX supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (growth medium) in flasks at 37°C with 
5% CO2 (Heracell 150i, Thermo Scientific). The cells were split once a confluency of ±80% 
was reached: The medium was aspirated and cells were rinsed once with pre-warmed PBS.  
After aspiration, enough TrypLE Express to cover the complete grown surface was added 
and after detachment of cells, the reaction was stopped by diluting 1:10 with pre-warmed 
medium. For maintenance the desired cell dilutions were made and transferred to new flasks. 
Alternatively, cells were plated for subsequent use in experiments (see below). 
 
Transient Transfection with FuGENE HD 
Transfection was done using FuGENE HD transfection reagent according to manufacturer’s 
instructions with a DNA: FuGENE ratio of 1:3. The transfection medium was exchanged for 
normal growth medium 4 h after transfection (37°C, 5% CO2).  
 
Amount of plasmid DNA used for the different downstream applications: 
Application Plasmids Amount per dish 












To standardise DNA amounts across conditions the empty pCMV Sport6 plasmid was added. 
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2.1.5.4 Immunocytochemistry (ICC) # 
All washing and incubation steps were performed under constant agitation. 
Cells were washed and fixed with 4% formalin/PBS for 10 min at RT. Next, cells were 
washed 3×5 min with PBS and incubated with PBS containing 0.4% TritonX-100 and 5% 
serum (donkey or goat depending on the host species of used antibodies) for half an hour at 
RT. Primary antibodies (AB) were diluted in antibody-solution (1% serum and 0.1% 
TritonX-100 in PBS) and applied overnight at 4°C. 
After 3 short and 3×5 min washes of cells with PBS, secondary antibodies coupled to 
AlexaFluor dyes were incubated for 2 h at RT. After 3 short and 3×5 min rinses with PBS, 
coverslips were mounted in SlowFade™ Gold Antifade Medium with DAPI (see Table 2-2 
for used antibodies). Samples were imaged with a Zeiss Axio Observer ZI using Axiovision 
software as described in 2.1.4.3.. 
 
2.1.5.5 Proximity Ligation Assay # 
In situ Proximity Ligation Assay (PLA; (Söderberg et al., 2006)) was performed for the 
detection of close proximity of ≤ 40 nm of TRPV1 and Vti1b; as described in (Leuchowius 
et al., 2011; Narayanan et al., 2016) with modifications. The Duolink® In Situ Detection 
Reagents Orange set was used. 
Twenty-four hours after plating and/or transfection of cells on MatTek dishes medium was 
aspirated and cells were rinsed two times with pre-warmed PBS. Next, fixation of cells was 
performed with 4% formalin/PBS for 10 min at RT and washed with PBS afterwards (3× 
short, 3×5 min). To minimize unspecific AB-binding, cells were incubated with PBS 
containing 0.4% TritonX-100 and 5% serum (depending on the host species of used 
antibodies) for 2 h at RT. Application of primary antibodies (in AB-solution: 1% serum and 
0.1% TritonX-100 in PBS) was overnight at 4°C. The following day, cells were rinsed 2× 
short and 4× 5 min in Duolink Wash Buffer A (0.01 M Tris, 0.15 M NaCl, 0.05% Tween20; 
pH 7.4). PLA PLUS and MINUS probes were diluted 1:10 in AB-solution and incubated 20 
min at RT before adding to the cells. Cells were incubated with PLA probes for 1 h at 37°C. 
After 2× short and 4×5 min rinses with Wash Buffer A, cells were incubated with ligation 
mix (1:5 dilution of Ligation Stock buffer and 1:40 Ligase in ddH20) for 30 min at 37°C to 
ligate PLA probes. Cells were washed three times with 1× Wash Buffer A for 10 min each. 
For the rolling circle amplification reaction, amplification stock was diluted 1:5 with ddH2O 
and the polymerase 1:80. Amplification was carried out for 100 min at 37°C and to end the 
reaction samples were rinsed two times for 10 min with Wash Buffer B (0.2 M Tris, 0.1 M 
NaCl, pH 7.5) and twice for 1 min with 0.01× Wash Buffer B. Samples were left in PBS at 
4°C prior to imaging with a Zeiss Axio Observer Z1 using Axiovision software. 
 
2.1.5.6 Live labelling of HEK293 cells # 
Live labelling was done as described by Schmidt et al. (Schmidt et al., 2009) with 
modifications. HEK293 cells were transfected with TRPV1-YFP and Vti1b-myc-DDK. 
Twenty-four hours after the transfection the live HEK cells were labelled with a rabbit 
TRPV1 antibody targeting an extracellular domain of rat TRPV1, which was diluted 1:50 in 
growth medium, for 20 min at 37°C. Subsequently, cells were washed 5× with fresh pre-
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warmed medium and then the donkey -rabbit Alexa Fluor 546 secondary AB were applied 
1:200 in growth medium for 10 min at RT. Subsequently, the cells were washed 2× with 
fresh medium and once with PBS, and then fixated with 2% formalin/PBS. Excessive 
formalin was removed by 3 subsequent PBS washes. Cells were immediately imaged at a 
Zeiss Axio Observer Z1. 
Following the imaging, intracellular Vti1b (targeting the myc-tag) was stained: cells were 
washed once with PBS and permeabilized with 0.1% TritonX-100 + 5% donkey serum in 
PBS for 30 min. The primary antibodies (in 5% donkey serum/PBS) were applied overnight 
at 4°C. The following day, cells were rinsed 5× with PBS and incubated with respective 
secondary antibodies for 2 h at RT, diluted 1:250 in 1% donkey serum/PBS. After 5 washes 
with PBS, cells were imaged immediately.  
 
2.1.5.7 Image analysis PLA and live labelling # 
Raw images were analysed by using NIH ImageJ/Fiji (Schindelin et al., 2012, 2015), in 
principle as described in section 2.1.4.3 with modifications: 
For PLA, the intensity of the background was estimated using the signal from three negative 
cells measured per image, to calculate a primary threshold per image. These primary 
thresholds were averaged and used across all images (within one experimental repetition). 
Only YFP-positive cells were considered for analysis. They were traced and their areas 
measured. The ratio PLA signal above threshold/ cell area (per cell) was compared between 
TRPV1 + Mock and TRPV1 + Vti1b conditions.  
For live labelling experiments, the threshold was calculated per cell, using the unstained area 
between punctate.  
 
2.1.5.8 Ratiometric calcium imaging # 
Experimental procedure 
Ratiometric calcium imaging was performed as described before (e.g. (Laínez et al., 2010)) 
with modifications using an inverted microscope (Zeiss Axio Observer Z1). The cells – 
either transfected DRG neurons or HEK cells – were washed four times carefully with pre-
warmed Assay Buffer (consisting of 1× Hanks’ Balanced Salt Solution (1.3 mM Ca2+) with 
10 mM HEPES) prior to a 30-60 min incubation at 37°C with Fura-2/AM (stock solution: 
50 µg Fura-2/AM with 50 µL DMSO and 50 µL Pluronic F-127 Acid) diluted 1:200 in Assay 
Buffer (2.5 mM Fura-2/AM + 0.04% Pluronic F-127 Acid). The duration of incubation 
varied depending on the length of the imaging protocol but was consistent across 
experimental replicates. Subsequent to incubation, cells were washed four times with pre-
warmed Assay Buffer and transferred to a recording chamber constantly perfused by a 
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Figure 2.1: Calcium imaging protocols 
Upper: TRPV1 stimulation protocol (HEK and DRG). bottom: TRPA1-DRG stimulation protocol. Caps, 
capsaicin; MO, mustard Oil; potassium chloride (KCl) was used on DRG cultures, ATP used to stimulate HEK 
cultures. Assay buffer was applied between each pulse. Figure modified with permission from A.Barry. 
 
Increase in intracellular calcium in response to TRP channel agonist application was studied 
via two imaging protocols (Fig. 2.1): (I) TRPV1 activation (DRG and HEK): six pulses of 
low Capsaicin (Caps; 100 nM) and a subsequent high Caps pulse (1 μM), in case of HEK 
cells an additional ATP pulse (20 μM), or (II) TRPA1 activation (only DRG): one 25 μM 
Mustard Oil (MO) pulse and one 50 μM) pulse followed by an application of KCl (60 mM). 
Dilution of stock solutions (in absolute EtOH) of agonists in assay buffer.  
Dynasore monohydrate (endocytosis inhibitor experiment) was added to the Assay Buffer 
from second minute of the wash out step of Caps pulse 5 until the end of pulse 6 at a final 
concentration of 5 μM. 
The calcium-sensitive dye Fura-2/AM was alternately excited at 340 nm and 380 nm, and 
emission acquired at 510 nm, using MetaFluor software (Molecular Device). The 340/380 
ratio – representing the bound/unbound calcium – describes the intracellular calcium 
concentration, and was sampled at 0.333 Hz. Background fluorescence was recorded from a 
region devoid of cells in each of the coverslips imaged.  
 
Data analysis  
Recorded data were analysed with Microsoft Excel: A baseline was calculated for each pulse 
as the mean of the 5 last 340/380 ratio values (ie 15 s before pulse) prior to pulse application. 
Responders: cells with amplitude values reaching 120% of the baseline within the time span 
from onset of stimulation until 15 s before the next stimulation.  Amplitudes: the maximum 
340/380 ratio from the onset of stimulation to 15 s before onset of the subsequent stimulation 
subtracted by the respective baseline to allow for comparison across cells and cultures. 
Coverslips where more than 20% of cells appeared unhealthy, ie. a high initial 340/380 
baseline and unstable trace recordings, were omitted from the analysis. At least two 
coverslips per condition from three to five independent culture preparations were analysed. 
The statistical analysis was carried out using GraphPad Prism 5.01 (San Diego, USA). For 
the comparison of two groups either the Mann Whitney test or unpaired two-sided Student's 
t-test was used where appropriate; for comparison of multiple groups either one- or two-way 
ANOVA were performed, followed by uncorrected Fisher’s LSD (least significant 
difference), Holm Sidak’s or Bonferroni posttests. For comparison of the fractions of 
responders Fisher’s exact test was used. P-values smaller than 0.05 were considered 
significant and marked with * p < 0.05, ** p < 0.01 and *** p < 0.001. 
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2.1.5.9 Electrophysiology # 
Electrophysiological recordings were performed by Niklas Michel, AG Schmidt. 
Whole-cell patch clamp experiments were performed using an EPC10 USB amplifier 
(HEKA Elektronik) and the PatchMaster software (HEKA). Micropipettes were generated 
from borosilicate glass capillaries (PG10165-4, World Precision Instruments) using a PIP 6 
(HEKA) vertical puller. The patch pipette resistance varied between 1.5 and 3 MOhm. The 
bath solution consisted of 160 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM 
HEPES and 8 mM glucose (adjusted to pH 7.4 with NaOH); pipette solution consisted of 
100 mM KCl, 45 mM NMDG, 10 mM BAPTAxK4, 10 mM HEPES and 5 mM EGTA 
(adjusted to pH 7.2 with NaOH) (García-Ferreiro et al., 2004). YFP-positive cells were 
subjected to whole-cell voltage clamp at a holding potential of -60 mV. Cells were subjected 
to linear voltage ramps from -100 to +100 mV with duration of 500 ms (de la Roche et al., 
2016; Leffler et al., 2008) applied every 5 s. 100 nM capsaicin were applied through a 
gravity-driven application system with a capillary, which was placed in close proximity to 
the cell of interest. Experiments were performed at RT. Data were analysed with the 
FitMaster software (HEKA). 
 
2.1.6 In vivo experiments  
2.1.6.1 Pain paradigms and behavioural tests *# 
Assessment of mechanical (hyper)sensitivity *# 
Mechanical (hyper-)sensitivity was determined with a Dynamic Plantar Aesthesiometer 
(#37450, Ugo Basile) according to standard procedures described in (Minett et al., 2013) 
and the manufacturer´s manual.   
The mice were placed separately in clear plexiglass compartments on a mesh floor and were 
acclimatized for 2 h. The hind paws were stimulated with a graded force (0-10 g in 40 s) to 
the plantar surface (for SNI/Sham mice to the lateral side of the plantar surface of each hind 
paw) and the time until withdrawal of paw was determined (withdrawal latency). Between 
each stimulus on the same mouse at least 2 min passed. From at least three readings per paw 
the average withdrawal latency was calculated. Deviation of single values of more than 5s 
from the median were excluded from the calculation of the average. In order to take 
differences in the latencies between the left and right paw prior to any treatment into account, 
the withdrawal latency of the left (treated) paw was also normalised to the right (untreated) 
one for each individual mouse and displayed in % ipsi/con (see Appendix Fig. 7.4).  
 
Assessment of thermal (hyper)sensitivity # 
The Hargreaves’ test (Hargreaves et al., 1988) was conducted to assess the heat sensitivity 
of the hind paws. A Plantar Test device (#37370, Ugo Basile, Italy) was used according to 
the manufacturer´s recommendations and standard procedures described in (Minett et al., 
2013). 
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Mice were habituated for 2 h in clear plexiglass compartments on a clear floor. The plantar 
surface of each hind paw was stimulated with a heat beam from a mobile radiant heat source. 
The infra-red intensity of the heat source was chosen to obtain average withdrawal values of 
naïve wild type mouse around 10 s (IR 25). The cut-off time was 30 s to avoid tissue damage 
and the averages per mouse determined as described above.  
 
Acute pain – Capsaicin injection # 
In order to assess TRPV1-mediated acute pain, nocifensive behaviour was observed after 
intraplantar injection of capsaicin (0.5 µg/paw in 5% EtOH/PBS) into the left hind paw. 
Mice were restrained gently by covering them with a tissue and thereby, cupping it under 
the hand. Left paw was hold firmly with plantar side facing upwards. A 28G Hamilton needle 
was inserted at a shallow angle into the centre of the paw and 10 µL capsaicin solution was 
injected slowly. The duration of nocifensive behaviours including shaking, licking, lifting, 
or flinching of the paw over a period of 6 min was taken. 
 
Inflammatory pain – Complete Freund’s Adjuvant (CFA) injection *# 
Persistent inflammatory pain in the hind paw was induced by intraplantar injection of CFA 
according to standard procedures (Minett et al., 2013).   
Ten microliters of CFA suspension (cell suspension contains 1 mg/mL of heat-killed and 
dried Mycobacterium tuberculosis) or vehicle (sterile PBS) were injected into the hind paw 
as described for capsaicin injections. 
* In order to minimize stress and therefore, avoid potential alterations of the proteome due 
to behavioural testing (Butler and Finn, 2009), CFA- and Veh-injected mice destined for 
tissue collection for the following calcium imaging and biochemistry experiments were not 
assessed for development of mechanical hypersensitivity at 24 h. Instead, a separate cohort 
of mice that had been injected in parallel was tested for mechanical hypersensitivity. All of 
the tested mice displayed significant mechanical hypersensitivity as described previously 
(Minett et al., 2013) and shown in Fig. 3-1 A. 
*, # all CFA-injected animals displayed pronounced paw edema (Minett et al., 2013), which 
was absent in mice injected with the vehicle solution. 
 
Neuropathic pain – Spared Nerve Injury (SNI) * 
The spared nerve injury (SNI) paradigm was induced according to (Bourquin et al., 2006; 
Decosterd and Woolf, 2000). The mice received buprenorphine (0.07 mg/kg body weight, 
subcutaneous (s.c.), Buprenovet®, Bayer) 10 min prior to surgery. The surgery was 
performed under isoflurane anaesthesia (4% induction, 1.8% maintenance). The shaved and 
disinfected left hind leg of the mouse was immobilized, and an incision was made at mid-
level of the thigh using the femur as a landmark. The biceps femoris was opened by 
stretching to expose the sciatic nerve and its branches, the common peroneal, tibial and sural 
nerves. Using a stereomicroscope, the nerves were freed from surrounding tissue and the 
common peroneal and tibial nerves were ligated with a 6.0 silk suture (Braun) and transected 
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together (distal to the ligation). A section of approximately 2 mm was removed of each 
nerve. Care was taken to avoid damage to the sural nerve. Sham surgery was performed 
using the same surgical techniques but without ligating and transecting the nerves. Muscle 
tissue was rearranged manually, and a thin layer of Lidocaine crème (5%, Xylocaine®, 
AstraZeneca) applied. Skin was closed with preferable 1 surgical micro clip. Mice received 
carprofen (5 mg/kg, s.c., Rimadyl®, zoetis) 5-8 h after the surgery. 
Behavioural test for mechanical hypersensitivity was conducted 2 days prior and 7, 14, 21 
and 26 days post surgery. The force was applied to the lateral side of the plantar surface of 
both hind paws. On day 28 post surgery mice were sacrificed for tissue isolation. Only lDRG 
from SNI mice which exhibited evident mechanical hypersensitivity at all tested time points 
were included for sample preparation for MS. 
As for inflammatory pain, to reduce stress due to mouse behavioural testing, the tissue 
collection (day 28 post surgery) was separated in time from behavioural testing (day 26 post 
surgery). 
 
2.1.6.2 In vivo validation of candidate proteins and networks  
Inhibition of mitochondrial ETC complex – Rotenone (Rot) injection * 
Inflammatory pain was induced as described above. Twenty-four hours after CFA- injection, 
mice were habituated for the mechanical sensitivity test (1-2 h). The inflamed hind paw was 
injected into the plantar surface with either 5 µL of Veh (0.63% DMSO/PBS) or a suspension 
of 5 µL of Rotenone (2.5 mM in 0.63% DMSO/PBS). Mice were acclimatized for another 
15 min and mechanical sensitivity was assessed for up to 1 h after injection of Rotenone/Veh 
as described in 2.1.6.1. Three independent mouse cohorts were tested. In line with other 
studies (Joseph and Levine, 2006, 2009), Rotenone did not affect general health or motor 
coordination. 
 
Inhibition of protein disulfide isomerases (PDIs) – PACMA31 injection * 
Inflammatory pain was induced as described above. Twenty-four hours after CFA-injection, 
mice received an i.p. injection (with a maximal volume of 200 µL) of PACMA 31 (20 mg/kg 
body weight) or Veh (6.9 % DMSO) in sterile PBS and were acclimatized for 2 h for testing 
of mechanical sensitivity as described. Withdrawal latencies of both hind paws were 
measured up to 6 h after injection of PACMA 31/Veh. Two independent mouse cohorts were 
tested. In line with another study (Xu et al., 2012), PACMA 31 did not affect general health 
or motor coordination. 
 
In vivo knockdown of Vti1b – Intra-sciatic nerve injection of AAV6 # 
To downregulate Vti1b expression in DRG neurons, AAV6-Vti1b miRNA-GFP virus 
particles were injected into the sciatic nerve. As control AAV6-scramble miRNA-GFP virus 
particles were injected. The intranerval injection was performed similar to a previously 
published procedure (Glatzel et al., 2000) with modifications. 
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The mice were injected with buprenorphine (0.07 mg/kg, s.c., Buprenovet®) 10 min prior to 
surgery. Throughout the surgery mice were anesthesized via isoflurane inhalation (4% 
induction, 1.8% maintenance). The left hind leg of the mouse was immobilized, hip/upper 
hind leg region shaved and disinfected, and an incision was made at upper level of the thigh. 
The sciatic nerve was exposed by dislodging the musculus biceps femoris and musculus 
gluteus superficialis and using retractor to keep the cavity open/tissue in place. The nerve 
was carefully placed under bent forceps and 0.9×10^8-1.3×10^9 virus particles (final 
volume of 10 µL (2:1, PBS: 20 (w/v)% mannitol) were injected with a 32G needle attached 
to a Hamilton syringe over a period of 10 min. After repositioning of nerve and muscle tissue 
and Lidocaine application onto the muscle layer, the skin was closed with preferable one 
surgical clip. Approx. 5-8 hours post-surgery, the mice received carprofen (5 mg/kg, s.c., 
Rimadyl®, zoetis). 
Mice undergoing virus injections were assessed for their thermal and mechanical sensitivity 
prior to surgery, 14/15 & 22/23 days after surgery. On day 24, CFA/Veh was injected to 
induce inflammatory pain as described above. Two independent cohorts were tested 24 h 
(day 1) after CFA-injection for thermal hypersensitivity and on day 2 for mechanical 
hypersensitivity as described above. Two further cohorts were tested 24 h (day 1) after CFA-
injection for mechanical hypersensitivity and on day 2 for thermal hypersensitivity as 
described above. On day 4 mice were sacrificed and ipsilateral lDRG 3-5 isolated and 
processed for immunohistochemistry (as described above). 
The cohorts destined for testing of acute pain behaviour, were injected with capsaicin on day 
24 after virus-injection as described above and sacrificed the same day for tissue isolation. 
 
2.1.7 Mass spectrometry and bioinformatic analysis  
2.1.7.1 Mass spectrometry and data analysis for project I* 
The SWATH-like DIA-MS and data analysis were performed by Roland Bruderer, 
Biognosys AG (Zuerich, Switzerland) as described in (Rouwette et al., 2016); in brief: 
Sample preparation for mass spectrometric analysis 
In total 12 samples (3 biological replicates per experimental group (SNI/Sham & CFA/Veh)- 
were prepared for MS analysis. The peptides were dissolved in 8 M urea/0.1 M ammonium 
bicarbonate and desalted using a C18 Ultra MicroSpin Column (The Nest Group). 
Photospectrometry revealed that the peptide concentration was in the expected range of 1 
µg/µL for all samples. After drying, peptides were dissolved in 1% acetonitrile in water with 
0.1% formic acid (LC solvent A). The HRM Calibration Kit (Biognosys) was spiked into all 
of the samples.Subsequently, samples were run for spectral library generation and Hyper 
Reaction Monitoring (HRM)-MS profiling. The peptides were separated by a linear gradient 
of 5-35% solvent B in 120 min followed by 35-100% B (3% water in acetonitrile with 0.1% 
formic acid) in 2 min and 100% B for 8 min (total gradient length for spectral library 
generation was 240 min).  
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Spectral library generation 
For generation of the spectral library, one sample from each of the four groups was run and 
the results pooled. DDA LC-MS/MS acquisitions were performed on a Q Exactive mass 
spectrometer. The LC-MS/MS data were analysed using Maxquant 1.4 software  with the 
following settings: protease: Trypsin/P with maximal two allowed missed cleavages; as fixed 
modification carbamidomethyl (C) was selected and as variable modifications oxidation (M) 
and acetylation (at protein N-term) were selected;  the false discovery rate was on peptide 
and protein level was set to 1 %; mass tolerance for precursor ions 20 ppm and fragment 
ions 20 ppm. The spectra were searched against a mouse Uniprot FASTA database (state 
05.06.2014). The generated spectral library comprised 16,971 peptide assays (15,850 
proteotypic ones) that mateched to 3,067 proteins (2,530 of these proteins were defined by 
at least one proteotypic peptide).  
DIA-MS and data analysis 
The HRM method (LC gradient of 2 h) consisted of loops of 1 survey scan followed by 19 
isolation windows/“SWATHs” covering 400 to 1,200 m/z. Spectronaut™ 5.0 software 
Biognosys AG (Zuerich, Switzerland)was used to analyse the 12 HRM measurements  and 
the spectral library generated beforehand was used for the targeted analysis of the DIA maps. 
The false discovery rate (FDR) on peptide level was chosen as 1%.  
Proteins showing a significant differential expression in either CFA vs. Veh or SNI vs. Sham 
were determined by state comparison analysis using a pairwise t-test. State comparison 
analysis and the calculation of fold changes were performed in MSstats 2.3.2 as described 
in (Bruderer et al., 2015). Multiple testing correction of p-values was done with the 
Benjamini Hochberg (BH) method and the q-values were calculated (Storey, 2002). 
The data have been uploaded to Peptide Atlas (http://www.peptideatlas.org, No. 
PASS00826, username: PASS00826, password: ZE5945at). 
Network analysis of candidate proteins  
Extensive manual literature search on Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/) 
was done along with querying the Pain Networks database (Perkins et al., 2013) to find out 
whether the 141 regulated candidates have previously been reported to be related to pain 
states in mice/rats and humans. To determine the novel pain-related proteins in our study, 
we excluded all genes/proteins (I) with an involvement in nociception and pain that has been 
reported previously, (II) which are pain-related genes in the Pain Networks database, or (III) 
members of the mitochondrial electron transport chain (ETC) given that inhibitors of 
mitochondrial ETC modulate pain (Ferrari et al., 2011; Joseph and Levine, 2009). 
Differentially regulated proteins were annotated with Gene ontology (GO) terms  (Ashburner 
et al., 2000) and enriched GO terms were determined with the DAVID functional annotation 
tool (Huang et al., 2008a). Only significantly enriched GO terms with BH corrected p-values 
< 0. are reported. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 
was used to search for/display direct and indirect interactions among all significantly 
regulated proteins in each pain model (Szklarczyk et al., 2015). STRING settings: 
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Confidence view; confidence level 0.4; clustering algorithm MCL set to 2. In Fig. 3.3 only 
with at least one connection are displayed and therefore, not all proteins showing a 
significant regulation are included in the displayed networks . 
 
2.1.7.2 Mass spectrometry and data analysis of TRPV1-CoIP samples # 
MS acquisition and raw data processing 
The elutes of the CoIPs were loaded on Prime Tris/glycine 8-16% gradient gels (Serva) and 
proteins separated by electrophoresis. After visualization of the proteins by Coomassie 
staining, each of the gel lanes was cut into 24 pieces of equal size that were subjected to 
automated in-gel digestion with trypsin (Schmidt et al. 2013). With help of a vacuum 
centrifuge, the digested peptides were dried and re-dissolved in 0.1% trifluoro acetic acid. 
To allow for absolute quantification later on, a standard digest of yeast enolase 1 (2.5 
fmol/µL, Waters Corporation) was added (Silva et al., 2006). Peptides were separated by 
nanoscale reversed-phase UPLC (Ultra Performance Liquid chromatography, Waters 
Corporation) and subsequently subjected to UDMSE (Ultra-definition MSE, a type of DIA-
MS;  (Distler et al., 2014, 2016)) analysis on a Waters Synapt G2-S quadrupole- time of 
flight (Q-TOF) with ion mobility shift (IMS) option. Acquisition of positive ions in the m/z 
range of 50-2000 and a resolution of ≥ 20,000 FWHM was done in the IMS-enhanced data 
independent acquisition mode (Silva et al., 2006) with drift time-specific collision energies 
(Distler et al., 2014, 2016). 
The initial signal processing of continuum LC-IMS-MS data was done with ProteinLynx 
Global Server v.3.0.2 (PLGS, Waters). For peptide and protein identification a customized 
database was generated by adding sequences of porcine trypsin and yeast enolase 1 to the 
UniProtKB/Swiss-Prot murine proteome (release 2016/11;16839 entries), as well as 
expanding it with the reversed sequences of all entries to allow for determination of the false 
discovery rate (FDR). Ion Mass tolerances of precursor and fragment ions were typically 
below 5ppm and 100ppm (root mean square), respectively, as determined automatically by 
PLGS v.3.0.2. Trypsin was set as digestion enzyme and 1 missed cleavage allowed for 
peptide identification. Methionine oxidation was set as variable modification and the 
carbamidomethylation of cysteine residues as fixed modification. At least two fragments per 
peptide, five fragments per protein, and one peptide per protein were the minimal 
requirements for ion matching.  An FDR of 1% was set as threshold for protein identification. 
For data post-processing and the label-free quantification, the open source software 
ISOQuant (http://www.isoquant.net; (Kuharev et al., 2015)) was used. This included 
retention time alignment, exact mass and retention time (EMRT) and ion mobility clustering, 
data normalization, isoform/homology filtering, and the absolute in-sample amount was 
determined by a modified TOP3 method (Distler et al., 2014, 2016; Kuharev et al., 2015). 
The stringency for reporting a protein was increased by only considering Peptides identified 
already in the first PLGS database search (described above) that consisted of at least 6 amino 
acids and had a score of ≥5.5. The FDR level was set to 1% at both peptide and protein level. 
Only for proteins with a minimum of 2 peptides, absolute protein quantities were estimated 
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with the TOP3 method. The LC-IMS-MS datasets from each of the 24 gel pieces of one gel 
lane were merged into one file.  To increase the overlap of peptide identifications across the 
3 biological replicates of one group, cross-annotation of feature clusters using the PLGS 
peptide information of matching features was enabled, but only within the 3 replicates of 
one group, not across the 3 different groups. 
The mass spectrometry acquisition as well as the data post processing and quantification as 
described above was done by Olaf Jahn (Proteomics group, MPIem). 
 
Data analysis for defining specific interactors of TRPV1 
Further data processing was done with Microsoft excel and the freely available Perseus 
software (v1.5.6.0.; (Tyanova et al., 2016)): 
The output list generated by ISOQuant was filtered for proteins exhibiting a PLGS score of 
at least 800 in one of the groups, yielding 1089 proteins.  The ratio of the TRPV1 amount in 
a CFA sample to the TRPV1 amount in the Veh sample that was run in parallel, was taken 
to normalize protein abundances in CFA. Then data was uploaded to Perseus and after log2-
transformation of the abundance values (in amol) of all 9 samples, they were plotted against 
each other and the Pearson correlation coefficient was calculated.  
The triplicate samples were grouped (CFA, Veh and KO) and filtered for having at least 3/3 
identifications in one of the three groups. 
To enable statistical analysis, missing values were imputated. Two different methods of 
imputation were used (I) with a constant value of 5.41 (log2 value of the lowest detected 
value over all runs, shifted down for one order of magnitude) and (II) random values taken 
from a normal distribution simulating low abundance values around the limit of detection of 
the mass spectrometer. The mean and standard deviation of the distribution of the protein 
abundancies from each group were calculated and a new distribution, respectively, with a 
width of 0.3 standard deviations and a downward shift of 1.8 standard deviations was created 
(Hanack et al., 2015; Hubner et al., 2010). 
To assess significantly enriched proteins in CFA/Veh vs. the KO control, group-wide 
comparison was done using a modified Student’s t-test (Tusher et al., 2001). The s0 
parameter was set to 1.58 (i.e. proteins need to exhibit a minimal fold change of 3) and the 
FDR (calculated by a permutation-based strategy) to 0.05. The outcome was plotted in a 
volcano plot with a cut-off curve representing a minimal fold change of 3 (s0 =1.58) and an 
FDR of 0.05.  
Subsequently, the fold change of significantly regulated proteins in CFA vs. Veh were 
calculated (only proteins significantly enriched in both or one of the groups compared to KO 
were considered). A threshold of a ±20% alteration between the groups was set to define 
pain-specific interactions.  
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Network analysis of candidate interactors 
The Database for Annotation, Visualization and Integrated Discovery (DAVID v6.8, 
https://david.ncifcrf.gov/home.jsp) was used to determine Gene Ontology terms of proteins 
significantly enriched compared to KO control. Furthermore, using the Functional 
Clustering tool (pre-set standard options and medium classification stringency) enriched 
annotation clusters were determined.  
The STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, https://string-
db.org/)  database was searched and used to visualize previously known and predicted 
interactions among significantly regulated proteins in CFA and Veh, respectively, STRING 
settings: Confidence view; confidence level 0.7; interaction sources: experiments and 
databases; clustering algorithm MCL set to 3. 
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2.2 Material 
Table 2-1: Details of material used in this study 
Product Company Cat # 
Acetone Rotisolv® HPLC Roth 7328.1 
Agarose Roth 3810.4 
Allyl isothiocyanate (Mustard oil, MO), 95% Sigma-Aldrich 377430-100G 
BAPTA×4K+ Life Technologies B1204 
Benchtop 1kb DNA Ladder Promega G754A 
BlueJuice™ Gel Loading Buffer, 10× Life Technologies 10816015 
BSA (Bovine serum albumin) Sigma-Aldrich A7030-50G 
CaCl2 Roth CN92.1 
Capsaicin  Sigma-Aldrich M2028-50MG 
CFA (Complete Freund's Adjuvant) Sigma-Aldrich F5881-10ML 
Collagenase, Type IV Life Technologies 13028014 
cOmplete™ ULTRA Tablets, 
Mini, EASYpack Protease Inhibitor Cocktail 
Roche 5892970001 
D-Mannitol Sigma-Aldrich M4125-100G 
n-Dodecyl-ß-D-maltoside Roth CN26.3 
DMEM (Dulbecco’s modified eagle medium), 
high glucose, GlutaMAX(TM), pyruvate 
Life Technologies 31966-021 
DMEM /Ham's F-12, GlutaMAX Life Technologies 31331-028 
DMSO (dimethyl sulfoxide), anhydrous, 
≥99.9% 
Sigma-Aldrich 276855 
Donkey serum Dianova 017-000-121 
DPBS (Dulbecco's phosphate-buffered saline), 
no calcium, no magnesium, 1× 
Life Technologies 14190-136 
DTT (Dl- Dithiothretol) solution (~1 M in 
H2O) 
Sigma-Aldrich 43816-10ML 
Duolink® In Situ Detection Reagents Orange Sigma-Aldrich DUO92007 
Dynabeads Protein G Life Technologies 10004D 
Dynasore Monohydrate Sigma-Aldrich D7693-5MG 
EGTA (ethylene glycol tetraacetic acid) Roth 3054.2 
FBS (Fetal bovine serum) Life Technologies 10270-106 
Fibronectin from bovine plasma Sigma-Aldrich F4759-1MG 
FuGENE ® HD transfection reagent Promega E2311 
Fura-2, AM (acetoxymethyl ester), cell 
permeant 
Life Technologies F1221 
alpha-D(+)-Glucose Monohydrat Roth 6887.1 
Glycerol Roth 7530.1 
Goat serum Dianova 005-000-121 
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HBSS (Hanks' Balanced Salt Solution), 
calcium, magnesium, no phenol red, 10× 
Life Technologies 14065049 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 1M 
Life Technologies 15630-056 
Horse serum Life Technologies 16050-122 
KCl Roth 6781.3 
Laminin Mouse Protein, Natural Life Technologies 23017-015 
Library Efficiency DH5α Competent Cells ThermoFisher Scientific 18263-012 
MgCl2 Roth KK36.1 
Milk powder Roth T145.2 
Na2CO3 Roth P028.1 
NaCl Roth P029.3 
NaOH (sodium hydroxide), 50% Roth 8655.1 
NMDG( N-Methyl-D-glucamine) Sigma-Aldrich M-2004 
(NH4)HCO3 Roth T871.1 
Novex Sharp Pre-stained Protein Ladder  Life technologies LC5800 
NucleoSpin® Gel and PCR Clean-up Macherey Nagel 740609 
NucleoSpin® RNA XS extraction kit Macherey Nagel 740902 
iBlot® Transfer Stack, PVDF Life Technologies IB401001 
NuPAGE® Antioxidant  Life Technologies NP0005 
NuPAGE® Bis-Tris 4-12% gradient gels  Life Technologies NP0336BOX 
NuPAGE® LDS Sample Buffer, 4× Life Technologies NP0007 
NuPAGE® MOPS SDS running buffer, 20× Life Technologies NP 0001 
NuPAGE® Sample Reducing Agent, 
10× (500mM DTT) 
Life Technologies NP0009 
Opti-MEM™ (Minimal Essential Medium)I 
Reduced Serum Medium 
Life Technologies 31985-062 
P3 Primary Cell 4D-Nucleofector® X Kit S 
(32 RCT) 
Lonza V4XP-3032 
PACMA31 (Protein Disulfide Isomerase 
Inhibitor III) 
Merck- 539225-25MG 
Papain, 20 U/mL Worthington LK003178 
PBS, pH 7.4, 10× Life Technologies 70011-051 
Penicillin-Streptomycin (5,000 U/mL) Life Technologies 15070-063 
PFA, Paraformaldehyde Aqueous Solution, 
EM Grade, 16% 
Science services E15710 
Poly-D-Lysine solution, 1.0 mg/mL Millipore A-003-E 
Power SYBR green PCR master mix Life Technologies 4367659 
PureLink® Quick Plasmid Miniprep Kits Life Technologies K210010 
QuantiTect Reverse Transcription Kit Qiagen 205313 
RapiGest™ SF Waters 186001861 
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Rotenone Sigma-Aldrich R8875 
RPMI (Roswell Park Memorial Institute) 1640 
medium 
Life Technologies 31870-017 
Slowfade Gold antifade reagent with DAPI Life Technologies S36938 
Sucrose Roth 4621.1 
SURE® 2 Supercompetent Cells  Agilent Technologies 200152 
Tris/Glycine-SDS Sample Buffer, 2× SERVA 42527 
TissueTek O.C.T. (optimal cutting 
temperature) compound 
Sakura 4583 
Tris-HCl Roth 9090.3 
Triton X-100 Roth 3051.3 
TrypLE™ Express Enzyme (1×), phenol red Life Technologies 12605010 
Tween 20 Roth 9127.1 
Water For Injection (WFI) for Cell Culture Life Technologies A1287301 
 
Table 2-2: Details of antibodies across experiments 
Antibody IHC Live CoIP ICC/PLA WB Details 






Rabbit -TRPV1 / / 12 µg / 1:200 
Alomone, 
ACC-030 




















/ 1:50 / / / 
Alomone, 
ACC-029 










1:100 / / / / 
Millipore, 
07-67 
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Donkey -Rabbit 
AF546 



















































Duolink® In Situ 
PLA® Probe Anti-
rabbit MINUS 
/ / / 1:10 / 
Sigma, 
DUO92005 
Duolink® In Situ 
PLA® Probe Anti-
Mouse PLUS 
/ / / 1:10 / 
Sigma, 
DUO92001 
Duolink® In Situ 
PLA® Probe Anti-
goat PLUS 
/ / / 1:10 / 
Sigma, 
DUO92003  
AF, Alexa Fluor; CoIP, Co-immunoprecipitation; Live, Live labelling; ICC, Immunocytochemistry;        
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Table 2-3: Details of DNA plasmids used in this study 
Construct Details 
TRPV1-YFP 
pcDNA5/FRT plasmid, YFP tagged, rat TRPV1, kind gift 
from Ardem Patapoutian  
Vti1b-myc-DDK 
pCMV6-Entry plasmid, Myc and DDK(Flag)-tagged, mouse 
Vti1b, Origene 
pCMV-Sport6 Empty Vector, kind gift from Ardem Patapoutian 
Vti1b-miRNA 231 pUC57-Entry plasmid, miRNA α mouse Vti1b, GeneScript 
AAV6-miRNA 231-
GFP 
Self-generated, see section 2.1.3.1 
AAV6-control 
miRNA-GFP 
See section 2.1.3.1, kind gift from Sebastian Kügler  
 
Table 2-4: Details of siRNA used in this study 
siRNA Details 
Control siRNA 
AllStar Negative Control siRNA, sequence: propriety 







FlexiTube GeneSolution targeting mouse Vti1b, Qiagen, 





Mm, Mus musculus 
 
Table 2-5: Details of qPCR-primers used in this study 
Primer name Primer sequence (5’-3’) 
Mm_GAPDH_forward CAATGAATACGGCTACAGCAAC 
Mm_GAPDH_reverse TTACTCCTTGGAGGCCATGT 
Mm_ β-actin_forward GATCAAGATCATTGCTCCTCCTG 
Mm_ β-actin_reverse CAGCTCAGTAACAGTCCGCC 
Mm_Vti1b_forward TCTTCGCTCAATGTCCAGAA 
Mm_Vti1b_reverse TACACCAGACCGACCAGGAT 
Mm, Mus musculus  
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3 Results  
3.1 Insights into chronic pain by standardized DRG proteome profiling  
This research was originally published in Molecular & Cellular Proteomics. Rouwette, 
Sondermann et al.. Standardized profiling of the membrane- enriched proteome of mouse 
dorsal root ganglia (DRG) provides novel insights into chronic pain. Mol Cell Proteomics. 
2015; 15(6), 2152-2168. © the American Society for Biochemistry and Molecular Biology. 
Thus, most of this section is based on Rouwette et al., 2016, with emphasis on the work I was 
significantly involved in.  
 
Effective treatment of chronic pain has not been achieved so far and faces major challenges. 
This is mainly due to the fact that (I) the molecular pathomechanisms are unknown for the 
variety of chronic pain syndromes and (II) as a consequence, current analgesics target 
molecules with key physiological function throughout our body, thus, are often accompanied 
by distressing side effects for the patients. A better understanding of the molecular events 
underlying pathological pain is desirable to develop better therapeutics. In fact, compounds 
targeting proteins highly enriched in the nociceptors – as they exert their function in the first 
line of noxious stimulus detection and accordingly critically shape the transmission of pain 
messages to the brain – represent a major goal in pain research. In order to identify proteins 
with a putative role in the chronification of pain, we used an unbiased MS-based approach 
– combining mouse behaviour with cutting-edge SWATH-like DIA-MS – to characterize 
the differential regulation of DRG-enriched proteins in different pain states in mice. Fig. 3.1 
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Figure 3.1: Scheme of the experimental workflow 
(A) Illustration of the 4 behavioural conditions used in this study (from left to right): Injection of Veh (vehicle solution) vs. 
injection of CFA into one hind paw, sham surgery (exposed but untouched sciatic nerve) vs. SNI (exposed and partial 
transected sciatic nerve). (B) Mice in the CFA and SNI groups show a decrease in paw withdrawal latency of the ipsilateral, 
i.e. treated site, indicating mechanical hypersensitivity. Paw withdrawal latencies of contralateral (contra) hind paws and 
in the Veh or Sham group did not change, *** p<0.001, N = 21-24 mice/condition, n = 3 independent cohorts, one-way 
ANOVA followed by Bonferroni’s multiple comparison tests. (C) Representative immunoblot of subfractions of our 
biochemical membrane enrichment (S1-4). The membrane marker Na+/K+-ATPase showed enrichment in the membrane-
enriched fraction (S4), whereas cytosolic markers β-actin and annexinA2 (AnxA2) were decreased. An opposite result was 
obtained in the cytosolic-enriched fractions (S1 and S2, n = 3 independent preparations). (D, E) Schematic representation 
of spectral library generation and DIA-MS profiling and follow-up experiments. This research was originally published in 
Molecular & Cellular Proteomics. Rouwette, Sondermann et al.. Standardized profiling of the membrane- enriched 
proteome of mouse dorsal root ganglia (DRG) provides novel insights into chronic pain. Mol Cell Proteomics. 2015; 15(6), 
2152-2168. © the American Society for Biochemistry and Molecular Biology. 
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3.1.1 Animal models of chronic pain and sample preparation  
As experimental models for chronic pain, we chose to investigate two established models of 
pathological pain with different aetiology (Minett et al., 2013): On the one hand, we induced 
persistent inflammatory pain by injecting complete Freund’s adjuvant (CFA; and saline as 
vehicle (Veh) control) into the hind paw of mice. This is accompanied by development of 
profound hypersensitivity of the injected paw starting within few hours after the injection, 
and reaching its peak at 24 h (Fehrenbacher et al., 2012). Injection of CFA at different sites 
is used to model inflammatory pain conditions that might occur in clinical settings of 
tendonitis and rheumatoid arthritis (Gregory et al., 2013). On the other hand, we subjected 
mice to the spared nerve injury (SNI; sham-operated mice (Sham) as control) as a model for 
peripheral neuropathic pain (Decosterd and Woolf, 2000). In the SNI surgery, the sural, 
common peroneal, and tibial nerve – the terminal branches of the sciatic nerve innervating 
the hind paw – are exposed and subsequently the common peroneal, and tibial nerve are 
transected, whereas the sural one is left untouched. Within 4 days of surgery and lasting for 
several months, the mice develop hypersensitivity to mechanical stimulation in the plantar 
region of the hind paw that is innervated by the sural nerve. Importantly, mechanical 
allodynia is a common manifestation of several neuropathic pain syndromes in humans 
(Woolf and Mannion, 1999). 
Accordingly, we assessed the development mechanical allodynia in the mice subjected to 
either SNI/Sham-surgery or CFA/Veh-injection (Fig. 3.1 B). Only tissue from mice that 
presented profound hypersensitivity were included in the study. Mice were sacrificed 24 h 
after injection (CFA) or 28 days later (SNI) for the isolation of the ipsilateral lumbar DRG 
(i.e. DRG innervating the affected hind paw). At these time points mice presented with 
profound mechanical hypersensitivity, which is in accordance with previous publications 
(Decosterd and Woolf, 2000; Minett et al., 2013). 
Transmembrane proteins together with membrane associated proteins (hereafter summarized 
as “membrane proteins”) expressed by the nociceptors located in the DRG, play an essential 
role in the detection and transfer of pain messages to the brain, therefore, we were especially 
interested in capturing their regulation. Yet, their identification and quantification by MS is 
hampered by their high resistance to digestion and extraction due to their inherent 
hydrophobicity, low solubility, and an overall low expression (Helbig et al., 2010). 
We aimed to increase probability of MS-detection by preparing membrane-enriched 
fractions of DRG tissue lysates by biochemical subcellular fractionation. As depicted in Fig. 
3.1 C, immuno-detection of Na+/K+-ATPase, a ubiquitous transmembrane protein, showed 
a clear enrichment in the membrane fraction (S4) compared to cytosolic fractions of our 
biochemical fractionation protocol. Conversely, cytosolic proteins like β-actin and annexin 
A2 (AnxA2) were not detectable in S4, indicating a successful depletion of cytosolic proteins 
in the membrane-enriched fraction (Fig. 3.1 C). 
 
3.1.2 Generation of a membrane-enriched spectral library of mouse DRG neurons 
Since the reliable identification and quantification of 1000s of proteins across several 
complex samples using SWATH-like DIA-MS relies on the a priori knowledge of the 
chromatographic and mass spectrometric signatures of peptides belonging to these proteins, 
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we first created our own sample-specific spectral library. To this end, one replicate of each 
condition (CFA, Veh, SNI, and Sham) was analysed by shotgun MS in the DDA mode. The 
resulting information/peptide signatures were used to build up a non-redundant spectral 
library (see supplemental Table S1 in (Rouwette et al., 2016)), containing 16,971 peptide 
signatures (15,850 were proteotypic) belonging to 3,067 proteins (2,530 were defined by at 
least 1 proteotypic peptide). 
Using DAVID (Database for Annotation, Visualization and Integrated Discovery v6.8; 
(Huang et al., 2008a)), we investigated the cellular compartments or molecular functions 
that were represented in our spectral library. Proteins were identified from a range of 
subcellular compartments and with the expected clear enrichment for membrane-associated 
proteins (see supplemental Fig. S2 in (Rouwette et al., 2016)). Among these were ion 
channels linked to somatosensation, for instance, TRPA1 and Piezo2 that were not detected 
in a previous MS study of DRG membrane-enriched tissue samples (Xiong et al., 2009). 
Comparing our spectral library to previously reported proteomes of SC (containing the 
central terminals of DRG neurons), DRG, sciatic nerve and neuromas, reveals that it is the 
largest compendium of mouse DRG proteins reported to date (Huang et al., 2008b; 
Melemedjian et al., 2013; Niederberger and Geisslinger, 2008; Xiong et al., 2009; Zou et al., 
2012). The generated data is stored in PeptideAtlas (http://www.peptideatlas.org/; (Deutsch 
et al., 2008)), a publicly accessible platform for sharing high-throughput proteomics data, 
and can be used for any DIA-MS experiment in any murine tissue of interest.  
 
3.1.3 DIA-MS reveals the differential regulation of proteins in rodent models of 
inflammatory and neuropathic pain  
To assess the differential regulation of proteins between pain and control condition, we 
submitted 3 biological replicates of each pain (SNI & CFA) and control (Sham & Veh) 
condition to SWATH-like DIA-MS, and for the targeted search of the acquired peptide 
signatures our spectral library was used. Across all replicates and samples more than 14,500 
peptides were identified corresponding to the same set of 2,526 proteins (Fig. 3.2 A). 
Moreover, in all CFA- and Veh-replicates an overlap of 2,581 proteins and an overlap of 
2,600 proteins in all SNI and Sham replicates were profiled, showing the high reproducibility 
of our workflow. Visualization of the protein abundances over all conditions and replicates 
in a heat map and volcano plot offers an overview of the global changes in abundance and 
reveals up- and downregulations of particular proteins (Fig. 3.2). Group-wise comparison 
using Student’s t-test and the q-value method to control the overall false discovery rate  
(Storey, 2002) revealed 64 significantly regulated proteins in inflammatory pain, and 77 
proteins in neuropathic pain, constituting in total about 3% of all quantified proteins (Fig. 
3.2 A; see supplemental Table S3 in (Rouwette et al., 2016) for complete dataset). 
Comparison of the significantly regulated proteins in both pain paradigms found only 12 
commonly regulated ones, proposing that the changes happening are rather specific to a pain 
model (Fig. 3.2 A; see supplemental Table S4 in (Rouwette et al., 2016) for list of 
overlapping proteins). 
To gain more insight into the kind of proteins that were regulated in the two different pain 
paradigms, we performed GO (gene ontology)-analysis. As shown in Fig. 3.2 B (and also 
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supplemental Fig. S6 in (Rouwette et al., 2016)), we found that the proteins affected, belong 
to a broad range of different and partially overlapping cellular locations as well as diverse 
functions.  
Looking for previously annotated links of the significantly regulated protein to painful 
pathologies (see section 2.1.7.1 for details on search), we found that several of them play a 
role in different (painful) pathologies of the somatosensory system, both in animal models 
and humans (examples are given in Table 1 in Rouwette et al., 2016). This shows that our 
DIA-MS is able to uncover meaningful candidates: For instance, one of the proteins 
upregulated in both inflammatory and neuropathic pain, was Dpp4/CD26. It is a cell surface 
glycoprotein. With its dipeptidyl peptidase activity, it regulates the concentration and 
activity of a variety of polypeptides, for example, the pain-modulating peptide SP (Guieu et 
al., 2006). Interestingly, CD26-deficient mice show exaggerated nociceptive responses, 
whereas in vivo inhibition reduces mechanical hypersensitivity in a model of diabetic 
neuropathy (Bianchi et al., 2011). Also, heat-shock protein 90b1 (HSP90b1), a molecular 
chaperone, and another commonly regulated protein in our dataset, has been linked to 
chronic diabetic neuropathy in mice (Urban et al., 2010, 2012).  
Our workflow also detected the regulation of proteins of which mutations are linked to 
human disorders. For instance, the ATPase ATP1A2, gene mutation underlies familial 
hemiplegic migraine type II (Fusco et al., 2003), and the ganglioside-induced differentiation-
associated protein-1 (Gdap1), mutations causing Charcot-Marie-Tooth 4A neuropathy, an 
inherited peripheral neuropathy (Baxter et al., 2002). 
On the other hand, for roughly 50% of our candidate proteins we did not find a connection 
to somatosensation and pain. As evidenced with the examples of proteins already previously 
linked to painful conditions, our workflow can detect meaningful candidates, thus, these 
proteins without a previous link to pain could represent interesting candidates to further 
investigate their role in inflammatory and neuropathic pain, respectively. 
 
We further wanted to validate the differential regulations of proteins detected by MS with 
complementary methods. Serca1, sarco/endoplasmic reticulum Ca2+-ATPase 1, was 
suggested to be upregulated in CFA and downregulated in SNI. Both western blots of 
membrane-enriched DRG lysates and in situ detection of Serca1 via IHC on DRG and sciatic 
nerves (from mice/samples exactly treated /prepared as for DIA-MS) confirmed the up- and 
downregulation, respectively (Rouwette et al., 2016). In addition, we could show that the 
differences detected in amount of Serca1are mirrored in the alteration of protein activity by 
measuring intracellular calcium levels in neuronal DRG cultures derived from CFA- and 
Veh-injected mice (Rouwette et al., 2016). 
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Figure 3.2: Differential regulation of proteins in inflammatory and neuropathic pain  
(A) Left, Visualisation of the abundance levels of the same set of 2,526 proteins profiled in all 4 conditions over all replicates 
in a heatmap (upon unsupervised hierarchical clustering analysis). Abundance changes are represented in the change of the 
colour. Insets show magnified regions with exemplary proteins that show abundance change. Right, Venn diagram 
displaying the number of proteins significantly regulated in either inflammatory or neuropathic pain and regulated in both 
(intersection). (B, C) Left, Volcano plot of all detected and quantified proteins by DIA-MS for inflammatory (CFA vs. 
Vehicle, B) and neuropathic pain (SNI vs. SHAM, C). The dashed line represents a q-value of 0.05 and thus, proteins above 
this line are counted as significantly regulated. Right, Bar diagrams representing the fractions of significantly regulated 
proteins that were annotated with the respective GO cellular component (CC) term. This research was originally published 
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in Molecular & Cellular Proteomics. Rouwette, Sondermann et al.. Standardized profiling of the membrane- enriched 
proteome of mouse dorsal root ganglia (DRG) provides novel insights into chronic pain. Mol Cell Proteomics. 2015; 15(6), 
2152-2168. © the American Society for Biochemistry and Molecular Biology.  
 
3.1.4 Alterations of major cellular signalling networks during chronic pain states  
As only the interplay of several proteins enables cell functioning, we searched for 
associations among the regulated proteins. Using STRING (Search Tool for the Retrieval of 
Interacting Genes/Proteins; (Szklarczyk et al., 2016)), we identified links between 56 out of 
77 proteins regulated in neuropathic pain, and 40 out of 64 proteins regulated during 
inflammatory pain. In Fig. 3.3 the proteins were grouped into signalling networks. Several 
major signalling networks were affected: for instance, structural proteins involved in myelin 
maintenance and nerve repair processes were downregulated in our SNI model of 
neuropathic pain.  These have been shown to be important for pain hypersensitivity in 
another nerve injury-mediated model of neuropathic pain (Vacca et al., 2014).  
Striking was the significant number of proteins linked to mitochondrial activity in the 
neuropathic pain paradigm. This is in line with previous studies relating mitochondrial 
dysfunction to several types of neuropathic pain. Any of the essential and interconnected 
functions mitochondria fulfil in cells can, if dysregulated, be related to neuropathic pain: 
their role in (I) the energy metabolism, any disbalance of the electron transport chain (ETC) 
can have detrimental effects in neurons as they have a high demand of energy (Joseph and 
Levine, 2006), (II) reactive oxidant species (ROS) production and degradation (oxidative 
stress)(Kim et al., 2004) and (III) buffering of intracellular calcium (Shishkin et al., 2002). 
Furthermore, proteins implicated in protein biosynthesis and maturation were affected (Fig. 
3.3). Only recently, endoplasmic reticulum (ER) stress has been suggested to be causative 
factor for pathological pain (Inceoglu et al., 2015). ER stress is triggered by accumulation 
of unfolded proteins due to disturbances of cellular redox regulation, calcium homeostasis 
as well as glucose deprivation (Oakes and Papa, 2015). Administration of reagents initiating 
ER stress causes lasting pain at the injection-site in healthy rodents, which could again be 
reversed by application of inhibitors of ER stress (Inceoglu et al., 2015). The exact 
mechanism how the ER stress signalling cascade initiates pain, has yet to be determined. 
Also, in the CFA-model of inflammatory pain regulated proteins were associated with 
protein biosynthesis and maturation as well as mitochondrial activity. This finding had not 
been reported previously and we decided to investigate the in vivo relevance of these protein 
networks for CFA-induced nocifensive behaviour in mice. To this end, we searched for 
reagents previously shown to enable interference with these signalling pathways in vivo, and 
that neither affect general health nor motor functions in naïve mice.  
Many of the regulated mitochondrial proteins are part of the ETC complex I (e.g. Ndufs4 
and Ndufv2, Fig. 3.3), thus, we decided for Rotenone, a blocker of the ETC complex I to 
manipulate mitochondrial functioning. For the pharmacological interference with protein 
maturation in the ER, we chose PACMA31 (Xu et al., 2012), inhibitor of protein disulfide 
isomerases (PDI). PDIs mediate protein folding by catalysing the breakage and reformation 
of disulfide bonds, and three subtypes of them, PDIA1, 3, and 6 showed a profound 
upregulation in the CFA-evoked inflammatory pain paradigm.  
Results  | 52 
Twenty-four hours after intraplantar injection of CFA, mice were injected with Rotenone (or 
vehicle as control) in the ipsilateral hind paw and assessed for their mechanical 
hypersensitivity. Similarly, another cohort of CFA-injected mice received PACMA31 (or 
vehicle; via i.p. injection, i.e. systemic administration) and were tested for hypersensitivity. 
Both compounds attenuated significantly the CFA-induced hypersensitivity to innocuous 
mechanical stimulation (Fig. 3.4). Whether the observed analgesia is solely dependent on 
the action of the inhibitors in somatosensory neurons, we cannot determine. Any off-target 
effects on non-neuronal cells (in the DRG or skin in case of Rotenone, or any tissue reached 
by the systemic administration of PACMA31) of these compounds would have to be 
investigated in somatosensory neuron-specific knockout mice. Yet, neither the withdrawal 
latencies of the non-injected, contralateral hind paw were affected, nor the general motor 
coordination, which together with observations from other studies using these inhibitors 
(Joseph and Levine, 2006, 2009; Xu et al., 2012) argues against major off-target effects. 
 
Taken together, we detected considerable and pain-model specific alterations in the 
abundance of several dozen proteins as well as within functional protein networks with our 
DIA-MS-based workflow. Importantly, orthogonal validation of the functional relevance of 
observed alterations in vitro and analysis of mouse pain behaviours demonstrated that 
significant protein regulations were discovered on the level of both single proteins and 
signalling networks.  
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Figure 3.3: Role of mitochondrial and PDI activity in chronic inflammatory pain in mice 
(A) Rotenone causes acute analgesia of CFA-evoked chronic inflammatory pain. Withdrawal latencies of the hind paws to 
mechanical stimulation of CFA-injected animals are depicted. Mice were injected ipsilaterally (ipsi) with either Veh or 
Rotenone (Rot) 24 h after CFA-injection, *** p < 0.001 and * p < 0.05, N = 17 mice/ condition, n = 3 independent cohorts, 
one-way ANOVA followed by Bonferroni’s multiple comparison tests. (B) PACMA 31-mediated inhibition of PDIs 
attenuated persistent inflammatory pain. Withdrawal latencies of hind paws from CFA-injected animals are displayed. The 
mice were injected i.p. with either PACMA 31 (PACMA) or Veh 24 h after CFA-injection, *** p < 0.001 and * p < 0.05,  
N = 10 mice/condition, n = 2 independent cohorts, one-way ANOVA followed by Bonferroni’s multiple comparison tests. 
Of note, withdrawal latencies of untreated/contralateral hind paws were similar between PACMA 31 and Veh arguing against 
unspecific motor effects upon systemic (i.p.) injection of PACMA 31. This research was originally published in Molecular 
& Cellular Proteomics. Rouwette, Sondermann et al.. Standardized profiling of the membrane- enriched proteome of mouse 
dorsal root ganglia (DRG) provides novel insights into chronic pain. Mol Cell Proteomics. 2015; 15(6), 2152-2168. © the 
American Society for Biochemistry and Molecular Biology. 
Figure 3.4: Functional association networks of significantly regulated proteins in the different pain paradigms 
Interactions were discovered between (A) 40 out of 64 regulated proteins during inflammatory pain and (B) 56 out of 77 
regulated proteins during neuropathic pain. Association networks were generated using STRING and thicker lines represent 
stronger evidence for the association (for details please see section 2.1.7.1). Dashed-lines represent inter-cluster edges. 
Colours of protein nodes encode protein clusters involved in mitochondrial function, protein biosynthesis and maturation, 
cytoskeleton and myelin maintenance, and others, respectively. This research was originally published in Molecular & 
Cellular Proteomics. Rouwette, Sondermann et al.. Standardized profiling of the membrane- enriched proteome of mouse 
dorsal root ganglia (DRG) provides novel insights into chronic pain. Mol Cell Proteomics. 2015; 15(6), 2152-2168. © the 
American Society for Biochemistry and Molecular Biology. 
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3.2 Identification and characterization of TRPV1 protein complexes 
The majority of this section is based on results that have been originally published in PAIN: 
Sondermann et al. Vti1b promotes TRPV1 sensitization during inflammatory pain. 2019; 
160(2), 508-527.  Copyright ©2019 by the International Association for the Study of Pain. 
No formal license is required from Wolters Kluwer (publisher) to reprint the figures. 
 
Sensitization of TRPV1 is involved in the development and maintenance of thermal 
hyperalgesia, a symptom of several pathological pain conditions. Amongst others, protein-
protein interactions modulating the channel’s responsiveness to stimuli contribute to this 
hyperactivity. Targeting interactions that only occur under pathological conditions holds the 
promise of preventing only the excessive activation of the channel. However, little is known 
about the regulation and protein scaffold of TRPV1 during different pain states. Several 
studies reported regulated trafficking of TRPV1 in response to exposure to inflammatory 
mediators (Camprubí-Robles et al., 2009; Mathivanan et al., 2016; Meng et al., 2016; 
Morenilla-Palao et al., 2004; Zhang et al., 2005). We searched the genome-wide RNA-
sequencing data of nociceptors (Thakur et al., 2014) for proteins involved in both stimulated 
exocytosis and inflammation. One candidate catching our interest was the Vesicle transport 
through interaction with t-SNAREs homolog 1B (Vti1b). It had already been found to be 
regulated under inflammatory pain conditions in our proteomics screen of the DRG 
membrane (section 3.1 and/or (Barry et al., 2018; Rouwette et al., 2016)). Thus, the 
functional relevance of a potential TRPV1-Vti1b interaction was assessed for TRPV1-
mediated pain signalling in vitro as well as for pain behaviour in vivo. In recent years, an 
approach called “functional proteomics” has been used successfully for elucidating protein 
complexes of ion channels (Schulte et al., 2011). It comprises the affinity-based co-
purification of the target ion channel with its interacting proteins followed by quantitative 
tandem-mass spectrometry for the unbiased identification of putative interactors. In the 
second part of this project, functional proteomics was applied to determine further TRPV1 
interactors that are specifically formed under inflammatory pain, a pain state TRPV1 is 
crucially involved in (Caterina et al., 2000). 
 
 
3.2.1 Validation of Vti1b as modulator of TRPV1-mediated nociceptive signalling  
3.2.1.1 Co-expression of Vti1b and TRPV1 in sensory neurons 
This section is based on Sondermann et al., 2019. 
 
Vti1b is an endosomal SNARE protein that has been reported to be involved in different 
steps of both the endocytosis and exocytosis in several different cell types (Antonin et al., 
2000; Kreykenbohm et al., 2002; Murray et al., 2005; Offenhäuser et al., 2011).  
First, I verified the expression of Vti1b in the sensory neurons in the DRG. Co-
immunostainings of lumbar DRG (lDRG) against TRPV1 and Vti1b revealed that Vti1b is 
expressed in approximately 80% of all lDRG neurons and showed co-expression with 
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TRPV1 in 70% of all TRPV1-positive neurons (Fig. 3.5 A, B). The expression of TRPV1 
was not different in DRG from WT mice and Vti1b-KO mice excluding a major effect of 
Vti1b on TRPV1 expression levels.   
 
Next, I investigated the subcellular localisation of Vti1b in lDRG neurons. Vti1b has been 
shown to be located to late endosomes and structures of the trans-Golgi network for other 
cell types (Kreykenbohm et al., 2002). Comparison of the subcellular distribution of Lamp1, 
a marker for late endosomes (LE) and lysosomes, with Vti1b revealed a partial overlap of 
the two proteins mainly in the perinuclear region of DRG neurons (Fig. 3.5 C), confirming 
previously reported localisation of Vti1b to LE and lysosomes in, for example, macrophages 
(Offenhäuser et al., 2011). Both proteins show a vesicular and/or tubular staining pattern. 
The expression pattern of the two proteins was comparable in TRPV1-negative and -positive 
cells (Fig. 3.5 C). Of note, the TRPV1 immunostaining was dispersed throughout the whole 
cytosol which made it impossible to determine any subcellular co-localisation of both 
proteins of interest. 
 
Figure 3.5: Co-expression of TRPV1 and Vti1b in lDRG neurons 
(A) Representative images of co-immunostainings against TRPV1 and Vti1b on lDRG sections from wild type mice. Co-
expressing neurons are marked with white asterisks in the merged image of the wild type (inset, TRPV1-expressing neurons 
in magenta and Vti1b in cyan). Inset represents a magnification of the white box. Scale bar, 50 µm. (B) Quantitation of the 
TRPV1 and Vti1b expression in DRG neurons from either Vti1b-KO (KO) or wild type (WT) mice. There is no significant 
difference in the TRPV1-positive neuronal population between conditions (TRPV1, WT: 27.5 ±2.0% vs. KO: 28.5 ±2.4%, 
ns) suggesting that the knockout of Vti1b (Vti1b, WT: 77.7 ±3.3% vs. KO: 0.65 ±0.4%, *** p < 0.0001) does not have a 
major effect on TRPV1-expression. Of the TRPV1-expressing neurons, 70.8 ±5.6% were also expressing Vti1b 
(Vti1b/TRPV1) in the WT as compared to the KO 0.6 ±0.6% (*** p < 0.0001). Count of neurons is given in the columns, 
n = 2-3 mice, Kruskal-Wallis test followed by Dunn’s multiple comparison test. Data represented as mean ±SEM. (C) Co-
immunostainings of dissociated mouse lDRG neurons against TRPV1, Vti1b and Lamp1. White asterisk indicates TRPV1-
positive cell. Nuclei are visualized by DAPI staining (blue). Both TRPV1-positive and TRPV1-negative neurons express 
Vti1b (cyan in overlay) and Lamp1, a marker for late endosomes (magenta in overlay). Their staining pattern shows a 
partial overlap of the labelling for both proteins. Scale bar, 15 µm. From Sondermann et al., 2019. 
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3.2.1.2 Vti1b modulates TRPV1 tachyphylaxis in heterologous expression systems 
This section is based on Sondermann et al., 2019. 
The live labelling and calcium imaging experiments in HEK cells were performed by Master Student 
Allison Barry under the author’s teaching and supervision and are summarized in her Master thesis. 
The electrophysiological recordings were done by Niklas Michel, a Ph.D. student of the Schmidt lab.  
  
To investigate the nature of the interaction of TRPV1 and Vti1b, we made use of 
heterologous expression systems. HEK293 cells are easier to manipulate and obtained results 
might show a better reproducibility due to the homogeneity of the cells, as compared to the 
difficult-to-transfect and heterogeneous population of cultured DRG neurons of which only 
a fraction is expressing TRPV1, and in varying amounts. 
As stated above, Vti1b is involved in trafficking processes and could potentially also regulate 
trafficking of the TRPV1 channel to and from the plasma membrane. We therefore asked 
whether Vti1b expression level influences the surface expression of TRPV1. To this end, we 
performed live labelling of HEK cells, overexpressing TRPV1-YFP and Vti1b, or TRPV1-
YFP alone, using an antibody against an extracellular domain of the TRPV1 channel. As the 
antibodies cannot penetrate the intact cell membrane (within the limited time of incubation 
during the staining protocol), only TRPV1 channels residing at the plasma membrane are 
labelled. In YFP-positive HEK cells, we observed a clear punctuated staining at the 
membrane marking the plasma membrane TRPV1 population. However, upon co-expression 
of Vti1b the membrane TRPV1 staining was noticeably reduced (Fig. 3.6 B), even though 
the overall number of TRPV1 expressing cells (i.e. YFP-positive cells) did not differ 
significantly (85 and 90 cells from 3 independent cultures were analysed, 21 regions per 
condition). This suggests that Vti1b regulates the trafficking to the surface, possibly 
increasing endocytosis or inhibiting exocytosis of the channel. 
Apart from regulating the availability of functional TRPV1 at the membrane, Vti1b could 
also modulate gating properties of the channel TRPV1. Therefore, we performed 
electrophysiological recordings of HEK cells transiently transfected with either TRPV1 + 
mock or TRPV1 + Vti1b. Cells were subjected to 500 ms voltage ramps, ranging from -100 
V to +100 V, in whole-cell patch clamp mode and applied a single pulse of 100 nM capsaicin 
(Fig. 3.6 A). As expected, we found the TRPV1-mediated current to be outwardly rectifying  
and saw an increase upon capsaicin stimulation (Caterina et al., 1997). When comparing the 
2 conditions, we observed a significant decrease in the current density amplitude for the 
TRPV1 and Vti1b co-expressing cells (both before and after capsaicin stimulation). Neither 
the slope of the I-V curve nor the reversal potential differed between conditions, suggesting 
no change in the ion selectivity or voltage dependency of the channel. An explanation for 
the decrease in current density could be less TRPV1 at the membrane which is supported by 
the findings of the live labelling. 
Next, we set out to investigate the functional relevance of the interaction by means of 
ratiometric calcium imaging. TRPV1 is permeable to calcium, therefore, rises in intracellular 
calcium levels correlate with channel activity. Another prominent feature of TRPV1 is its 
rapid desensitization to agonist stimulation, in particular to repetitive pulses (also referred to 
as tachyphylaxis (Koplas P. A. et al., 1997)). To observe potential changes in the 
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desensitization behaviour, we challenged HEK cells with 6 pulses of 100 nM capsaicin 
(Caps) followed by a saturating pulse of capsaicin (1µM; see 2.1.5.8 for details). The HEK 
cells were overexpressing either TRPV1 + Vti1b or only TRPV1 alone. Stimulation 
protocols with several consecutive stimuli are often used in literature to study TRPV1 
desensitization phenomena in vitro and this 6-pulse protocol was modified from Bonnington 
and McNaughton as well as Hanack et al. (Bonnington and McNaughton, 2003; Hanack et 
al., 2015).  
In Fig. 3.6 C, the averaged traces of responder to the capsaicin stimulation are depicted, 
showing noticeable differences in the changes of intracellular level of calcium between the 
two experimental groups upon application of capsaicin (for amplitude data to each pulse see 
Appendix Fig. 7.1 A). The percentage of responders to each of the capsaicin pulses, 
especially notable for the initial 1st capsaicin pulse (% is referred to the count of all TRPV1-
expressing cells, i.e. sum of cells responding to one or more capsaicin pulses) was lower in 
the TRPV1 + Vti1b group. This suggest that co-expression of Vti1b decreases the amount 
of functional TRPV1 at the membrane, which is in line with the results of the live labelling 
and whole cell recordings above. However, this observation could simply stem from 
artefacts due to overexpression of the protein which may compromise the cells’ health and 
ability to express and target the proteins to their correct location. 
To investigate differences in the tachyphylaxis behaviour, we compared the number of cells 
responding to the 1st pulse to those responding to the 6th pulse. We found that the fraction of 
non-responder (i.e. desensitized cells) is not different in cells co-expressing TRPV1 and 
Vti1b, while cells expressing only TRPV1 exhibited the expected tachyphylaxis, i.e. less 
cells responding to the 6th than to the 1st pulse (Fig. 3.6 D left). The changes in number of 
responders were supported by similar changes in the amplitudes (Fig. 3.6 C, D right).  
As mentioned above the overexpression of proteins could impair cell health, thus, we applied 
ATP – activating endogenously expressed purinergic channels in the HEK cells (He et al., 
2003) – at the end of the protocol to compare the overall health status of the two conditions. 
Yet, no difference was observed (Appendix Fig. 7.1), excluding that a general compromised 
cellular health caused the observed differences.  
 
To sum up, on one hand, Vti1b co-expression resulted in an attenuated responsiveness to 
capsaicin that could be attributed to less functional TRPV1 at the membrane already prior to 
the 1st application of the agonist. One the other hand, the typically observed 
desensitization/tachyphylaxis of TRPV1, measured by a decrease in cells responding to 
consecutive pulses as well as a decrease in the response amplitude, is diminished and/or 
absent in TRPV1 and Vti1b co-expressing cells. Both could be explained with impaired 
endo- or exocytosis of the channel to the membrane.  
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3.2.1.3 Modulation of Vti1b expression levels alters TRPV1-dependent sensitization of 
sensory neurons in vitro  
This section is based on Sondermann et al., 2019. 
 
To explore a functional relevance for the proposed TRPV1-Vti1b interaction on TRPV1-
mediated nociceptive signalling, we moved from the heterologous expression system to 
dissociated cultures of sensory neurons from mouse lDRG. We modulated the Vti1b 
expression level by siRNA-mediated knockdown in cultures derived from mice either 
injected with CFA, or Veh as controls, to mimic inflammatory pain. Ratiometric calcium 
imaging with a similar 6 × 100 nM capsaicin pulse protocol as in section 3.2.1.2 was 
performed to assess differences in the capsaicin-evoked desensitization behaviour of 
TRPV1-expressing sensory neurons (Fig. 3.7). The neurons were imaged 72 h after 
transfection with siRNA against Vti1b, or negative control (Ctlr) siRNA (see Fig. 3.7 A for 
proof of successful knockdown).  
The siRNA-mediated knockdown of Vti1b did not lead to statistically significant differences 
in the percentage of TRPV1-expressing neurons responding to the initial capsaicin pulse (P1, 
Fig. 3.7 C), neither in the Veh group nor in the CFA group. Also, the response amplitudes 
to the first pulse were not different between groups or conditions (Fig. 3.7 D).  
To take a closer look at the potential influence of the reduced Vti1b level on the sensitization 
of TRPV1expressing neurons, I wanted to assess whether tachyphylaxis, i.e. the fraction of 
cells responding to the 6th pulse, differed between groups and conditions (Fig. 3.7 E, F). 
There was a noticeable effect of CFA on the desensitization of the neurons already for the 
control condition. Only 22.5% of all TRPV1-expressing neurons responded to the 6th pulse 
in the Veh group (Veh c) vs. 51.1% in the CFA group (CFA c, Fig. 3.7 E), suggesting that 
Figure 3.6: Overexpression of Vti1b alters surface expression, function and desensitization of heterologously 
expressed TRPV1 channels 
(A, left) Peak current densities evoked by application of 100 nM capsaicin (Caps). HEK293 cells were transiently 
transfected with either TRPV1-YFP + Mock or TRPV1-YFP + Vti1b. For +100 mV, *** p = 0.0003, and for -100 mV, ns, 
p = 0.2755, two-way ANOVA followed by Holm-Sidak’s multiple comparisons test. (A, right) Averaged I–V relationships 
before (w/o Caps) and after the application of 100 nM Caps in HEK293 cells overexpressing either TRPV1-YFP + Mock 
and TRPV1-YFP + Vti1b, n = 11-13 independent cultures. (B, left) Representative images of live-labelling of TRPV1 at 
the plasma membrane. HEK293 cells were transiently transfected with either TRPV1-YFP + Mock or TRPV1-YFP + Vti1b 
and were live-labelled with an antibody against extracellular epitope of TRPV1 for 10 min at 37°C. Only the surface 
population of TRPV1 was labelled by the TRPV1 antibody (TRPV1-extr). Upon co-expression of Vti1b less YFP-positive 
cells show intense surface labelling. Scale bar, 15 m. (B, right) Sample quantification of (B, left) represented as fraction 
of membrane TRPV1-positive area (to total cell area) in YFP-positive cells. *** p < 0.0001, n = 3 independent cultures; 
Mann-Whitney test. (C) Representative traces of rises in intracellular calcium as fluorescence absorbance ratio 340/380 
i.a.u.. Graph displays averaged traces (mean ±SEM) of HEK293 cells transiently transfected with either TRPV1 + Mock 
(light blue, N = 91 cells) or TRPV1 + Vti1b (dark blue, N = 27 cells) that were able to respond to all 6 consecutive Caps 
pulses. When comparing the amplitudes of P6 to P1 (indicated by black vertical bars) within one condition, it becomes 
apparent that for the TRPV1 + Vti1b condition nearly no tachyphylaxis is seen. (D, left) The fraction of responders 
(colored) and non-responders (white) of TRPV1-expressing cells are shown in stacked bar graphs for the P1 and P6 pulse 
for each condition. For P1 TRPV1 + Mock vs. P1 TRPV1 + Vti1b: *** p < 0.0001; for P1 TRPV1 + Mock vs. P6 TRPV1 
+ Mock: *** p < 0.0001; for P1 TRPV1 + Vti1b vs. P6 TRPV1 + Vti1: ns, p = 0.5411, n = 3 independent cultures, Fisher’s 
exact test.  (D, right) Averaged response amplitudes of TRPV1-expressing cells are displayed for the P1 and P6 pulse for 
each condition. For P1 TRPV1 + Mock vs. P1 TRPV1 + Vti1b: *** p < 0.001; for P1 TRPV1 + Mock vs. P6 TRPV1 + 
Mock: *** p < 0.0001; for P1 TRPV1 + Vti1b vs. P6 TRPV1 + Vti1b: ns, p = 0.2209, n = 3 independent cultures; one-way 
ANOVA + Holm-Sidak multiple comparisons test. A-C & D, left: data are displayed as mean ±SEM and cell count above 
scatter/ in column. From Sondermann et al., 2019. 
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CFA-mediated sensitization of TRPV1 channels can override the tachyphylaxis observed in 
DRG neurons derived from Veh-injected mice. In CFA-treated cultures the knockdown of 
Vti1b (CFA si) resulted in tachyphylaxis, i.e. significantly less responder to the 6th pulse as 
compared to CFA c. In addition, the amplitude of the responders was reduced in CFA si as 
compared to CFA c. Overall, the magnitude of tachyphylaxis in CFA si was similar to that 
seen in the Veh si group (Fig. 3.7 E). Of note, the overall number of TRPV1-expressing 
neurons, i.e. number of neurons responding to one or more capsaicin pulses, was not changed 
between groups or conditions. This suggests – together with the finding that responses to the 
initial capsaicin pulse (P1) were not different – that the modulation of Vti1b expression does 
not compromise the general TRPV1-expression in sensory neurons. 
 
Taken together, these data indicate that Vti1b promotes the sensitization of TRPV1-
expressing lDRG neurons treated with CFA. Since Vti1b has been suggested to play a role 
at different steps of intracellular trafficking, one working hypothesis was that the decrease 
in expression of Vti1b leads to an increase in the stimulated endocytosis of TRPV1 after 
repetitive stimulation under inflammatory conditions. Therefore, I decided to inhibit 
clathrin-dependent endocytosis to see whether this could rescue the decrease of CFA-
mediated sensitization when Vti1b is downregulated. To this end, I applied dynasore 
(inhibitor of dynamins, a group of GTPases responsible for the scission of clathrin-coated 
pits from the plasma membrane (Macia et al., 2006)) to neuronal lDRG cultures from CFA-
injected mice, in which I downregulated Vti1b expression via siRNA, followed by calcium 
imaging. The same stimulation protocol as above was used, except that I applied dynasore, 
which acts within seconds after application, in the washout between the 5th and 6th capsaicin 
pulse until the end of the 6th pulse. In Fig. 3.7 E the effect of dynasore on the fraction of 
cells responding to the 6th pulse is displayed, showing that with addition of dynasore the 
sensitization (i.e. an increase in responders to the 6th pulse) is restored. The restored 
sensitization was also reflected in the response amplitudes (Fig. 3.7 F). Preventing 
internalization of TRPV1 via clathrin-mediated endocytosis successfully rescued the 
sensitization of the Vti1b knockdown, suggesting Vti1b has a role in regulating the activity-
dependent trafficking of TRPV1. However, we cannot tell at which step of the trafficking 
Vti1b comes into play. Previously, Vti1b has been related to both stimulated exocytosis as 
well as lysosomal degradation via mediating the fusion of LE and lysosomes in  immune 
cells (Dressel et al., 2010; Murray et al., 2005; Offenhäuser et al., 2011). Further calcium 
imaging experiments using for example, lysosomal inhibitors would be needed to address 
this point.  
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Figure 3.7: Vti1b knockdown affects CFA-induced sensitization of TRPV1-expressing sensory neurons 
(A, left) Representative images of primary lDRG cultures stained against Vti1b and TRPV1 72h after transfection with 
either Vti1b siRNA (lower panels) or negative control siRNA (upper panels). Scale bar, 25 m. (A, right) Quantification 
of efficient siRNA-mediated downregulation of Vti1b expression. The percentage of Vti1b-positive neurons is significantly 
reduced upon siRNA-mediated knockdown, * p < 0.05, n = 3 independent culture preparations, unpaired Student’s t-test.  
(B) Representative traces of rises in intracellular calcium (fluorescence ratio 340/380 i.a.u.) in dissociated cultures of lDRG 
from Veh-/CFA-injected mice, treated with Vti1b siRNA (si) and control siRNA (c), respectively. They were challenged 
with 6 pulses of 100 nM capsaicin (P1-P6, Caps). Note that cells are only counted as “responder” if the rise in calium 
exceeds 20% of the baseline for each pulse. (C) Fraction of responders (to TRPV1-expressing neurons, colored) and non-
responders (white) to the 1st Caps pulse (P1), ns, n = 4 independent cultures; Fisher’s exact test. (D) Averaged response 
amplitudes (peak of fluorescence ratio 340/380 above baseline) to P1; n = 4 independent cultures; one-way ANOVA 
followed by Holm-Sidak’s multiple comparisons test. (E) Fraction of responders (colored) and non-responders (white) to 
the 6th capsaicin pulse (P6).  Veh c vs. CFA c: *** p < 0.0001; Veh si vs. CFA si: ns; CFA c vs. CFA si: *** p = 0.0002. 
Incubation with Dynasore between P5 and P6: CFA si vs. Dynasore CFA si: * p = 0.0146, n = 3-4 independent cultures, 
Fisher’s exact test. (F) Averaged response amplitudes (peak of fluorescence ratio 340/380 above baseline) to P6. CFA c 
vs. CFA si: * p = 0.0349; CFA si vs. Dynasore CFA si: ** p = 0.001, cell counts in the columns, n = 3-4 independent 
cultures, one-way ANOVA followed by Holm-Sidak’s multiple comparisons test. A, D, F: data displayed as mean ±SEM; 
A, C-F: count of neurons in columns; if not indicated otherwise, all comparisons ns. From Sondermann et al., 2019. 
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3.2.1.4 Vti1b does not interact with TRPA1 in sensory neurons 
TRPA1 experiments were performed by Master Student Allison Barry under the author’s teaching 
and supervision and are summarized in her Master thesis. 
 
Nearly all TRPA1-expressing DRG neurons co-express TRPV1 (Story et al., 2003) and 
several lines of evidence suggest an interaction of both channels (Akopian et al., 2007; Salas 
et al., 2009; Staruschenko et al., 2010; Weng et al., 2015). We therefore investigated whether 
Vti1b also modulates TRPA1-mediated activity in DRG neurons. RNAi-mediated 
knockdown of Vti1b in mouse lDRG cultures was followed by ratiometric calcium imaging 
(Fig. 3.8). We stimulated the cells with a 25 µM mustard oil (MO) pulse, followed by a       
50 µM MO pulse and subsequently, the cells were depolarized with KCl to determine the 
total population of neuronal cells. Neither the percentage of responders to each pulse, nor 
the respective response amplitudes, nor the total number of cells responding to one or more 
MO pulses (i.e. TRPA1-expressing neurons) was changed between conditions (Fig. 3.8 A-
C). Also, the desensitization of TRPA1 did not show any significant changes as presented 
in Fig. 3.8 D by comparing the fraction of neurons responding to both MO pulses. This 
suggests that Vti1b is not interacting with TRPA1. This was further supported by results 
from a mass spectrometric screening for TRPA1 interactors performed in my host laboratory, 
in which Vti1b was not detected (Luca Avenali, personal communication).
 
Figure 3.8: Knockdown of Vti1b does not influence TRPA1-mediated neuronal activity 
(A) Representative traces of rises in intracellular calcium (fluorescence absorbance ratio 340/380 i.a.u.). Graph displays 
averaged traces (mean ±SEM) of DRG neurons transiently transfected with either control siRNA (green) or Vti1b siRNA 
(black), 72 h after transfection, that responded to both the 25 µM and 50 µM MO application; N = 27 neurons for control 
and N = 38 for Vti1b siRNA. (B) Percentage of responder (to TRPA1-expressing cells) to each MO pulse (mean ±SEM). 
(C) Proportion of cells responding to any of the MO pulses (i.e. TRPA1-expressing cells); N = 204 for control and N = 
219 for Vti1b siRNA. (D) Fraction of cells responding to both MO pulses; N = 72 for control siRNA and N = 89 for 
Vti1b siRNA. None of the data showed significant differences between control and Vti1b siRNA; two-way ANOVA (B, 
C) and Fisher’s exact test (C, D). Data from n = 2 independent cultures. Graphs adapted with permission from A. Barry. 
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3.2.2 In vivo knockdown of Vti1b attenuates thermal hyperalgesia in an inflammatory 
pain model  
The major part of this section is based on Sondermann et al., 2019. 
 
As the results suggest a functional relevance for the Vti1b-TRPV1 interaction, I tested 
whether Vti1b also modulates TRPV1- dependent pain behaviour in mice. 
First, Vti1b-deficient mice (a global, constitutive KO; (Atlashkin et al., 2003)) were assessed 
for basal pain thresholds (both mechanical and thermal), acute capsaicin-evoked pain 
behaviour and the development of thermal hyperalgesia in the CFA model of inflammatory 
pain. However, no significant differences in any of the behavioural tests was observed 
(Appendix Fig. 7.3). The missing of a phenotype in constitutive KO mice can often be 
related to compensation by a homologous protein. In the case of Vti1b, the closely-related 
Vti1a (30% amino acid homology) could be a candidate for a compensation, as the double 
KO of Vti1b and Vti1b is perinatal lethal (Kunwar et al., 2011), whilst deletion of one of 
them leads to a minor phenotype (Atlashkin et al., 2003). 
To circumvent this problem, I established the virus-mediated local knockdown of Vti1b in 
lDRG. Adeno-associated virus, serotype 6 (AAV6) encoding GFP-coupled miRNA 
targeting Vti1b (and as control scramble miRNA-GFP) was injected unilaterally into the 
sciatic nerve of mice. After 3 weeks the successful knockdown of Vti1b was confirmed by 
immunohistochemistry against Vti1b and GFP on lDRG (Fig. 3.9 A). On average, 15-18% 
of all lDRG neurons showed GFP expression (GFP, Fig. 3.9 B), i.e. were successfully 
transduced with either AAV6-scramble miRNA-GFP or AAV6-Vti1b miRNA-GFP. Only 
3% of the transduced neurons were positive for Vti1b in the case of AAV6-Vti1b miRNA-
GFP, whilst in the control no reduction of the Vti1b expression in GFP-positive cells was 
observed (Vti1b/GFP, Fig. 3.9 B). Interestingly, 28% of all TRPV1-expressing neurons were 
also positive for GFP (GFP/TRPV1, Fig. 3.9 C). This did not differ between the scramble 
and Vti1b miRNA group (Fig. 3.9 C) revealing that the knockdown of Vti1b does not have 
a major effect on TRPV1 expression. 
To assess changes in somatosensory behaviours upon downregulation of Vti1b, mice were 
tested prior to virus injection for (i) their basal mechanical pain threshold with the dynamic 
aethysiometer (withdrawal latency of the hind paw to a mechanical stimulation), and (ii) 
their thermal threshold with the Hargreaves test (withdrawal latency to a radiant heat 
stimulus). These behavioural tests were repeated 3 weeks after the injections and did not 
reveal any changes in the basal sensitivity upon knockdown of Vti1b (Fig. 3.9 D). Our in 
vitro calcium imaging data show that knockdown of Vti1b leaves normal/non-sensitized 
functioning of TRPV1 untouched as the responses to the initial, single capsaicin stimulus 
were not different to control siRNA. To investigate whether normal function of TRPV1 is 
also unchanged in vivo, I performed an intradermal injection of a single dose of capsaicin. 
WT mice show acute nocifensive behaviour (e.g. licking, shaking and flinching) 
immediately after the application of capsaicin, which is absent in Trpv1-KO mice (Caterina 
et al., 2000). Mice were treated with AAV6-Vti1b miRNA and scramble miRNA as 
described above and the total duration of nocifensive behaviour after intradermal capsaicin 
injection was recorded over a period of 6 min (Fig. 3.9 E). As an additional control, a group 
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of naïve WT mice were injected in parallel. The capsaicin-evoked nocifensive behaviour 
was similar between all 3 groups, suggesting the Vti1b-TRPV1 interaction is not relevant 
for the normal activity of TRPV1. On the other hand, the CFA-mediated sensitization was 
found to be compromised in vitro. Thus, intraplantar injection of CFA to induce 
inflammatory pain was performed in another cohort of AAV6-Vti1b miRNA/scramble 
miRNA-treated mice. Twenty-four hours post CFA the mice were tested for the development 
of thermal hyperalgesia (Fig. 3.9 F and Appendix Fig. 7.4). Both the control group and 
Vti1b miRNA mice exhibited a decrease in the withdrawal latency to a heat stimulus 
(hyperalgesia). However, the reduction in latency compared to the contralateral paw was 
significantly lower in the Vti1b miRNA group, indicating a reduced development of thermal 
hyperalgesia if Vti1b expression is downregulated. This supports the notion that Vti1b is 
pro-algesic and facilitates TRPV1 sensitization. In a next step, I investigated whether Vti1b 
might affect pain behaviours upon inflammation which are largely independent of TRPV1.  
I did not observe any differences in the development of mechanical allodynia 24 h and 48 h 
after the CFA-injection (Fig. 3.9 G and Appendix Fig. 7.4) for which TRPV1 is postulated 
to only contribute to a small degree (Caterina et al., 2000; Gavva et al., 2005; McGaraughty 
et al., 2008).  These results lend partial support for a selective effect of Vti1b on TRPV1.  
 
Figure 3.9: AAV6-mediated knockdown of Vti1b reduces thermal hyperalgesia after inflammation  
(A, B) Co-immunostainings on lDRG of mice injected with AAV6-Vti1b miRNA-GFP (Vti1b miR, upper panels) and 
AAV6-scramble miRNA-GFP (Scramble miR, lower panels). (A) Representative images show successful knockdown of 
Vti1b (red) in GFP-positive cells (green) of the Vti1b miR group 3 weeks after virus injection. Exemplary GFP-
immunoreactive neurons are labelled with white asterisks. Note that in the merged images of the scrambled miRNA most 
of the cells that show overlap of GFP and Vti1b do not appear completely yellow, as the Vti1b staining does not fill the 
complete cytoplasm. Scale bar, 50 µm. (B) Quantitation to determine the Vti1b knockdown. Percentage of neurons 
immunoreactive for GFP (GFP) did not differ significantly, but the percentage of Vti1b-positive (Vti1b, ** p < 0.01) as 
well as the fraction of neurons immunopositive for Vti1b to GFP-positive ones (Vti1b/GFP, *** p < 0.001). Cell count per 
label in columns; in total N > 2400 neurons from 4 mice (3 lDRG/mouse) per condition analysed. Significance was 
determined with one-way ANOVA followed by Bonferroni's multiple comparison tests. (C) Quantitation of co-
immunohistochemistry on lDRG sections from Vti1b miR and scrambled miR-injected mice (sacrificed after capsaicin 
treatment) labelled for TRPV1 and GFP. No significant differences were determined by one-way ANOVA; cell count per 
label in columns; in total N > 2000 neurons from 4 mice per condition (3 lDRG/mouse. (D) Knockdown of Vti1b does not 
change basal sensitivity to a radiant heat stimulus (D, left) or punctuate mechanical pressure (D, right), as no change in 
the withdrawal latency of the ipsilateral paws was observed. Mice were tested prior to virus injection (pre AAV6) and 3 
weeks after the injection (pre CFA). No significant differences were determined by Kruskal-Wallis test, N > 10 mice for 
each group, n = 2 independent cohorts. (E) Capsaicin-induced nocifensive behaviour is unaffected by Vti1b knockdown. 
Mice injected with Vti1b miR or scramble miR and naïve WT mice received intradermal capsaicin injections (0.5 µg). The 
time spent licking, shaking, flinching or lifting the treated hind paw was measured over a period of ten minutes. No 
significant differences were determined by Kruskal-Wallis test, N > 6 mice per condition, n = 2 independent cohorts. (F) 
Vti1b knockdown diminishes heat hyperalgesia after CFA-induced inflammation. Mice injected with Vti1b miR or 
scramble miR developed heat hyperalgesia 24 h after CFA injection. This is reflected in the reduction of the withdrawal 
latency to a radiant heat stimulus for the ipsilateral paw. The mice injected with Vti1b miR exhibited significantly less 
hyperalgesia, * p = 0.0128, N = 10 per group, n = 2 independent cohorts, Mann Whitney test. (G) Vti1b knockdown does 
not affect mechanical hypersensitivity after CFA-induced inflammation. Mice injected with Vti1b miR or scramble miR 
developed mechanical hypersensitivity 24 h after CFA injection. This is reflected in the reduction of the withdrawal latency 
for the ipsilateral paw to a mechanical stimulus. No significant difference was observed between groups, N = 8-10 per 
group, n = 2 independent cohorts, Mann Whitney test. All Data represented as mean ±SEM. D, F, G: withdrawal latencies 
for the contralateral paws as well as normalized values (% to contralateral paws) can be found in Appendix Fig. 7.4. From 
Sondermann et al., 2019. 
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3.2.3 Vti1b belongs to the TRPV1 interactome 
This section is based on Sondermann et al., 2019. 
 
All data shown so far propose that Vti1b has a pro-algesic role in lDRG neurons by targeting 
TRPV1. Thus, one would assume that both proteins can be found near each other in a neuron 
to interact with each other. To test this hypothesis, I performed a Proximity Ligation Assay 
(PLA), a technique to investigate the close proximity of two proteins in situ. The procedure 
is similar to an ICC in that primary antibodies against the target proteins are applied. 
However, the 2 secondary probes have to be ≤40 nm apart from each other to be able to 
interact. This interaction then gives rise to a measurable signal (Söderberg et al., 2006). Fig. 
3.10 A, middle panel shows a representative image of the PLA with antibodies against 
TRPV1 and Vti1b on cultured WT lDRG neurons. As control for the specificity of the PLA 
signal, the PLA was done on neurons from Trpv1-deficient mice. Fig. 3.10 A, right panel 
shows the fraction of cell area that was PLA-positive (%area, i.e. the area showing PLA 
signal above threshold) per individual cell for WT and Trpv1-deficient DRG neurons. None 
of the Trpv1-deficient neurons showed PLA-positive signal for more than 7% of their cell 
surface area, indicating that the increased PLA signal in WT neurons is specific for the 
Vti1b-TRPV1 interaction. 
Furthermore, we performed PLA on HEK cells overexpressing TRPV1 either with Vti1b or 
the mock plasmid (Fig. 3.10 B). Signal quantification is presented in Fig. 3.10 B as cell area 
with PLA signal above threshold per individual cell. In TRPV1+ Vti1b expressing cells on 
average 50.8 ±3.6% of the cell area was PLA-positive, whilst in only TRPV1 expressing 
cells only 4.6 ±1.3% of the area was PLA-positive, indicating close proximity of the two 
proteins also in the heterologous expression system.  
We wanted to further verify the co-localisation of the two proteins by a different method, 
thus, we performed co-immunoprecipitation (CoIP) against TRPV1 from HEK293 cells 
overexpressing Vti1b and TRPV1. Fig. 3.10 C shows the immunoblot of CoIPs from HEK 
cells transiently transfected with either both Vti1b-myc-DDK and TRPV1-YFP plasmids, or 
TRPV1-YFP and mock (empty pcDNA-Sport6 plasmid). Vti1b was successfully pulled 
down when co-expressed with TRPV1-YFP, suggesting a physical binding of the two 
proteins in a non-sensory cell context – however, not necessarily a direct binding, as the 
TRPV1-Vti1b interaction could be mediated by a third unknown protein.  
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Figure 3.10: Vti1b is in close proximity to TRPV1 both in DRG neurons and upon heterologous expression  
(A, left) Close proximity of Vti1b and TRPV1 is revealed by PLA with antibodies targeting TRPV1 and Vti1b in primary 
cultures of mice lDRG neurons of wild type mice as compared to neurons from TRPV1-KO mice that were treated similarly. 
Exemplary neurons that show PLA signal in >20% of their cell area are marked with white arrows. Scale bar, 25 µm. (A, 
right) Sample quantification of (A, left). Results are displayed as %area, ie. the % of cell area with PLA signal above 
threshold per individual cell. Wild type vs. TRPV1 KO: *** p < 0.0001, neuron count above scatter, n = 2-3 independent 
cultures, Mann-Whitney test. (B, left) Representative images of PLA with antibodies targeting myc (Vti1b) and TRPV1 on 
HEK cells that were transiently transfected with TRPV1-YFP + Vti1b-myc-DDK, or as control TRPV1-YFP + Mock. Scale 
bar, 15 µm. (B, right) Quantification of PLA signal on HEK cells (B, left). Results are displayed as % area, i.e. the % of 
cell area with PLA signal above threshold per individual cell (only YFP-positive cells were considered). TRPV1-YFP + 
Vti1b vs. TRPV1-YFP + Mock: *** p < 0.0001, neuron count above scatter, n = 3 independent cultures, Mann-Whitney 
test. (A, B) Data represented as mean ±SEM. (C) Representative western blot of co-immunoprecipitation against TRPV1 
from HEK cells transiently transfected with TRPV1-YFP + Vti1b-myc-DDK, TRPV1-YFP + Mock or only Mock (n = 5). 
Membranes were incubated with anti-TRPV1-Ab (upper panel) and anti-Vti1b-Ab (lower panel). TRPV1 was detected in 
the elute of both TRPV1 + Mock- and TRPV1 + Vti1b-transfected cells. Vti1b was detected only in the input and elute of 
the TRPV1 + Vti1b co-expressing cells. Of note, the lower, less intense band in the input of the TRPV1 + Vti1b-condition 
is an unspecific band. Appendix Fig. 7.5 displays the corresponding image of the whole immunoblot. From Sondermann 
et al., 2019. 
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3.2.4 Identification of pain-specific interactors of TRPV1 by quantitative mass 
spectrometry 
A part of this section is based on Sondermann et al., 2019. 
 
Yet another method to identify interaction partners is functional proteomics – CoIP of the 
protein of interest followed by quantitative tandem mass spectrometry. We wanted to co-
immunopurify native TRPV1 from murine lDRG to confirm that Vti1b is a member of the 
TRPV1 complex, but also go one step further and see whether we could detect a pain 
dependent regulation of the Vti1b-TRPV1 interaction as well as detect further members of 
the TRPV1 complex. 
Inflammatory pain was induced by injecting CFA into the hind paw of wild type mice, which 
leads to a local swelling and inflammation of the paw accompanied by development of 
thermal and mechanical hypersensitivity. The mice were sacrificed 24 h after the injection 
and the lDRG innervating the inflamed paw were excised. After detergent-aided tissue lysis 
a CoIP was performed against the native TRPV1 channel. Subsequently, TRPV1 and co-
purified proteins were analysed and quantified by UDMSE (see section 2.1.7.2 for details). 
Since the idea was to profile the interactome dynamics between the pain condition and a 
physiological control, a second group of mice that were injected with the vehicle (Veh) was 
processed as described above. In addition, to reduce the list of false positive interactors due 
to unspecific binding to the affinity matrix, I performed the CoIP also from lDRG of Trpv1-
deficient (KO) mice. To take into account the biological variability as well as possible 
variances in sample preparation, 3 biological replicates of each condition (CFA, Veh, and 
KO) were prepared and analysed. 
 
In total 1089 proteins were identified and quantified in all 9 samples (see section 2.1.7.2 for 
details).  For the bait TRPV1 34 unique peptides (54% sequence coverage) were consistently 
detected in each of the 3 replicates of the Veh and CFA group. In the samples from the KO 
mice, serving as negative controls, TRPV1 was not detected. The amount of TRPV1 
quantified across all replicates was not equal (see below). 
To access the similarity of the replicates within and between the groups, the log2-
transformed abundance values of all 9 samples were plotted against each other and the 
Pearson correlation coefficient was calculated (see Appendix Fig. 7.6). On average, the 
samples showed high correlation (0.681-0.968). As expected, the correlation within one 
group was higher than between the groups of one replicate round. Furthermore, the samples 
of the first replicate round showed a trend to lower correlation coefficients when being 
compared to the other replicates, round 2 and 3, respectively. All samples had been analysed 
on the same LC-MS platform, however, round 2 and 3, which were run consecutively, were 
acquired six months after round 1, indicating run-to-run differences in the acquisition. 
Next, the detected amount of proteins in Veh or CFA, respectively, were compared to the 
KO group with regard to their fold change and the statistical significance of this enrichment.  
Two issues had to be dealt with before a fair comparison could be carried out: 
(I) Different amounts of the bait TRPV1 had been detected in the replicates of the CFA and 
Veh group, which could explain the observed differences in the detected amount of 
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interactors between the conditions. Therefore, the amount of bait in CFA was divided by the 
amount in Veh (of the respective replicate round) and all proteins in the CFA group were 
normalized with this replicate-specific ratio. 
(II) Many proteins had not been detected in 3/3 replicates and/or all conditions. Missing 
values pose a problem onto the statistical analysis using a t-test, which requires 3 valid values 
per group. One could simple omit the proteins not detected in 3/3 replicates over all 
conditions, but this would most probably lead to the loss of weak or transient interactors, 
which might just not have crossed the detection limit of the mass spectrometer in one or the 
other run.  Another well-established option, which is commonly used, is to impute the 
missing values, either by a constant value near the detection limit of the mass spectrometer, 
or by random values taken from a normal distribution simulating low abundance values 
(Hubner et al., 2010). I decided to try out both methods in parallel and compare the outcome. 
First, any protein that had not been detected in at least one group in 3/3 replicates was omitted 
(reducing the number of proteins to 1015), then missing values were imputed with  
(a) a constant value of 5.41 (log2 value of the lowest detected value over all runs, shifted 
down for one order of magnitude), and  
(b) random values of a normal distribution from low abundant values (see Appendix Fig. 
7.7) for distribution of imputed values and section 2.1.7.2 for further details on imputation). 
Second, I used a modified version of the Student’s t-test (Tusher et al., 2001) to determine 
the difference between observed protein abundances in CFA / Veh and the KO control. In 
this version of the test an additional parameter called s0 is considered.  In simple terms, one 
could understand the s0 as a minimal fold change that a protein must show next to a sufficient 
p-value to become a significant hit.  
Proteins with q-values < 0.05 and s0 > 1.58 (equals a fold change of 3) were stated as 
significantly enriched and defined as putative interactors of TRPV1. Plotting the observed 
log2 fold change versus the negative logarithm of the p-value results in a “volcano plot” 
(Fig. 3.11 A, B), where putatively interesting candidates (i.e. high fold change & high -log 
p-value) can be easily distinguished from background binders (Hubner et al., 2010).  These 
proteins that bind unspecifically to the matrix accumulate around the zero-line (low fold 
change ratio). The fraction of proteins in the upper left quadrant (i.e. significantly enriched 
in the KO group) can also be discarded for the further analysis as binding completely 
unspecific to the affinity matrix. 
 
In total 95 proteins for CFA and 115 for Veh showed an at least 3-fold enrichment to the KO 
control, when imputation of missing values was done with random values (b). Of these 
proteins, 55 were enriched in both CFA and Veh. On the contrary, if imputing with a constant 
value of 5.41, 127 proteins for CFA and 169 for Veh showed an enrichment and 89 proteins 
were enriched in both groups (Fig. 3.11 C). 
The list of significantly enriched proteins (of imputation method (b)) was compared with 
entries of the TRIP Database 2.0 (http://www.trpchannel.org/summaries/TRPV1), an online 
databank containing previously reported interactors of mammalian TRP channels.  Both 
TRPV2, a well-established interactor of TRPV1 (Hellwig et al., 2005) and the dynactin 
subunit 1 (Dctn1, Stein et al., 2006) were found previously by complementary methods. In 
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addition, extended synaptotagmin-1 (Esyt1) was detected that had been found previously in 
the interactomics screen from Hanack et al. (Hanack et al., 2015). 
Vti1b was detected in both Veh and CFA (log2 fold change Veh/KO = 4.1; CFA/KO = 4.43, 
Fig. 3.11 A, B, #3). Strikingly, the detected amount of Vti1b in CFA was approx. 20% less 
than in Veh suggesting a decrease in the interaction with TRPV1 upon inflammatory pain. 
This is in line with our proteomics data (Barry et al., 2018; Rouwette et al., 2016). 
Subsequently, to define the pain-specific interactors, the significantly enriched proteins of 
Veh and CFA were compared to each other. Supposing that a 20% regulation of the 
interaction might be biologically relevant (as demonstrated for Vti1b), I defined pain-
specific interactors among the proteins (significantly enriched compared to KO) as having a 
log2 fold change of CFA/Veh > 0.263 or < -0.263, respectively. This resulted in 50 (57) 
proteins that associate with TRPV1 only under inflammatory conditions, while 83 (126) 
dissociate (see Appendix Table 7-1).  
The imputation of missing values with the constant value of 5.41 yielded overall more 
proteins that were counted as putative interactors of TRPV1.  Most of the proteins that were 
not detected using the imputation with random values are low abundant ones (log2 
abundance values ranging from 8-12) with the need of imputing 3 values for the KO control 
group (i.e. detected in 0/3 replicates). Therefore, if one imputes with random values from a 
normal distribution simulating low abundant values (mostly values between 8-11), these do 
not cross the threshold for being considered significantly enriched compared to the KO group 
(log2 fold change > 1.58). Setting a low value like 5,41 avoids this problem as exemplary 
shown for Stx8 (compare location of #4 in Fig. 3.11 A, B and values in D). However, for 
cases in which only 1/3 or 2/3 values are missing, it seems more reasonable to impute with 
random low abundance values to avoid the artificial decrease in the group mean (if imputing 
with 5.41) that in case of Stx8 leads to defining the protein as “pain- specific” (log2 fold 
change < or > 0.263), in contrast to not being detected above threshold to KO (log2 fold 
change < 1.58) at all (Fig. 3.11 D).  
Optimally, one would analyse the cases with 0/3 detections in the KO (and also for 0/3 in 
CFA or Veh) separately, without performing a t-test (see Appendix Table 7-2). However, 
they should not be attributed with a fold change (CFA/KO or Veh/KO or CFA/Veh) as one 
cannot be certain that the protein was really not present in the KO samples (abundance of 0), 
or maybe it was just below the detection limit in 3/3 replicates of the KO group (unknown 
abundance value > 0) and therefore, any calculated fold change would be erroneous.  
 
For the final analysis of the interactomics data as published in Sondermann et al., 2019, we 
decided to use the imputation with random values from a normal distribution simulating low 
abundant values to exclude unsecure candidates like Stx8. Also, we set a more stringent 
threshold for significantly regulated proteins (q-value < 0.01, compare Figure 6 and 
Materials and methods 2.19.2. in Sondermann et al., 2019) to further decrease the probability 
of false positives. 
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Using the Database for Annotation, Visualization and Integrated Discovery (DAVID), I 
investigated the biological implication behind the putative pain-specific interactors. Several 
clusters of GO annotation terms were found to be enriched, amongst others “intracellular 
protein transport” for the proteins dissociating from TRPV1 under inflammatory pain and 
“actin binding” for the ones associating with TRPV1 under inflammatory pain (Appendix 
Table 7-3 and 7-4). To identify predicted associations among the candidates, I uploaded the 
dataset to STRING and did a network analysis, reporting direct and/or functional interactions 
based on experimental validation and curated databases (Appendix Fig. 7.8 and 7.9). Yet, 
no extensive clusters of interactions were revealed.  
To sum up, the functional relevance of one putative interactor of TRPV1, Vti1b, was 
assessed for TRPV1-mediated nociceptive signalling. These functional studies revealed 
differences in TRPV1-mediated neuronal responses to capsaicin. More specifically, Vti1b 
affects the desensitization behaviour of TRPV1-expressing sensory neurons upon repetitive 
capsaicin stimulation. In vivo local knockdown of Vti1b in lDRG did not affect basal 
nociceptive thresholds and TRPV1-dependent acute pain, but only the CFA-induced 
development of thermal hyperalgesia was diminished after 24 h.  
Furthermore, I applied a functional proteomics approach to identify the TRPV1 interactome 
under CFA-induced inflammatory pain in mouse DRG neurons. A significant regulation of 
the TRPV1 interactome upon induction of inflammatory pain was revealed.  
 
  
Figure 3.11: Determination of high confidence interacting proteins 
(A, B) Volcano plots of Veh vs. KO, and CFA vs. KO: imputation of missing values was done with random values 
simulating low abundancy values in (A), and imputation done with constant value in (B). The log2 (Veh/KO or CFA/KO) 
ratio depicts the difference between the means of the 2 conditions in each t-test (reflecting the enrichment of proteins) and 
is plotted against the negative log p-value of the t-tests. The cut-off line is based on an estimation of the FDR by 
permutation. Proteins (on the right side of the vertical zero line) are considered as high confidence interactors when being 
right from the cut-off curve, while proteins with negative ratio or ratio close to zero are considered as unspecific binders. 
Numbers 1, 2, 5 represent examples of previously reported interactors of TRPV1: 1, TRPV2; 2, Dctn1; 3, Vti1b (see section 
3.2.1); 4, Stx8 and 5, Esyt1. Number 4 highlights Stx8, as an example of how the fold change and significance of putative 
interactors depends on the chosen imputation method (compare D). (C) Venn diagram displaying the overlap of 
significantly enriched proteins in the CFA and Veh group. (D) Tables displays measured log2 abundance values for Stx8, 
imputed values for missing values and the calculated fold changes. Fold changes in the case of imputation with random 
values does not exceed the required minimal log2 fold change of 1.58, therefore the protein is not considered for the 
comparison CFA/Veh in that case. na, not applicable, NaN, not a number. 
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4 Discussion 
4.1 Insights into chronic pain by standardized DRG proteome profiling 
This section is based on Rouwette et al., 2016. 
Standardized and reproducible detection and quantitation of the constituents of protein 
signalling networks is crucial for deciphering the molecular underpinnings of physiological 
and pathophysiological processes. Here, we present a multi-layer DIA-MS-based workflow 
that allows to detect and quantify alterations in the mouse DRG proteome in two chronic 
pain models in a standardized way. 
DRG harbour the somatosensory neurons that detect both noxious and innocuous stimuli. 
These neurons undergo phenotypic changes under pathological conditions causing 
exaggerated transmission of pain messages to the brain, thereby, contributing to chronic pain 
symptoms like hypersensitivity and spontaneous pain (Basbaum et al., 2009). Therefore, 
studying the molecular changes underlying pathological pain states in DRG neurons is key 
for identifying potential novel drug targets. Interference with the first step of nociceptive 
signalling by local targeting of the DRG represents a promising alternative to the systemic 
application of drugs, or drugs targeting the CNS, especially with respect to adverse side 
effects (Patapoutian et al., 2009; Sapunar et al., 2012).  
Matching our DIA-MS data with our self-generated spectral library, we reproducibly 
identified several dozens of proteins that showed significant and mostly pain model-specific 
up- or downregulation in the chosen pain paradigms. Since the DRG comprises several 
different cell types, we cannot confer the observed changes solely onto sensory neurons. Yet, 
we partially dealt with this problem by using in situ immuno-labelling of proteins and cell 
type-specific functional assays to relate the detected abundance changes to neurons.  
We found several proteins previously reported to be relevant for painful pathologies in 
vertebrates with our DIA-MS-based workflow. This demonstrated that we were able to 
obtain meaningful and interesting candidates. Approximately 50% of all regulated proteins 
had not been related to somatosensation and pain before and among these are some scarcely 
characterized ones, which represent an especially interesting subgroup of candidates for 
further investigations on their role in nociception and pathological pain.  
Further insight into the molecular signature of chronic pain can be gained by zooming out 
from single regulated proteins and looking at the interdependencies between many of them, 
ultimately creating cellular signalling networks. The consequences of dysregulation of major 
signalling pathways have already been implicated in chronic neuropathic pain, for instance, 
mitochondrial dysfunction (Baloh, 2008; Fernyhough et al., 2010; Joseph and Levine, 2006) 
and disturbances of protein biosynthesis (Inceoglu et al., 2015; Lupachyk et al., 2013; Zhang 
et al., 2015). Given the complexity of these protein networks, the limited use of classical 
interventions targeting single proteins for analgesia become evident. Thus, emerging 
“network medicine” strategies are aimed at correcting functional misalignments of cellular 
processes (Barabási et al., 2011; Borsook et al., 2014; Schapira, 2012). Interference on the 
network level was shown to be successful for several animal studies (Inceoglu et al., 2015; 
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Joseph and Levine, 2006; Lupachyk et al., 2013) and might provide promising tools for 
achieving analgesia. Analysing our significantly regulated proteins with STRING, we report 
abundance changes of dozens of proteins belonging to complexes of the mitochondrion and 
proteins important for protein biosynthesis and maturation in the ER for both chronic pain 
models. In order to validate the in vivo relevance of these networks in inflammatory pain, 
we applied inhibitors of either the mitochondrial ETC-complex I or PDIs. With both 
inhibitors we achieved acute analgesic effects in fully-established persistent inflammatory 
pain. These data support and complement previous studies linking dysfunction of the 
mitochondrial respiratory chain and ER stress to painful peripheral neuropathies (Inceoglu 
et al., 2015; Joseph and Levine, 2006; Lupachyk et al., 2013). We could demonstrate the 
relevance of these signalling network also in persistent inflammatory pain induced by CFA-
injection and moreover, identifying regulated members of these networks. These could 
therefore represent putative targets for novel analgesic treatments. 
However, our data did not confirm previously reported regulations of several nociceptive 
ion channels under pathological pain. The nocisensor TRPA1, for example, was reported to 
be upregulated under CFA-evoked inflammatory pain (da Costa et al., 2010), however, our 
data do not support a significant regulation. A number of technical factors could account for 
this and further discrepancies to other studies. We (and others using MS techniques) not only 
used the lDRG 3-5 that contribute the major innervation of the hind paw, but pooled them 
with lDRG 1+2 to have enough tissue for our sample preparation and the following mass 
spectrometry. But even within one DRG some neurons may be strongly affected, whilst 
others are only weakly affected by the treatment, as this depends on whether the pain-
evoking agents spread into the innervation field/receptive fields of the neurons in the 
periphery (Laedermann et al., 2014). 
Other parameters to consider when comparing our data to previous proteomic studies 
profiling chronic pain are the species differences and the pain model used (Laedermann et 
al., 2014), the time point of tissue isolation and the biochemical sample preparation. As 
mentioned before membrane proteins are essential for pain signalling, yet, typically under-
represented in MS studies (Helbig et al., 2010). We therefore decided to prepare a 
membrane-enriched fraction to facilitate the MS detection of membrane proteins, by that we 
depleted many cytosolic proteins. This could explain the marginal overlap with previous MS 
studies, most of them analysing whole cell lysates (Melemedjian et al., 2013; Niederberger 
and Geisslinger, 2008; Vacca et al., 2014; Zou et al., 2012). 
 
The use of a reference spectral library in DIA-MS enables the unambiguous identification 
and reliable quantification of 1000s of proteins across many samples, yet, if a peptide 
signature is not stored in the applied library, the belonging protein cannot be detected. Our 
customized library contains the peptide signatures of several ion channels, such as TRPV1 
and TRPA1, which are crucially implicated in the development of pathological pain and 
therefore, represent prime targets for the development of novel analgesics (Patapoutian et 
al., 2009). Unfortunately, the library lacks the signatures of the voltage-gated sodium 
channel Nav1.7, mutations of which confer congenital insensitivity to pain in humans (Cox 
et al., 2006), however, related and also nociceptor-specific Nav- subtypes Nav1.8 and Nav1.9 
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(Waxman and Zamponi, 2014) were detected. A reason could be insufficient solubilisation 
combined with an overall low expression of the Nav1.7 in the DRG, so that even with our 
membrane enrichment, we did not yield enough peptides for identification by MS. 
 
4.1.1 Conclusion and outlook 
We successfully applied emerging DIA-MS to reveal significant proteome changes 
expanding our knowledge about the molecular mechanisms of chronic pain conditions. 
Our spectral library, which contains the information required for the standardized 
identification and quantification of 100s of membrane-associated DRG proteins, constitutes 
a unique resource for the further research on these proteins in any mouse model of interest.  
Furthermore, our DIA-MS dataset can be re-analysed in silico using an updated version of 
the spectral library extended with previously not detected proteins (see (Barry et al., 2018)). 
In this line, my host laboratory put efforts in extending the profiling onto different stations 
along the pain signalling pathway – from the periphery up to the brain – as well as for several 
further pain models. This should facilitate the comprehensive characterization of the distinct 
molecular underpinnings of well-defined pain syndromes. Ultimately, these efforts could 
help for the identification of putative drug targets as well as of biomarkers for chronic pain 
syndromes to allow for a better diagnosis.  
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4.2 Identification and characterization of TRPV1 protein complexes 
A large part of section 4.2 is based on Sondermann et al., 2019. 
 
Ion channels are embedded in a network of proteins modulating their localisation and 
function. Stable protein-protein interactions (PPIs) are required for their general function but 
some of them, mostly of transient nature, can modulate the channels’ properties as required 
in response to changes in the cellular status or environment (Schulte et al., 2011). 
The TRPV1 channel has been shown to interact with different proteins that modulate its 
responsiveness to stimuli as well as its trafficking to and from the plasma membrane. 
Thereby the sensitization of nociceptive sensory neurons can be regulated. Here, Vti1b was 
identified as a novel interactor of TRPV1. Vti1b influences the sensitization of TRPV1 in an 
inflammatory pain condition. In primary cultures of sensory neurons inflammation-induced 
sensitization of TRPV1 was facilitated by Vti1b during repetitive stimulation. Yet, Vti1b did 
not affect the normal functioning/gating of TRPV1. Remarkably, only the development of 
inflammation-evoked thermal hypersensitivity was reduced in mice in which Vti1b 
expression was downregulated in lDRG. 
Little is known about the dynamics of the TRPV1 interactome during different pain states. 
To examine whether the TRPV1-Vti1b interaction is differentially regulated between an 
inflammatory pain and a physiological condition, I employed a functional proteomics 
approach. To this end, I induced inflammatory pain in mice by injecting CFA and combined 
affinity-based co-purification of native TRPV1 and associated proteins from DRG with 
highly sensitive quantitative mass spectrometry. Vehicle (Veh)-injected wild type mice and 
Trpv1-KO (KO) mice served as controls. With this I confirmed the Vti1b-TRPV1 interaction 
and showed that under inflammatory conditions less Vti1b is detected within the TRPV1 
complex. Furthermore, I shed light on the protein scaffold interacting with TRPV1 under 
patho-/physiological conditions. I found that the TRPV1 interactome undergoes pronounced 
changes upon induction of inflammatory pain.  
 
4.2.1 Validation of the Vti1b-TRPV1 interaction in vitro 
The sensitization of TRPV1 by inflammatory mediators is in part responsible for the 
enhanced responsiveness of nociceptors under pathological conditions. One of several 
causes of this sensitization is an increased insertion of TRPV1 into the plasma membrane 
(Camprubí-Robles et al., 2009; Ferrandiz-Huertas et al., 2014; Ji et al., 2002; Morenilla-
Palao et al., 2004; Zhang et al., 2005). Interestingly, this regulated exocytosis has been 
shown to be at least in part dependent on SNARE proteins, as it can be opposed by a peptide 
interfering with the action of  the SNARE protein SNAP-25 (Camprubí-Robles et al., 2009). 
Furthermore, the vesicular proteins Snapin and synaptotagmin IX were reported to interact 
with the N-term of TRPV1 and to mediate the rapid delivery of TRPV1 to the plasma 
membrane as response to PKC phosphorylation.  In this context it should be noted that Vti1b 
has been suggested to be a rate-limiting factor for the stimulated exocytosis of the pro-
inflammatory cytokine TNFα in macrophages (Murray et al., 2005), and to be involved in 
the secretion of cytolytic proteins by cytotoxic T-cells after antigen stimulation (Dressel et 
al., 2010). 
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The calcium imaging data show that in sensory neurons Vti1b is not required for 
translocation of TRPV1 to the plasma membrane prior to any stimulation. Nor does it 
influence TRPV1’s activation, as there was no significant variation in the response to the 
initial first pulse of capsaicin. Yet, this is in contrary to what I observed for the first pulse in 
HEK cells overexpressing TRPV1 and Vti1b. This controversy could be attributed to some 
generalized artificial effects of the overexpression of both TRPV1 and Vti1b that lead to 
disturbance of protein trafficking in HEK. Overexpression of (tagged) proteins is known to 
cause mislocalisation (Gibson et al., 2013). Also, Vti1b could have different interactors and 
consequently, fulfil different tasks in non-neuronal vs. neuronal cells. 
In addition, HEK cells overexpressing TRPV1 and Vti1b showed less tachyphylaxis to 
repetitive capsaicin stimulation, i.e. the TRPV1-dependent calcium influx was maintained 
over 6 pulses of capsaicin. Sensory neurons derived from Veh-treated mice displayed the 
expected tachyphylaxis after repetitive capsaicin stimulation regardless whether Vti1b 
expression was downregulated via siRNA. In the CFA condition however, I observed a CFA-
induced sensitization, i.e. less tachyphylaxis.  Yet, when Vti1b was downregulated, less 
TRPV1-expressing neurons were sensitized, i.e. fewer responded to the 6th pulse of 
capsaicin. One explanation could be less functional TRPV1 residing at the membrane upon 
Vti1b knockdown as compared to control. Unfortunately, up to now there is no commercially 
available antibody that binds to the extracellular parts of the mouse TRPV1 channel. Also, 
experiments with surface biotinylation to determine differences in TRPV1 levels at the 
plasma membrane were not successful (data not shown). 
If the diminished CFA-evoked sensitization is based on less functional TRPV1 residing at 
the plasma membrane after repetitive stimulation, two opposing mechanisms are possible: 
(i) Vti1b could promote a rapid replenishment of functional TRPV1 at the membrane after 
capsaicin-induced internalization, or (ii) it could prevent the internalization of TRPV1 from 
the membrane after capsaicin stimulation. Little is known about the regulation of the 
membrane content of TRPV1 via endocytosis (Ferrandiz-Huertas et al., 2014). One study by 
Holland et al. found that the sensory neuron-specific knockout of the E3 ubiquitin ligase 
MYCBP2 prevents capsaicin-induced desensitization of sensory neurons via prevention of 
internalization of TRPV1 (Holland et al., 2011). They found that the MYCBP2-KO leads to 
a constitutive activation of p38 MAP kinase pathway, a pathway known to sensitize TRPV1-
expressing neurons, yet, it is unknown how the p38 activation leads to inhibition of 
endocytosis (Holland et al., 2011).  
Of course, also other mechanisms known to modulate TRPV1 de-/sensitization like gating 
properties such as open probability could be affected. We tried to apply the same 6-pulse 
stimulation protocol during electrophysiological recordings but were not able to acquire 
stable traces. Therefore, and due to the well-established role of Vti1b in trafficking 
processes, we decided to continue with calcium imaging and block the internalization of 
TRPV1 from the plasma membrane. Thereby the amount of functional TRPV1 at the 
membrane would only be regulated by the biosynthetic/secretory pathway (and of course, 
trafficking-independent desensitization mechanism). Application of dynasore to prevent 
internalization of TRPV1 via clathrin-mediated endocytosis between the 5th and 6th pulse, 
recovered the desensitization in the Vti1b knockdown to the extent of the control condition 
of the CFA group. This supports a role for Vti1b in the activity-dependent trafficking of 
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TRPV1. However, we cannot tell from this experiment at which step of the trafficking Vti1b 
comes into play. With dynasore the very first step of the endocytic pathway is inhibited, 
namely, the scission of clathrin-coated pits from the membrane, therefore, any step later on 
could potentially involve Vti1b. Membrane proteins that undergo endocytosis either follow 
the recycling pathway, i.e. retrograde transport to the trans-Golgi network, or they are 
degraded via multi-vesicular bodies/late endosomes (LE). Different SNARE proteins are 
suggested to mediate membrane fusion at all these trafficking steps (Chen and Scheller, 
2001). The SNARE Vti1b was shown to be involved in both LE-LE fusion (Antonin et al., 
2000) and fusion of LE with lysosomes (Offenhäuser et al., 2011). In line with this, I  
detected a partial co-localisation of Vti1b with LE and lysosomes in DRG neurons, which 
for other cell types has been reported previously (Kreykenbohm et al., 2002; Offenhäuser et 
al., 2011). Sanz-Salvador et al. reported that the prolonged exposure of capsaicin (for 20 
min) triggered an initial rapid endocytosis of TRPV1 with subsequent targeting of the 
channel for lysosomal degradation in DRG neurons (Sanz-Salvador et al., 2012). However, 
since the effect we observed is very immediate, it is rather unlikely that within the short 
duration of our protocol TRPV1 is already being transported to and degraded by lysosomes.   
 
4.2.2 In vivo validation of the Vti1b-TRPV1 interaction 
Given the apparent functional relevance of the Vti1b-TRPV1 interaction for TRPV1-
mediated nociceptive signalling in vitro, the next question was whether modulation of the 
Vti1b expression in vivo has consequences on pain behaviour in mice.  
To this end, I silenced Vti1b expression in lDRG of mice. The local Vti1b knockdown did 
not result in changes of the basal thresholds for mechanical and thermal stimuli. In addition, 
the Vti1b knockdown in vivo did not perturb nocifensive behaviour evoked by a single dose 
of capsaicin, which solely relies on TRPV1-activation (Caterina et al., 2000). These results 
are in line with my calcium imaging data showing that normal functioning under 
physiological conditions stays intact and only CFA-mediated TRPV1 sensitization is 
affected. 
To see whether CFA-evoked sensitization is also altered in vivo, the mice with Vti1b 
knockdown (or control) received an intraplantar CFA injection and were tested for thermal 
hypersensitivity after 24 h. The mice with Vti1b knockdown showed a diminished 
development of thermal hyperalgesia compared to the control group, 24 h after induction of 
inflammatory pain. Even though Trpv1-KO mice show profound deficits in development of 
heat hyperalgesia after inflammation, also other channels crucially contribute to CFA-
induced thermal hyperalgesia after inflammation, for example, TRPM3 (Vriens et al., 2011). 
Therefore, I cannot claim that the anti-nociceptive effect of the Vti1b knockdown is solely 
due to the disruption of the Vti1b-TRPV1 interaction, but also other nociceptive channels 
might be affected. However, the test for mechanical allodynia 24 h and 48 h after CFA-
injection did not show differences in the pain behaviour between the groups. Initially TRPV1 
was proposed to not contribute to mechanical hypersensitivity after inflammation (Caterina 
et al., 2000), subsequent studies with TRPV1 antagonists as well as acute knockdown via 
shRNA against TRPV1 supported a role for TRPV1 in the development of mechanical 
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hypersensitivity, yet, to a smaller degree than thermal hypersensitivity (Kanai et al., 2007; 
Szabo, 2005). Thus, obtained results argue for a rather TRPV1-specific effect.  
On the other hand, it could be that the knockdown of Vti1b acts indirectly via modulation of 
the initial inflammatory processes such as the secretion of pro-inflammatory mediators on 
the development of hypersensitivity (compare Murray et al., 2005). This could be 
investigated by measuring the level of secreted inflammatory mediators, or by assessing the 
expression of certain receptors crucial for the inflammatory response in DRG (Lin et al., 
2011).  
 
Regarding the question how Vti1b might affect TRPV1-mediated nociceptive signalling, it 
should also be noted that one SNARE complex partner of Vti1b was detected to interact with 
TRPV1, too.  Stx8 – which amongst others can make up a SNARE complex with Vti1b, Stx7 
and Vamp8 (Antonin et al., 2000) – has been found to increase the cell surface localisation 
of the TrkA receptor (Chen et al., 2014). TrkA receptors are responsive to NGF and thus, 
their activation is involved in the sensitization of nociceptors (Basbaum et al., 2009). 
Consequently, shRNA-mediated knockdown of Stx8 resulted in analgesia in the formalin 
model for inflammatory pain (Chen et al., 2014). In my MS screen Stx8 was not detected in 
the KO at all and when I only compare CFA and Veh without imputing missing values for 
the KO, Stx8’s interaction with TRPV1 is suggested to be significantly stronger in the pain 
condition. It is not known whether overexpression of Stx8 enhances pain in vivo. 
Interestingly, the global knockout of Vti1b leads to an increased degradation of Stx8 in 
several tissues (PNS tissue was not tested; (Atlashkin et al., 2003)). Therefore, it is tempting 
to speculate that the detected decrease of Vti1b expression in the DRG overall (Rouwette et 
al., 2016), and the decrease in the interaction with TRPV1 upon CFA might be an attempt 
of the body to counterbalance putative pro-algesic effects of a Stx8-Vti1b-TRPV1 
interaction: When downregulating Vti1b in vivo, also the amount of Stx8 decreased, and 
consequently, I observed the analgesic effect. Thus, it would be interesting to assess whether 
the amount of Stx8 is changed upon AAV6-Vti1b miRNA-mediated knockdown in vivo. 
Depending on the results it could be worth examining the effect of a double knockdown of 
Stx8 and Vti1b.   
 
4.2.3 Quantitative MS to identify TRPV1 pain-specific interactors 
Several methods can be used to elucidate PPIs. Functional proteomics has become the 
method of choice as it enables the detection of PPIs in their native cellular environment. 
Furthermore, it is not restricted to only detecting binary PPIs as it is the case with the yeast-
2-hybrid system (Schulte et al., 2011). Several crucial interaction partners of ion channels 
expressed in the CNS have been elucidated by this means (Nadal et al., 2003; Schulte et al., 
2006; Schwenk et al., 2009). Recently, Hanack et al. discovered the interaction of GABAB1 
receptor subunit and TRPV1 by functional proteomics (Hanack et al., 2015). They pulled 
down TRPV1 from DRG of knockin mice overexpressing a tagged version of the channel. 
Strikingly, the described interaction only takes place under pathological conditions, when 
TRPV1 is sensitized (Hanack et al., 2015). 
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With my functional proteomics experiment I confirmed Vti1b as a member of the TRPV1 
protein complex and showed that upon inflammatory pain the amount of Vti1b is diminished 
in the TRPV1 complex. This is in line with our DIA-MS screen where Vti1b showed a 
downregulation in the CFA group (log2 fold change = -0.158, multiple testing-corrected q-
value = 0.005 (Barry et al., 2018)). 
 
Moreover, the idea of my functional proteomics experiment was to directly compare the 
interaction partners of TRPV1 between a pathophysiological and physiological state. The 
results reported in section 3.1/Rouwette et al., 2016 and further large-scale studies profiling 
the overall change in protein expression in different PNS tissues upon induction of pain 
(Barry et al., 2018; Huang et al., 2008b; Vacca et al., 2014) have shown that indeed it is 
possible to detect meaningful protein network changes between physiological and 
pathophysiological states with MS. Also, alterations of protein interactions between different 
cellular states were successfully detected by functional proteomics. For instance, Gerold et 
al. found that upon binding of hepatitis C virus to its host receptor CD81 (expressed on 
hepatocytes), a certain set of proteins in the target cell associate with the receptor in order to 
promote virus entry (Gerold et al., 2015).  
 
The high sensitivity of modern mass spectrometers allows for single-step enrichment of the 
bait, and to omit lengthy purification protocols which not only entail a loss of sample but 
also negatively affect transient and weak interactions. Yet, the sensitivity comes at the price 
of detecting a lot of unspecific proteins binding to the affinity matrix that have to be filtered 
out. In order to efficiently eliminate these background binders, negative controls are used, 
i.e. pulldowns from knockout tissue (Schulte et al., 2011). For the subsequent filtration step 
the fold change, i.e. ratio of abundance of a protein in experimental condition vs. KO 
condition, can combined with calculating a significance score for each interaction (Hubner 
et al., 2010). Applying a standard t-test requires that the experiment be done at least in 
triplicates and in addition, proteins should have been detected in all three runs. Yet, 
especially for low abundance proteins it is common that missing values occur across the 
runs, which need to be imputed to allow for statistical comparison (Nesvizhskii, 2012).  
As exemplified with the case of Stx8 in my dataset, the chosen method for imputation – 
either a constant value, or random values taken from a normal distribution simulating low 
abundance values – can have a profound effect on the subsequent data analysis. One could 
divide the dataset prior to imputation into 2 subcategories: (i) proteins with only random, 
isolated values missing across the replicates in my 3 groups – due to run-to-run differences 
or inevitable differences in sample preparation – and (ii) proteins that were not detected in 
any of the replicates in one group making a random missing rather unlikely. For (i) the 
imputation with random values simulating low abundance values near the detection limit of 
the mass spectrometer seems more reasonable than a constant low value (as seen for Stx8). 
For (ii) the question is whether to perform statistical tests and calculation of a fold change at 
all for the first step of comparison (CFA/KO and Veh/KO) if the protein was not detected at 
all in the KO. The imputation with random low abundance values would lead to an erroneous 
low fold change assuming the protein was really absent from the samples of one group. But 
in case of low abundant proteins that might not have crossed the detection limit in all 
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repetitions of the KO group by chance, imputing with a “0” or any constant value below the 
detection limit, would yield erroneous high fold changes. Overall, to not miss potentially 
pain-specific candidates, these “only CFA” and “only Veh” proteins should be submitted to 
the second step of analysis, i.e. CFA/Veh, yet, with reservations if they exhibit a low 
abundance in CFA and Veh. 
 
In order to discriminate high confidence interactors from false positive hits, there are no 
universal cut-off parameters that work for each and every interactomics dataset (Hubner and 
Mann, 2011). Previously described interactions could give guidance for where to set the cut 
off, and in case of simple organisms studied in detail, such as yeast, this might be feasible 
(Keilhauer et al., 2015), but what if information about  interactors is missing, or the known 
ones are not detected?  
I only found the TRPV2, a channel which is reported to form heteromers with TRPV1-
subunits (Helliwell et al., 1998), dynactin subunit 1, an interactor that so far only showed up 
in a yeast-2-hybrid screen (Stein et al., 2006) and extended synaptotagmin-1 reported to be 
a putative interactor by Hanack et al. (Hanack et al., 2015). Neither did I detect the GABAB1 
(Hanack et al., 2015) nor the Kvβ2-subunit (Bavassano et al., 2013), another TRPV1 
interactor proposed by a functional proteomics experiment. Also, these two studies detect 
only very few previously described TRPV1 interactors. Yet, one should keep in mind that 
the interactome detected by MS for a certain experiment can only represent a fraction of the 
complete and dynamic interactome of TRPV1. 
Furthermore, several obvious differences in the study design could account for the missing 
overlap: Firstly, Hanack et al. used tissue from mice that overexpressed a tagged version of 
the channel and even though they proved the functional integrity of the overexpressed 
channel (Hanack et al., 2015), overexpression and the tag might disturb the “physiological” 
network of proteins interacting with the native channel. In addition, they did not use a 
stringent KO control but rather used wild type mice as controls. Secondly, differences in 
sample preparations must be taken into consideration that could crucially affect the fraction 
of TRPV1 interactome that is detected (Helbig et al., 2010; Schulte et al., 2011), for example, 
the amount of detergent used to solubilize the transmembrane protein TRPV1 varies. 
Detergents can differ greatly in their nature and strength, yet all of them inevitable affect 
PPIs. Thus, depending on the amount and kind of detergent used, different sets of PPIs are 
preserved, whilst especially dynamic interaction partners might be lost. Further, any kind of 
sample prefractionation steps, e.g. for enrichment of membrane fractions as done by Hanack 
et al., affects PPIs (Helbig et al., 2010). The use of antibodies against different epitopes of 
TRPV1 for the co-purification step could also explain the missing overlap/differences in the 
suggested interactors (Schulte et al., 2011). Thirdly, the MS platform used for analysis 
(instrument type, DDA vs. DIA) of the samples differs substantially and could explain for 
the detection of different subfractions of the TRPV1 interactome. 
 
Yet, despite the missing overlap with previously described TRPV1 interactors, the follow up 
work of Bavassano et al. (Kvβ2) and especially Hanack et al. (GABAB1) as well as in my 
case the foregoing validation of Vti1b illustrate that the chosen functional proteomics 
approach was able to detect meaningful TRPV1 interactors. 
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In order to gain more information about what kind of proteins had been detected by my 
interactomics screen, I looked for enriched cellular functions within the putative TRPV1 
interactors. For the proteins significantly enriched in the CFA condition/inflammatory pain, 
an enrichment of actin-binding proteins was observed. Structural plasticity of neurons in the 
PNS and CNS – involving remodelling of both the actin and microtubule cytoskeleton – is 
suggested to be important for the transition from acute to chronic pain (Kuner and Flor, 
2016). Increased peripheral target innervations have been reported to underlie 
hypersensitivity associated with different types of pathological pain (Costigan et al., 2009). 
Also, under CFA-induced persistent inflammatory pain cutaneous sensory hyperinnervation 
is observed (Chakrabarty et al., 2013). The increased axonal outgrowth was dependent on 
Angiotensin II and correlated with thermal hypersensitivity in established inflammatory 
pain, as pharmacological blockade of the Angiotensin 2 receptor (which is expressed by 
nociceptors) not only reduced the hyperinnervation several days after CFA injection, but 
also reversed the accompanied thermal hypersensitivity in rats (Chakrabarty et al., 2013).  
Among the proteins significantly enriched in the Veh group, a clear enrichment of proteins 
connected to annotation terms related to “intracellular protein transport” was found. The rate 
of endo- and exocytosis determines the amount of TRP ion channels at the plasma 
membrane, thereby regulating their activity (Planells-Cases and Ferrer-Montiel, 2007) . As 
discussed above, the sensitizing action of several inflammatory mediators on TRPV1 has 
been shown to be mediated by stimulating the SNARE-dependent exocytosis of TRPV1 
(Camprubí-Robles et al., 2009; Mathivanan et al., 2016; Morenilla-Palao et al., 2004). Also, 
Vti1b belongs to this group of proteins.  
 
4.2.4 Conclusion and outlook 
I validated the functional relevance of the Vti1b-TRPV1 interaction for TRPV1-mediated 
nociceptive signalling in vitro and more importantly, for pain behaviour in mice.  
Still, there are unanswered questions in respect of the exact mechanism underlying the 
interaction and whether the analgesic effect of the Vti1b knockdown in vivo relies only on a 
direct effect on TRPV1. Pharmacological blockade of different steps of intracellular protein 
transport in vitro as well as high-resolution fluorescence microscopy with markers of 
subcellular compartments could help to clearly define the role Vti1b for TRPV1 
trafficking/degradation. 
Unfortunately, one cannot use Trpv1-KO mice to determine that the observed analgesic 
effect of Vti1b knockdown on thermal hypersensitivity is TRPV1-specific and not an “off-
target” effect, as the CFA-induced thermal hypersensitivity is already profoundly impaired 
in Trpv1-KO mice (Caterina et al., 2000). For this reason, measuring the expression and 
secretion of inflammatory mediators and their targets should reveal whether knockdown of 
Vti1b in sensory neurons rather dampens the overall inflammatory response to CFA injection 
which also would also lead to a diminished TRPV1 sensitisation. 
As my investigation of the Vti1b knockdown on pain models in vivo, relied mainly on the 
assessment of changes in nociceptive thresholds, i.e. stimulus-evoked behaviour, the validity 
of my findings is limited in some respects. Clinical manifestations of chronic pain are not 
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only accompanied by hypersensitivity to external stimuli, but also by ongoing, spontaneous 
pain along with the effects on the mood of the patient/patient’s quality of life. However, 
parameters other than stimulus-evoked behaviour are difficult to assess in rodents and this 
represents a major limitation in the use of animals in pain research (Tappe-Theodor and 
Kuner, 2014). This is increasingly recognized by researchers and in recent years, several 
surrogate behavioural measurements, e.g. changes in voluntary behaviour and sociability, 
have been investigated for their applicability and validity for assessing animal well-being in 
rodent pain models (Cobos et al., 2012; Pitzer et al., 2016; Urban et al., 2011). 
Including these non-evoked measures into future studies would help with defining the 
relevance of the Vti1b-TRPV1 interaction for nociception and pain in vivo. 
The mass spectrometry-based screen for state-specific constituents of the TRPV1 protein 
complex proved the interaction with Vti1b and also detected that a part of the TRPV1 
interactome undergoes significant changes under inflammatory pain conditions. This adds 
to the notion that dynamic and pain-specific PPIs exist. Blocking TRPV1 has been shown 
have an analgesic effect in many different chronic pain models. Yet, TRPV1-antagonists 
have been challenged by severe side effects in preclinical trials due to interference with the 
physiological functions of TRPV1. Therefore, defining the proteins modulating TRPV1 
activity under pathological conditions is a crucial step for the development of novel drugs 
that target PPIs specific for pathological pain, whilst leaving nociceptive pain untouched. 
My list of candidates may therefore provide a valuable resource for further investigation on 
PPIs specific for inflammatory pain. Especially, novel proteins that have not yet been 
investigated in the peripheral nervous system/nociception are interesting targets to follow 
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Figure 6.1: Additional information about calcium imaging experiments in HEK cells overexpressing TRPV1 + 
Mock or TRPV1+Vti1b 
(A) Averaged response amplitudes to each capsaicin pulse (measured as peak of fluorescence absorbance ratio 340/380 
i.a.u. above baseline). Response amplitudes were significantly different between TRPV1+Mock and TRPV1+Vti1b for all 
Caps pulses, except the 3rd one, * p < 0.05, N > 173 cells for TRPV1 + Mock and N > 76 for TRPV1 + Vti1b, two way-
ANOVA followed by uncorrected Fisher’s LSD. Data represented as mean ± SEM. (B) Proportion of cells responding to 
ATP as a measure of overall cellular health, ns, cell count above columns, Fisher’s exact test. (C) Comparison of the 
number of cells responding to one or more Caps pulses (i.e. TRPV1- expressing cells) revealed a significant reduction of 
TRPV1-expressing cells in TRPV1 + Vti1b. TRPV1 + Mock: 0.43 vs. TRPV1 + Vti1b: 0.37, * p < 0.05, cell count above 
columns, Fisher’s exact test. Graphs adapted with permission from A. Barry. 
 
Appendix  | 109 
  
Figure 6.2: Additional information on calcium imaging experiments in lDRG neurons 
(A) Quantification of Vti1b knockdown in DRG cultures. 72 h after transfection with control (Ctlr) or Vti1b siRNA 
siRNA DRG cultures were fixed and stained with antibodies against Vti1b. Apart from a decrease in positive cells (see 
Fig. 3.7 A ) also the integrated intensity of the Vti1b- staining is significantly decreased in the Vti1b siRNA group in  2 
out of 3 independent cultures (replicate (rep) 1-3, in arbitrary units (AU)). Ctlr siRNA vs. Vti1b siRNA rep 1: ns; rep 2: 
*** p < 0.001; rep 3: *** p < 0.001, N > 80 neurons, n = 3 cultures, two-way ANOVA followed by Bonferroni posttests.  
(B) Fraction of responders (colored) and non-responders (white) to the 1 µM Caps pulse given after 6x 100 nM Caps 
pulses to estimate the whole TRPV1-positive population. CFA c vs. CFA si: *** p < 0.0001; Veh c vs. CFA c, Veh c:  
* p < 0.0128; Dynasore CFA c vs. CFA c: *** p < 0.0001, count of responders in columns, n = 3-4 independent cultures, 
Fisher’s exact test. (C) Averaged response amplitudes (peak of fluorescence ratio 340/380 above threshold) to 1 µM 
Caps. Veh c vs. CFA c: ** p = 0.0057, cell count in columns, n = 3-4 cultures, one-way ANOVA followed by Holm-
Sidak's multiple comparisons test.  Data represented as mean ± SEM. Figure from Sondermann et al., 2019. 









Figure 6.3: Vti1b-KO mice show normal basal sensitivity to mechanical and thermal stimuli and normal capsaicin- and 
CFA-induced pain behaviour 
(A) Capsaicin-induced nocifensive behaviour does not differ between wild type and Vti1b KO mice. Time spent with 
nocifensive behaviour (licking, lifting and hiding of paw) was measured for 15 min after intraplantar injection of 0.5 µg 
capsaicin, ns, N = 12 mice per condition, n = 3 independent cohorts, unpaired Student’s t-test. (B) Basal sensitivity to thermal 
or mechanical stimuli is not changed in Vti1b KO mice. Mean withdrawal latencies of hind paws to radiant heat stimulus or 
blunt mechanical probe did not differ significantly between genotypes, ns, N = 11 mice per condition, n = 2 independent 
cohorts, unpaired Student’s t-test. (C) Development of thermal hyperalgesia in Vti1b KO mice is similar to WT mice. Twenty-
four hours after intraplantar CFA-injection the withdrawal latency to a radiant heat stimulus was assessed for both contralateral 
and ipsilateral hind paws. Ipsilateral paws showed significant decrease in the latency time, indicating hyperalgesia. Neither the 
values for the ipsilateral nor contralateral paws were significantly different between genotypes, ns, N = 7-9 mice per condition, 
n = 2 independent cohorts, unpaired Student’s t-test. Data are represented as mean ±SEM. 
Appendix  | 111 
 
  
Appendix  | 112 
 
  
Figure 6.4: Additional information on sensory behavioural tests in AAV6-Vti1b miRNA mice 
Additional information to Fig. 3.9. Knockdown of Vti1b does not change basal sensitivity to a radiant heat stimulus (A) 
or punctuate mechanical pressure (B), as no change in the withdrawal latency of the contralateral (con) paws 
(withdrawal values in seconds, left diagrams) and the normalized withdrawal latencies of injected (ipsi) to con paws 
(ipsi/con in %, right diagrams). Behavioural testing took place before the virus injection (pre AAV6) and 3 weeks after 
the injection (pre CFA). No significant differences were determined by Kruskal-Wallis test; N > 10 mice for each group, 
n = 2 independent cohorts. (C) Three weeks after virus injection (either AAV6-Vti1b miR or -scramble miR) 
inflammatory pain was induced by CFA-injection into ipsi paw. The development of thermal hypersensitivity was 
assessed 24h post CFA with the Hargraeves test. The left graph displays the withdrawal latencies in s of the non-injected 
con paws (p = 0.3099) and in the right graph the normalized withdrawal latencies (%ipsi/con, * p = 0.0158) are shown. 
N = 11(-12) mice per group, n = 2 independent cohorts. (D) Three weeks after virus injection (either AAV6-Vti1b miR 
or -scramble miR) inflammatory pain was induced by CFA-injection into ipsi paw. Hypersensitivity to a punctuate 
mechanical stimuli was assessed 24 h post CFA. The left graph displays the withdrawal latencies in s of the non-injected, 
con paws (p = 1.0000) and in the right graph the normalized withdrawal latencies (%ipsi/con, p = 0.8371) are shown. 
All comparisons are ns, N = 7-9 mice per group, n = 2 independent cohorts. (E, left) Three weeks after virus injection 
(either AAV6-Vti1b miR or -scramble miR) inflammatory pain was induced by CFA-injection into ipsi paw. 
Hypersensitivity of the ipsi paw to punctuate mechanical stimuli 48 h post CFA injection was measured as withdrawal 
latency in s (p = 0.5362; same cohort tested for thermal hypersensitivity 24 h after CFA, Fig. 3.9). (E, middle) 
Withdrawal latencies of the non-injected paw to punctuate mechanical stimuli 48 h post CFA injection (p = 0.7325). 
(E, right) Normalized withdrawal latencies of injected (ipsi) to con paws (%ipsi/con, p = 0.7396) for each individual 
mouse to punctuate mechanical stimuli 48 h post CFA injection. All comparisons ns, N = 7-10 mice per group, n = 2 
independent cohorts. D-E: Significance was determined with the Mann Whitney test. All data are represented as mean 
±SEM. All comparisons are ns if not indicated otherwise. Figure from Sondermann, et al., 2019. 





Figure 6.5: Western blot of co-immunoprecipitation of TRPV1 and Vti1b in HEK cells  
Vti1b is pulled down with TRPV1 (V1) in HEK293 cells (compare Fig. 3.10 C). The protein lysate prior to the 
addition of an antibody is designated with ‘Input’. ‘N’ = CoIP against TRPV1 was performed with the goat α-
TRPV1 antibody targeting a N-terminal region of TRPV1.  ‘C’ = CoIP against TRPV1 was performed with the 
rabbit α-TRPV1 antibody targeting a C-terminal region of TRPV1. Mock = cells that were transfected with the 
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Figure 6.6: Correlation of the biological replicates between and within the groups 
Multi-scatter plot of log2-transformed abundance values of all 3 biological replicates of each group (KO, Veh and nCFA). 
The Pearson correlation coefficient for each comparison is written in the upper left corner of each scatter plot. From 
Sondermann et al., 2019. 
 





Figure 6.7: Distribution of abundance values and imputed values 
Histograms show in blue the frequency distribution of detected log2 abundance values and in red the distribution of the 
values imputed by taking random values from a normal distribution simulating low abundance value for each of the 
replicates. 
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Table 7-1: Pain-specific interactors of TRPV1 
Putative interactors of TRPV1, i.e. proteins significantly enriched compared to KO (detected with log2 
(CFA/KO) or (Veh/KO) > 1.58 and q-value < 0.05) and showing a difference of ±20% between CFA and Veh 
(log2 (CFA/Veh) > 0.263 or < -0.263). T-tests were done with the missing values being imputed with random 
values from a normal distribution simulating low abundance values. Ribosomal and other proteins directly 















Y-box-binding protein 3  Q9JKB3 0,006 6,05 0,898 -0,28 6,33 
Translocon-associated protein 
subunit alpha  
Q9CY50 0,000 5,51 0,796 0,56 4,95 
Actin-binding LIM protein 2  Q8BL65 0,000 5,86 0,599 0,94 4,92 
Ig mu chain C region  P01872 0,000 4,93 0,980 0,03 4,90 
Heterogeneous nuclear 
ribonucleoprotein M  
Q9D0E1 0,000 5,37 0,702 0,71 4,66 
von Willebrand factor A 
domain-containing protein 5A  
Q99KC8 0,000 5,55 0,408 1,09 4,46 
Sorting and assembly 
machinery component 50 
homolog  
Q8BGH2 0,007 5,07 0,860 0,67 4,40 
Farnesyl pyrophosphate 
synthase  
Q3UQN2 0,006 3,15 0,767 -0,71 3,86 
IQ motif and SEC7 domain-
containing protein 2  
Q5DU25 0,041 4,04 0,906 0,51 3,54 
Cysteine and glycine-rich 
protein 1  
P97315 0,006 3,29 0,958 -0,08 3,37 
Dihydropyrimidinase-related 
protein 1  
P97427 0,042 3,12 0,915 -0,24 3,36 
Alpha-centractin  P61164 0,004 3,63 0,907 0,27 3,36 
Laminin subunit gamma-1  P02468 0,037 3,06 0,957 -0,08 3,14 
Dystonin  Q91ZU6 0,005 4,02 0,558 0,90 3,12 
Cytoplasmic FMR1-interacting 
protein 2  
Q5SQX6 0,044 2,16 0,620 -0,81 2,98 
T-complex protein 1 subunit 
gamma  
P80318 0,025 3,16 0,884 0,37 2,78 
Beta-adducin  Q9QYB8 0,004 4,28 0,313 1,62 2,67 
Nuclease-sensitive element-
binding protein 1  
P62960 0,036 3,22 0,724 0,65 2,56 
Ras-related protein Rab-8B  P61028 0,006 2,97 0,812 0,52 2,44 
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Hemoglobin subunit epsilon-
Y2  
P02104 0,006 3,21 0,686 0,77 2,44 
Somatomedin-B and 
thrombospondin type-1 
domain-containing protein  
Q3UPR9 0,040 2,82 0,798 0,50 2,32 
Collagen alpha-1(VI) chain  Q04857 0,003 4,29 0,135 2,00 2,29 
Kinectin  Q61595 0,016 4,05 0,124 2,14 1,91 
Filamin-B  Q80X90 0,003 4,61 0,019 2,99 1,62 
Protein flightless-1 homolog  Q9JJ28 0,035 2,44 0,669 0,83 1,60 
Unconventional myosin-Id  Q5SYD0 0,006 2,71 0,410 1,21 1,50 
LIM domain and actin-binding 
protein 1  
Q9ERG0 0,006 3,07 0,128 1,71 1,35 
Lumican  P51885 0,027 2,77 0,441 1,49 1,28 
F-actin-capping protein subunit 
beta  
P47757 0,006 3,03 0,111 1,85 1,19 
Catalase  P24270 0,000 9,11 0,000 8,10 1,01 
Vinculin  Q64727 0,006 5,89 0,000 4,90 0,99 
Fibrinogen alpha chain  E9PV24 0,003 4,21 0,004 3,29 0,92 
Ras-related protein Rab-11B  P46638 0,003 3,51 0,040 2,64 0,87 
F-actin-capping protein subunit 
alpha-1  
P47753 0,028 2,52 0,145 1,73 0,80 
Ras-related protein Rab-6A  P35279 0,047 2,59 0,110 1,85 0,73 
Twinfilin-1  Q91YR1 0,006 2,69 0,149 1,96 0,73 
Microtubule-associated 
proteins 1A/1B light chain 3A  
Q91VR7 0,023 2,63 0,263 1,94 0,70 
Ras-related protein Ral-A  P63321 0,004 4,97 0,001 4,43 0,54 
Serine/threonine-protein kinase 
MARK2  
Q05512 0,004 4,13 0,000 3,67 0,46 
Signal recognition particle 
receptor subunit beta  
P47758 0,028 2,54 0,110 2,09 0,45 
Transient receptor potential 
cation channel subfamily V 
member 2  
Q9WTR1 0,005 4,35 0,000 3,90 0,45 
Splicing factor U2AF 65 kDa 
subunit  
P26369 0,006 3,59 0,020 3,19 0,40 
Coronin-2A  Q8C0P5 0,035 2,24 0,083 1,88 0,36 
Apoptosis-inducing factor 1, 
mitochondrial  
Q9Z0X1 0,006 2,84 0,046 2,57 0,27 
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RNA-binding protein 14  Q8C2Q3 0,006 3,45 0,001 3,74 -0,30 
Vesicle transport through 
interaction with t-SNAREs 
homolog 1B  
O88384 0,004 4,11 0,000 4,43 -0,32 
Cytospin-A  Q2KN98 0,006 2,87 0,003 3,21 -0,33 
Unconventional myosin-If  P70248 0,123 2,64 0,019 3,02 -0,38 
Dynactin subunit 1  O08788 0,003 3,49 0,000 3,88 -0,39 
Lysocardiolipin acyltransferase 
1  
Q3UN02 0,087 2,38 0,046 2,80 -0,42 
Clathrin light chain B  Q6IRU5 0,006 4,54 0,001 5,02 -0,48 
Cytoplasmic dynein 1 light 
intermediate chain 2  
Q6PDL0 0,006 3,06 0,003 3,57 -0,51 
TSC22 domain family protein 
4  
Q9EQN3 0,045 2,28 0,013 2,81 -0,52 
Ataxin-2  O70305 0,092 2,94 0,014 3,52 -0,59 
Actin-binding LIM protein 1  Q8K4G5 0,086 2,31 0,030 2,91 -0,60 
Ras-related protein Rap-1A  P62835 0,003 3,48 0,001 4,09 -0,60 
Staphylococcal nuclease 
domain-containing protein 1  
Q78PY7 0,027 2,46 0,007 3,12 -0,67 
Ataxin-2-like protein  Q7TQH0 0,006 3,38 0,000 4,14 -0,76 
Probable ATP-dependent RNA 
helicase DDX6  
P54823 0,070 2,43 0,003 3,21 -0,77 
Histone H1.3  P43277 0,007 4,94 0,000 5,73 -0,79 
Protein LSM12 homolog  Q9D0R8 0,025 3,62 0,001 4,47 -0,85 
AP-3 complex subunit delta-1  O54774 0,084 1,93 0,004 2,78 -0,85 
Pleckstrin homology domain-
containing family A member 6  
Q7TQG1 0,006 5,40 0,000 6,29 -0,89 
Lactoylglutathione lyase  Q9CPU0 0,124 2,14 0,031 3,03 -0,90 
ATP-citrate synthase  Q91V92 0,011 2,75 0,005 3,67 -0,92 
Thy-1 membrane glycoprotein  P01831 0,127 2,04 0,038 3,00 -0,96 
Alpha-adducin  Q9QYC0 0,006 3,40 0,000 4,38 -0,98 
Muscleblind-like protein 1  Q9JKP5 0,004 4,33 0,000 5,41 -1,08 
Dedicator of cytokinesis 
protein 11  
A2AF47 0,021 2,96 0,000 4,16 -1,19 
Unconventional myosin-Ie  E9Q634 0,187 1,38 0,031 2,76 -1,38 
Coatomer subunit gamma-1  Q9QZE5 0,008 3,10 0,000 4,50 -1,40 
Nexilin  Q7TPW1 0,080 1,96 0,005 3,40 -1,44 
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Translationally-controlled 
tumor protein  
P63028 0,285 1,44 0,019 2,95 -1,51 
Proteasome subunit alpha type-
6  
Q9QUM9 0,113 1,89 0,004 3,44 -1,55 
Spectrin alpha chain, 
erythrocytic 1  
P08032 0,437 1,24 0,015 2,85 -1,61 
Tubulin beta-1 chain  A2AQ07 0,471 1,10 0,001 3,19 -2,10 
Nck-associated protein 1  P28660 0,908 0,31 0,048 2,73 -2,42 
Partner of Y14 and mago  Q8CHP5 0,277 1,33 0,000 3,87 -2,54 
Heat shock protein HSP 90-
alpha  
P07901 0,832 0,41 0,004 3,00 -2,59 
AP-2 complex subunit alpha-2  P17427 0,954 0,14 0,008 2,74 -2,60 
Proteasome subunit beta type-1  O09061 0,957 -0,15 0,035 2,56 -2,72 
Parvalbumin alpha  P32848 0,796 0,56 0,002 3,47 -2,91 
Filamin-A  Q8BTM8 0,770 0,56 0,000 3,71 -3,15 
2-oxoglutarate dehydrogenase, 
mitochondrial  
Q60597 0,966 0,09 0,004 3,40 -3,30 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2  
O55143 0,999 0,00 0,001 3,33 -3,33 
LIM and SH3 domain protein 
1  
Q61792 0,924 -0,25 0,002 3,11 -3,36 
V-type proton ATPase subunit 
E 1  
P50518 0,929 -0,25 0,004 3,18 -3,43 
Protein RUFY3  Q9D394 0,904 0,26 0,000 3,71 -3,45 
Unconventional myosin-VIIa  P97479 0,728 -0,75 0,014 2,80 -3,54 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A  
P26883 0,983 0,06 0,003 3,72 -3,66 
Collagen alpha-1(XIV) chain  Q80X19 0,820 -0,43 0,001 3,49 -3,92 
Cold shock domain-containing 
protein E1  
Q91W50 0,887 -0,31 0,002 3,65 -3,96 
RNA-binding motif protein, X 
chromosome  
Q9WV02 0,836 0,54 0,000 4,75 -4,21 
Nascent polypeptide-
associated complex subunit 
alpha, muscle-specific form  
P70670 0,007 3,69 0,000 7,93 -4,25 
ADP-ribosylation factor-like 
protein 8A  
Q8VEH3 0,874 -0,43 0,002 3,95 -4,38 
Cysteine-rich protein 2  Q9DCT8 0,723 0,72 0,000 5,12 -4,40 
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BMP-2-inducible protein 
kinase  
Q91Z96 0,833 -0,52 0,002 3,99 -4,51 
Band 4.1-like protein 3  Q9WV92 0,122 1,72 0,000 6,24 -4,52 
ATPase family AAA domain-
containing protein 1  
Q9D5T0 0,683 -0,66 0,001 3,89 -4,55 
LIM and calponin homology 
domains-containing protein 1  
Q3UH68 0,000 5,81 0,000 10,43 -4,62 
Peptidyl-prolyl cis-trans 
isomerase FKBP2  
P45878 0,796 -0,56 0,004 4,07 -4,64 
DnaJ homolog subfamily C 
member 9  
Q91WN1 0,966 -0,11 0,000 4,69 -4,79 
Oxysterol-binding protein-
related protein 3  
Q9DBS9 0,655 0,80 0,000 5,80 -5,00 
Cathepsin B  P10605 0,759 -0,82 0,002 4,56 -5,38 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 10  
Q9DCS9 0,990 -0,02 0,000 5,53 -5,55 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform  
Q76MZ3 0,004 -3,06 0,045 2,52 -5,58 
Septin-2  P42208 0,634 0,70 0,000 6,33 -5,64 
Mitogen-activated protein 
kinase 1  










0,761 0,57 0,000 6,54 -5,97 
Alpha-actinin-2  Q9JI91 0,971 -0,10 0,000 5,95 -6,05 
Integrin alpha-6  Q61739 0,830 0,54 0,000 6,78 -6,24 
Coatomer subunit beta  Q9JIF7 0,124 -1,85 0,000 4,45 -6,30 
Plasmolipin  Q9DCU2 0,905 -0,34 0,000 6,21 -6,55 
Charged multivesicular body 
protein 4b  
Q9D8B3 0,928 -0,35 0,000 7,16 -7,51 
SH3 domain-binding glutamic 
acid-rich-like protein  
Q9JJU8 0,466 -0,99 0,000 6,57 -7,56 
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Excluded proteins (Ribosome & 
Translation, Keratin) 
39S ribosomal protein L11, 
mitochondrial  
Q9CQF0 0,059 2,34 0,000 5,58 -3,23 
40S ribosomal protein S2  P25444 0,004 3,46 0,896 0,25 3,21 
40S ribosomal protein S27  Q6ZWU9 0,006 3,04 0,000 3,63 -0,59 
40S ribosomal protein S27-like  Q6ZWY3 0,016 2,95 0,001 3,88 -0,93 
60S ribosomal protein L38  Q9JJI8 0,801 0,49 0,002 3,24 -2,74 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 2  
Q8R010 0,258 2,26 0,039 3,29 -1,04 
ATP-dependent RNA helicase 
DDX3Y  




Q8CGC7 0,005 3,80 0,698 0,69 3,11 
Eukaryotic translation 
initiation factor 2 subunit 3, X-
linked  
Q9Z0N1 0,906 0,38 0,001 4,13 -3,75 
Eukaryotic translation 
initiation factor 3 subunit B  
Q8JZQ9 0,062 2,93 0,008 3,67 -0,74 
Eukaryotic translation 
initiation factor 3 subunit C  
Q8R1B4 0,018 2,29 0,004 2,74 -0,45 
Eukaryotic translation 
initiation factor 4 gamma 3  
Q80XI3 0,004 5,11 0,000 5,58 -0,47 
Isoleucine--tRNA ligase, 
cytoplasmic  
Q8BU30 0,006 2,69 0,531 0,90 1,79 
Lysine--tRNA ligase  Q99MN1 0,028 2,58 0,723 0,78 1,80 
Phenylalanine--tRNA ligase 
beta subunit  
Q9WUA
2 
0,000 7,03 0,938 -0,11 7,14 
Ribosome-binding protein 1  Q99PL5 0,077 2,61 0,000 4,79 -2,18 
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Table 7-2: Putative TRPV1 interactors not detected in the KO group 
Proteins listed in this table were not detected in the KO at all, but not declared as significantly regulated in 
CFA vs. KO or Veh vs. KO, by the t-test due to the missing value imputation via normal distribution. Log2 
(CFA/Veh) denotes the log2 fold change of these proteins, or states whether the protein was only found in 






Transmembrane protein 263  Q9DAM7 only CFA 
Proteasome subunit beta type-3  Q9R1P1 only CFA 
Ras-related protein Rab-8A  P55258  only CFA 
Myosin-6  Q02566 only CFA 
Ras-related protein Rap-2c  Q8BU31  only CFA 
Rho-related GTP-binding protein RhoB  P62746 only CFA 
Eukaryotic translation initiation factor 5A-2  Q8BGY2  only CFA 
ADP/ATP translocase 4  Q3V132 only CFA 
Tubulin alpha-8 chain  Q9JJZ2 only CFA 
Ras-related protein Rab-8B  P61028 2,44 
Filamin-B  Q80X90 1,62 
Microtubule-associated proteins 1A/1B light chain 3A  Q91VR7 1,24 
Catalase  P24270 1,01 
Vinculin  Q64727 0,99 
Fibrinogen alpha chain  E9PV24 0,92 
Ras-related protein Rab-11B  P46638 0,87 
Syntaxin-8  O88983 0,76 
Ras-related protein Rab-6A  P35279 0,73 
Twinfilin-1  Q91YR1 0,73 
Ras-related protein Ral-A  P63321 0,54 
Dynein light chain roadblock-type 1  P62627  0,47 
Serine/threonine-protein kinase MARK2  Q05512 0,46 
Signal recognition particle receptor subunit beta  P47758 0,45 
Transient receptor potential cation channel subfamily V 
member 2  
Q9WTR1 0,45 
Splicing factor U2AF 65 kDa subunit  P26369 0,40 
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Dephospho-CoA kinase domain-containing protein  Q8BHC4 0,27 
Apoptosis-inducing factor 1, mitochondrial  Q9Z0X1 0,27 
Double zinc ribbon and ankyrin repeat-containing protein 1  Q8C008 -0,28 
Kinesin heavy chain isoform 5C  P28738 -0,31 
26S proteasome non-ATPase regulatory subunit 13  Q9WVJ2  -0,35 
BAG family molecular chaperone regulator 2  Q91YN9  -0,37 
Growth hormone-inducible transmembrane protein  Q91VC9 -0,38 
39S ribosomal protein L14, mitochondrial  Q9D1I6  -0,45 
Mapk-regulated corepressor-interacting protein 1  Q3UGS4 -0,49 
Mitotic checkpoint protein BUB3  Q9WVA3 -0,49 
Gap junction alpha-1 protein  P23242 -0,54 
26S proteasome non-ATPase regulatory subunit 14  O35593 -0,66 
Nucleoside diphosphate kinase B  Q01768  -0,74 
General vesicular transport factor p115  Q9Z1Z0  -0,77 
Myosin light chain 4  P09541 -0,80 
Kinesin-1 heavy chain  Q61768 -0,89 
Kinesin heavy chain isoform 5A  P33175  -0,94 
Chloride intracellular channel protein 1  Q9Z1Q5  -0,96 
Heat shock 70 kDa protein 4  Q61316 -1,06 
Calcium-binding protein 39  Q06138 -1,19 
Protein-L-isoaspartate(D-aspartate) O-methyltransferase  P23506 -1,30 
Clathrin light chain A  O08585 -1,89 
26S proteasome non-ATPase regulatory subunit 2  Q8VDM4 only Veh 
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  Q8QZS1  only Veh 
Adenylate kinase isoenzyme 1  Q9R0Y5 only Veh 
Alpha-synuclein  O55042 only Veh 
ATP synthase subunit g, mitochondrial  Q9CPQ8 only Veh 
ATP synthase-coupling factor 6, mitochondrial  P97450  only Veh 
Calmegin  P52194  only Veh 
Calpain small subunit 1  O88456 only Veh 
Cellular nucleic acid-binding protein  P53996 only Veh 
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Cytochrome c oxidase subunit 5A, mitochondrial  P12787 only Veh 
Dehydrogenase/reductase SDR family member 7  Q9CXR1 only Veh 
Endoplasmic reticulum resident protein 29  P57759 only Veh 
Erlin-1  Q91X78 only Veh 
ES1 protein homolog, mitochondrial  Q9D172 only Veh 
Ferritin light chain 1  P29391 only Veh 
Golgi-associated plant pathogenesis-related protein 1  Q9CYL5 only Veh 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-2  
P63213 only Veh 
Guanine nucleotide-binding protein subunit alpha-14  P30677 only Veh 
Heat shock 70 kDa protein 4L  P48722 only Veh 
Heme oxygenase 2  O70252  only Veh 
Inorganic pyrophosphatase  Q9D819 only Veh 
Isovaleryl-CoA dehydrogenase, mitochondrial  Q9JHI5 only Veh 
LanC-like protein 1  O89112 only Veh 
Microtubule cross-linking factor 1  Q3UHU5 only Veh 
Microtubule-associated protein RP/EB family member 3  Q6PER3 only Veh 
NADH dehydrogenase [ubiquinone] 1 subunit C2  Q9CQ54 only Veh 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  
Q9D6J6 only Veh 
Prefoldin subunit 2  O70591 only Veh 
Proteasome subunit alpha type-5  Q9Z2U1  only Veh 
Proteasome subunit beta type-5  O55234 only Veh 
Protein deglycase DJ-1  Q99LX0 only Veh 
Protein lin-7 homolog C  O88952 only Veh 
Protein S100-A13  P97352  only Veh 
Protein sel-1 homolog 1  Q9Z2G6 only Veh 
Rab GTPase-binding effector protein 1  O35551  only Veh 
Serine/threonine-protein phosphatase 2B catalytic subunit 
alpha isoform  
P63328 only Veh 
SLIT-ROBO Rho GTPase-activating protein 3  Q812A2 only Veh 
Small nuclear ribonucleoprotein E  P62305 only Veh 
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Superoxide dismutase [Mn], mitochondrial  P09671 only Veh 
Trans-2-enoyl-CoA reductase, mitochondrial  Q9DCS3 only Veh 
Translocating chain-associated membrane protein 1  Q91V04 only Veh 
Ubiquitin carboxyl-terminal hydrolase 5  P56399 only Veh 
UMP-CMP kinase  Q9DBP5 only Veh 
X-ray repair cross-complementing protein 6  P23475 only Veh 
Excluded proteins (Ribosome & Translation)     
60S ribosomal protein L38  Q9JJI8 only Veh 
Eukaryotic translation initiation factor 2 subunit 3, X-linked  Q9Z0N1 only Veh 
Eukaryotic translation initiation factor 4 gamma 3  Q80XI3 -0,47 
Eukaryotic translation initiation factor 3 subunit C  Q8R1B4 -0,45 
Eukaryotic translation initiation factor 3 subunit B  Q8JZQ9 -0,74 
Keratin, type I cytoskeletal 27  Q9Z320 only Veh 
Keratin, type I cytoskeletal 28  A6BLY7 only Veh 
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Table 7-3: Enriched annotation term clusters for Veh-enriched proteins and proteins 
only detected in Veh  
Functional annotation clustering tool from DAVID was used to determine enriched annotation terms (see 
section 2.1.7.2 for further details) GO-Categories: CC, cellular component; MF, molecular function, BP, 
biological process; P-Value, significance of gene-term enrichment with a modified Fisher’s exact test; Proteins, 
uniprot_ID of proteins linked to the respective GO term; Fold enrichment (FEn), magnitude of enrichment 
comparing the enrichment of genes in input list vs. background (whole mouse genome); Benjamini (Benj), 




Enrichment Score: 5.7           
Category Term % P-Value Proteins FEn Benj 
MF 
GO:0098641~cadherin 
binding involved in cell-cell 
adhesion 
10,4 1,05E-07 
Q9D8B3, Q9WUA3, Q61792, 
Q7TQH0, P54823, P42208, 
Q9QYC0, Q61739, Q9Z1Z0, 







Q9D8B3, Q9WUA3, Q61792, 
Q7TQH0, P54823, P42208, 
Q9QYC0, Q61739, Q9Z1Z0, 







Q9Z1Z0, Q9WUA3, Q61792, 
Q78PY7, Q7TQH0, P54823, 
P42208, Q9QYC0 
5,8 0,097 
              
Annotation 
Cluster 2 
Enrichment Score: 3.4           





Q9Z1Z0, O54774, Q9JIF7, 
P17427, Q9QZE5, O08585, 














Q9Z1Z0, O54774, Q9JIF7, 
P57759, P17427, Q9QZE5, 







Q9Z1Z0, O54774, Q9JIF7, 
O88952, Q9D8B3, P17427, 
Q9QZE5, Q91V04, P70670, 







Q9Z1Z0, O54774, Q9JIF7, 
Q9CYL5, Q9QZE5 
1,9 0,771 
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Annotation 
Cluster 3 
Enrichment Score: 2.6           





O35593, Q9Z2U1, O55234, 







P10605, O35593, Q9Z2U1, 












type endopeptidase activity 
3,0 5,73E-04 





involved in cellular protein 
catabolic process 
3,7 7,50E-04 





processing and presentation 
of exogenous peptide 
antigen via MHC class I, 
TAP-dependent 
3,0 0,001 






2,2 0,005 O35593, Q8VDM4, Q9WVJ2 26,7 0,079 
BP GO:0006508~proteolysis 6,7 0,059 
P10605, O35593, Q99LX0, 
Q9Z2U1, O55234, Q9QUM9, 






P10605, O35593, Q99LX0, 







P23475, Q9Z2U1, O55234, 
P54823, P56399, P50518, 
O09061, P63328, P10605, 
O55143, O35593, Q8QZS1, 






dependent protein catabolic 
process 
2,2 0,291 Q9Z2U1, O55234, Q8VDM4 2,8 0,998 
              
Annotation 
Cluster 4 
Enrichment Score: 2.1           
Category Term % P-Value Proteins FEn Benj 
MF GO:0003774~motor activity 3,7 0,002 







P09541, E9Q634, P97479, 
P70248 
11,6 0,074 
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Table 7-4: Enriched annotation term clusters for CFA-enriched proteins and proteins 
only detected in CFA 
Functional annotation clustering tool from DAVID was used to determine enriched annotation terms (see 
section 2.1.7.2 for further details) GO-Categories: CC, cellular component; MF, molecular function, BP, 
biological process; P-Value, significance of gene-term enrichment with a modified Fisher’s exact test; Proteins, 
uniprot_ID of proteins linked to the respective GO term; Fold enrichment (FEn), magnitude of enrichment 
comparing the enrichment of genes in input list vs. background (whole mouse genome); Benjamini (Benj), 
global correction of individual p-values for multiples testing. 
Annotation 
Cluster 1 
Enrichment Score: 8.0           
Category Term % P-Value Proteins FEn Benj 
MF GO:0003779~actin binding 23,2 2,37E-10 
Q91YR1, Q8BL65, P47753, 
Q9ERG0, Q02566, P47757, 
Q80X90, Q9QYB8, Q8C0P5, 
Q91ZU6, Q64727, Q5SYD0, 
Q9JJ28 
12,7 3,13E-08 
CC GO:0005903~brush border 14,3 1,87E-09 
P47753, Q9ERG0, P47757, 







P47753, Q9ERG0, P47757, 





Enrichment Score: 4.7           





P47753, Q9ERG0, P47757, 





actin filament capping 
7,1 1,22E-05 





capping protein complex 
5,4 2,73E-04 P47753, P47757, Q9QYB8 117,0 0,006 
Annotation 
Cluster 3 
Enrichment Score: 4.1           
Category Term % P-Value Proteins FEn Benj 
CC GO:0005903~brush border 14,3 1,87E-09 
P47753, Q9ERG0, P47757, 





binding involved in cell-cell 
adhesion 
14,3 1,79E-05 
Q91YR1, P47753, Q9ERG0, 







Q91YR1, P47753, Q9ERG0, 







Q91YR1, P47753, Q9ERG0, 
P47757, Q80X90, Q05512 
10,8 0,018 
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5,4 0,109 Q91YR1, P47753, Q64727 5,2 0,434 
Annotation 
Cluster 4 
Enrichment Score: 2.9           
Category Term % P-Value Proteins FEn Benj 
MF GO:0019003~GDP binding 10,7 9,32E-07 
P62746, P55258, Q8BU31, 




mediated signal transduction 
14,3 4,79E-06 
P62746, P55258, Q8BU31, 
P61028, P35279, P46638, 
P63321, P47758 
11,6 8,33E-04 
MF GO:0005525~GTP binding 16,1 1,62E-05 
Q9JJZ2, P62746, P55258, 
Q8BU31, P61028, P35279, 






Q9JJZ2, P62746, P55258, 
P61028, P35279, Q02566, 
P63321, P26369, Q8BHC4, 
P80318, Q9D0E1, Q8BU31, 





























P62746, P55258, Q8BGY2, 






5,4 0,008 P55258, P61028, P46638 22,4 0,075 
CC GO:0005768~endosome 10,7 0,018 
P62746, P55258, Q8BU31, 
P46638, O88983, Q5SYD0 
3,9 0,129 
BP GO:0006810~transport 19,6 0,033 
P62746, P55258, Q8BGY2, 
P61028, P35279, Q3V132, 
P46638, P02104, O88983, 
P62627, Q9WTR1 
2,1 0,652 
CC GO:0005622~intracellular 16,1 0,075 
Q91YR1, P62746, P55258, 
P61028, P35279, P46638, 
P63321, P47758, Q9WTR1 
2,0 0,343 
  


































Figure 6.8: Protein-protein interaction network of Veh-enriched proteins 
Figure displays known protein-protein interactions of Veh-enriched proteins and proteins only detected in Veh (denoted 
by gene names) as predicted with high confidence level by STRING, based on curated databases and experimental evidence 
(see section 2.1.7.2 for details). Unbiased MCL clustering revealed clusters (nodes are displayed in the same colour) and 
clusters with > 3 nodes are annotated. Dashed lines indicated intercluster associations. Thickness of edges represent the 
confidence of the association. 
 

















Figure 6.9: Protein-protein interaction network of CFA-enriched proteins 
Figure displays known protein-protein interactions of CFA-enriched proteins and only detected in CFA (denoted by gene 
names) as predicted with high confidence level by STRING, based on curated databases and experimental evidence (see 
section 2.1.7.2 for details). Thickness of edges represent the confidence of the association.  
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